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Abstract 
Background Rheumatoid arthritis (RA) is associated with both local and systemic 
inflammation which influences the function of the whole body as well as local tissues in 
the joints. Significant consequences of this are changes in metabolism. Hence, we 
hypothesised that chronic inflammation alters metabolism and that the metabolic profile of 
an individual patient with early inflammatory arthritis predicts the subsequent course of 
disease. Furthermore, we suggested that these metabolic changes would identify 
biomarkers of response to treatment in inflammatory arthritis and provide novel insights 
into disease mechanisms.   
Methods Using NMR spectroscopy of serum, urine and synovial fibroblasts we derived 
metabolic profiles and subjected these to multi-parameter analyses to identify metabolic 
differences associated with inflammation. 
Results We were able to predict outcome in patients with early arthritis using material 
derived from cultured synovial fibroblasts but were unable to do so using serum. There 
was a significant association between CRP levels in the patients’ serum and the metabolic 
profile of their synovial fibroblasts and their serum. There was also a significant 
association between the metabolomic fingerprint of synovial fibroblasts and the 
fibroblasts’ IL6 production. We found differences in metabolites between urine samples of 
RA and psoriatic arthritis (PsA) patients and were able to predict responses to anti-TNF 
therapy in patients with RA.  
Discussion Our results demonstrate that underlying inflammatory processes drive 
significant changes in metabolism that can be measured in the peripheral blood, synovial 
fibroblasts and urine samples in patients with inflammatory arthritis. 
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1 
 
1.0 Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by swelling, 
tenderness and destruction of synovial joints (Smolen and Aletaha 2008).  It leads to 
severe disability and premature mortality (Kyburz and Finckh 2013).  Its aetiology is not 
fully understood but genetic and environmental factors both contribute (Smolen and 
Aletaha 2008).  In addition to synovitis a systemic inflammatory response is also seen 
involving changes in many systems and organs.  
 
Systemic inflammation leads to alterations in metabolism and several studies have 
investigated the resulting changes in low molecular weight metabolites in patients and 
animal models of inflammation (Bezabeh et al. 2009;Lin et al. 2009;Marchesi et al. 
2007;Sinclair et al. 2010;Young et al. 2009).  Nuclear magnetic resonance (NMR) has 
been used to identify alterations in a broad range of different metabolites simultaneously 
and from such studies several key metabolites have been identified, providing insights into 
the mechanisms of disease and also representing potential biomarkers which can be used to 
follow the disease and assess responses to therapy (Brindle et al. 2003;Sreekumar et al. 
2009).  RA has significant effects on metabolism and in this project I aimed to use NMR to 
identify potential biomarkers for outcome and response to therapy in inflammatory arthritis 
and to provide novel insights into mechanisms of disease.   
1.1 Rheumatoid Arthritis 
1.1.1 Classification 
Careful classification of diseases is an important step in allowing more accurate and 
consistent identification of patient populations with clearly defined characteristics for 
inclusion in research studies and the first criteria for RA were proposed in 1956 by a 
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committee of the American Rheumatism Association (Bennett et al. 1956)  These 
classified patients as having ‘definite’, ‘probable’ or ‘possible’ RA. In 1958 the same 
committee made revisions to improve sensitivity and specificity but the criteria were 
(Ropes et al. 1959) felt to be cumbersome and were never widely used. Not until 1987 
were classification criteria widely accepted and these were developed by the American 
College of Rheumatology (ACR) (Arnett et al. 1988)(Table 1.1). Over this 30 year period 
several forms of arthritis which had previously been classified as RA (including many of 
the seronegative spondyloarthropathies) had been given separate identities necessitating 
the development of new RA criteria. The new criteria demonstrated 91-94% sensitivity and 
89% specificity for RA when compared to control subjects who did not have RA (Arnett et 
al. 1988).  
Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement 
2. Arthritis of 3 or 
more joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 
14 possible areas are right or left PIP, MCP, wrist, elbow, knee, 
ankle, and MTP joints 
3. Arthritis of hand 
joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP 
joint 
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas (as defined in 
2) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs is acceptable without absolute symmetry) 
5. Rheumatoid 
nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions, observed by a physician 
6. Serum 
rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects 
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posterioanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localised in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify) 
Table 1.1 The 1987 revised criteria for the classification of rheumatoid arthritis* 
*For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she 
has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been present for at 
least 6 weeks. Patients with 2 clinical diagnoses are not excluded.  
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Although the 1987 classification criteria were used widely for several decades, they were 
criticised for their lack of sensitivity in early RA (Harrison et al. 1998) and so this led to 
the development of the 2010 American College of Rheumatology/European League 
Against Rheumatism (ACR/EULAR) classification criteria for RA (Aletaha et al. 2010) 
(Table 1.2). Several recent studies have assessed how accurately these identify patients 
with early RA in patients with newly presenting inflammatory arthritis and they have 
found that the 2010 criteria allowed earlier classification of RA than the 1987 criteria 
(Cader et al. 2011;Humphreys and Symmons 2013;van der Helm-van Mil AH and 
Huizinga 2012), but that they also led to over-classification of RA in patients as several 
patients, whose arthritis had resolved, were classified as having RA (Cader et al. 2011). 
Researchers have found that the sensitivity of the 2010 criteria has increased compared to 
the 1987 criteria but the specificity has decreased (van der Helm-van Mil AH and 
Huizinga 2012). This is concerning as these criteria are classification criteria used to 
standardise inclusion into studies rather than to make a diagnosis of RA so specificity is 
extremely important.  
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Criterion Score 
A. Joint involvement 
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large joints) 
>10 joints (at least 1 small joint) 
 
0 
1 
2 
3 
5 
 
B. Serology (at least 1 test result is needed for classification) 
Negative RF and negative ACPA 
Low=positive RF or low-positive ACPA 
High-positive RF or high-positive ACPA 
 
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 
Abnormal CRP or abnormal ESR  
 
 
0 
1 
 
D. Duration of symptoms 
<6 weeks 
>6 weeks 
 
 
0 
1 
Table 1.2 The 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis 
*For classification purposes, a patient shall be said to have definite rheumatoid arthritis 
with a score of > 6/10 
 
1.1.2 Aetiology 
1.1.2.1 Genetic factors 
Rheumatoid arthritis has a complex aetiology with genetic and environmental factors 
contributing to pathological events. Based on twin studies the relative contribution of 
genetic factors is approximately 50% for the entire syndrome of RA (MacGregor et al. 
2000). There have been extensive efforts to identify the associated genes and most of these 
studies have focussed on linkage and candidate gene associations.  More recently genome-
wide association studies have been used to study RA and several other autoimmune 
conditions (Burton et al. 2007).  The association between RA and alleles of the HLA-
DRB1 locus (shared epitope) has long been recognised (Gregersen et al. 1987) and these 
are the strongest genetic risk factors for RA. They encode a common amino acid motif, 
called the shared epitope (SE), in the β chain of the MHC class II HLA-DR molecule. The 
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presence or absence of genetic polymorphisms within the DRB1 locus is an important 
susceptibility factor. The genetic association of HLA-DR with RA, together with the 
presence of MHC class II-expressing cells and T cells in the rheumatoid synovium, led to 
the hypothesis that MHC class II-dependent T-cell and B-cell activation is responsible for 
driving the disease process in RA.  
 
The second most important genetic risk factor in RA is PTPN22 (protein tyrosine 
phosphate, non-receptor type 22), a gene encoding a protein tyrosine phosphatase that has 
a role in T cell and B cell signalling (Begovich et al. 2004;Burkhardt et al. 2006;Hinks et 
al. 2005). A single nucleotide polymorphism (SNP) that results in the substitution of 
arginine to tryptophan (R620W) affects its interaction with Src tyrosine kinases involved 
in regulation of T cell receptor (TCR) signalling. This leads to altered regulation of TCR 
signalling during thymic selection and may permit autoreactive T cells to escape clonal 
deletion, thereby predisposing to autoimmunity (Vang et al. 2005). The PTPN22 R620W 
polymorphism has been associated with increased IgG autoantibodies against an 
immunodominant collagen type II epitope in early rheumatoid arthritis (Burkhardt et al. 
2006).  
 
More recently, several other genetic loci associated with RA susceptibility have been 
identified by large-scale genotyping of RA patients for SNPs. Such studies have 
highlighted RA-associated polymorphisms in a region containing TNF receptor-TRAF-1 
and C5 complement (Plenge et al. 2007a;Plenge et al. 2007b), and in the gene encoding 
signal transducer and activator of transcription 4 (STAT4) (Remmers et al. 2007). Four 
SNPs in the STAT4 gene are associated with an increased risk of RA, most significantly 
6 
 
rs7574865. STAT4 is an intracellular molecule that transduces signals downstream of type 
I interferons, IL-12 and IL-23 and regulates differentiation of Th1 and Th17 cells, and is 
known to be upregulated in the RA synovium. Other loci associated with disease 
susceptibility and severity include CTLA4 which down regulates CD28-mediated T cell 
co-simulation; peptidyl arginine deiminase type IV (PADI4) which catalyses post-
translational modifications of arginine to citrulline; and TNFα-induced protein 3 
(TNFAI3) which functions as a negative regulator of NF-κB (Eyre et al. 2012). A range of 
other potential genetic associations remain to be investigated.  
 
All the genes that have been identified so far are associated with multiple autoimmune 
diseases including juvenile idiopathic arthritis, type 1 diabetes, coeliac disease and Graves 
disease.  So far, no locus has been identified which is exclusively associated with RA 
(Barton and Worthington 2009).  Although, there has been some progress in identifying 
the genetic factors that contribute to RA the most important genetic factors (the SE and 
PTNP22) seem only to predispose to ACPA (anti-citrullinated protein antibody) positive 
disease (Bax et al. 2011), suggesting that ACPA positive RA may be a completely 
different disease to ACPA negative RA. The heritability of ACPA negative RA is 
comparable to that of ACPA positive RA but the genes responsible for this association 
have not yet been identified due to the smaller population sizes studied (van der Woude et 
al. 2009).  
 
Hence, it seems that although genes are important, interactions of the genotype with 
environmental factors are necessary to precipitate and drive the disease.  The factors which 
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contribute to the other 50% of the aetiology include age, infections, diet, smoking and 
hormones which are considered in the following sections.   
  
1.1.2.2 Environmental factors 
1.1.2.2.1 Smoking 
Smoking is known to increase the risk of RA with several studies showing a positive link 
in women.  Fewer studies have been carried out in males but the risk is felt to be even 
greater (Sugiyama et al. 2010).  A population-based case-controlled study conducted in 
Norfolk (NOAR) found that people who had ever smoked had an increased risk of 
developing RA (Symmons 2005) and a recent prospective study demonstrated an increased 
risk of developing RA in antibody positive patients with this risk increased if they had a 
high body mass index (de Hair et al. 2013). 
 
Several studies have shown a relationship between smoking and RF positivity.  In those 
that smoke, glutathione S-transferase M1 has been linked to increased severity of RA 
(Mattey et al. 2002).  Glutathione S-transferase polymorphisms affect the ability to 
detoxify chemicals in cigarette smoke which may influence the progression of RA.   
 
Smoking can affect metabolism in other ways.  Chronic smoking causes marked oxidative 
stress which may be responsible for a constant inflammatory process.  Oxidative stress is 
associated with low antioxidant levels (Baka et al. 2009) and smoke contains high amounts 
of free radicals. Smoking induces the depletion of the endogenous antioxidant glutathione, 
resulting in cell injury (Moriarty et al. 2003).   
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Recent data suggest that smoking is linked only to ACPA positive RA (Baka et al. 2009).  
ACPA positive RA and ACPA negative RA are thought to be genetically distinct where 
HLA-DRB1 shared epitope alleles and the RA susceptibility polymorphisms in PTPN22 
are associated only with ACPA positive RA (Bowes and Barton 2008).  Data suggest that 
smoking increases the risk of ACPA positive RA only in shared epitope positive patients 
(Baka et al. 2009;Mahdi et al. 2009).  There seems to be a 4 way relationship between 
smoking, periodontitis, the shared epitope and ACPA positive RA with periodontitis being 
more common in patients that smoke and linked to the shared epitope (Lundberg et al. 
2010) and periodontitis being more prevalent in patients who have ACPA positive RA 
(Dissick et al. 2010).  These epidemiological and longitudinal studies have helped to 
produce data which can give us insights into the pathogenesis of ACPA positive RA. 
 
Current research suggests that smoking triggers citrullination in the lungs and 
autoimmunity (to citrullinated self-molecules) starts in the lungs and then spreads to other 
areas such as the joints (Klareskog et al. 2011).  The citrullination of proteins in the lung 
causes enhanced binding of citrullinated peptides and in genetically susceptible individuals 
this could lead to the production of ACPA.  Inflammatory arthritis accompanied by 
citrullination of proteins in the joints develops later and recruitment of ACPA from the 
circulation leads to the formation of immune complexes. Evidence of increased 
citrullination has been seen in the lungs, arthritic joints, extra-articular inflammatory sites 
in RA, inflamed muscle and inflamed lymphoid organs (Klareskog et al. 2008). Immune 
complex formation leads to the production of cytokines and autoantibodies and results in 
chronic RA (Klareskog et al. 2008).  
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1.1.2.2.2 Diet 
Antioxidants neutralize the actions of reactive oxygen species and hence reduce some of 
the effects of inflammation.  The NOAR (Norfolk Arthritis Register) EPIC study found 
that those individuals with the greatest vitamin C intake had the lowest risk of developing 
polyarthritis (Pattison et al. 2004a).  In contrast, high red meat intake has been shown to be 
associated with an increased risk of developing RA (Pattison et al. 2004b).  Red meat is a 
rich source of iron and could promote oxidative damage since it has been shown to 
accumulate in the rheumatoid synovial membrane (Blake et al. 1981).  Fish consumption 
and omega-3 fatty acids have also been found to be associated with a reduced incidence of 
RA and this may be due to the eicosanoids in omega-3 fatty acids competing with 
arachidonic acid resulting in less proinflammatory eicosanoids (Shapiro et al. 1996).  
 
Data demonstrate that alcohol consumption has a protective effect on the development of 
RA, with a 40-50% reduction in risk for the highest consumers (Bergstrom et al. 
2013;Kallberg et al. 2009).  Further studies have shown that alcohol consumption 
influences the severity of RA, as measured by radiographic progression, with a trend 
towards reduced radiographic progression in alcohol drinkers compared to non-drinkers.  
In particular, male patients with RA who consume alcohol had less radiographic 
progression than male non-drinkers (Nissen et al. 2010).  This shows that lifestyle may 
have a very important part to play in the aetiology of RA.   
1.1.2.2.3 Infections 
Several infections including Epstein-Barr virus (EBV) have been linked to RA. RA 
patients have higher titres of anti-EBV antibodies and impaired T-cell responses to EBV 
antigens compared to controls, and EBV DNA has been found in the synovium of patients 
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with RA (Toussirot and Roudier 2008).  However, an epidemiological study using the 
NOAR cohort, looking at a range of infections, found no association between RA and 
measles, rubella, glandular fever, hepatitis or TB (Symmons et al. 1997).  This study did, 
however, find an association between development of RA and previous blood transfusions 
(Symmons et al. 1997).   
 
Periodontitis, which is a chronic inflammatory disease causing significant tooth loss, has 
also been linked to RA.  Epidemiological and clinical studies have suggested that 
periodontitis and tooth loss are more prevalent in individuals with RA but the strength of 
this association is uncertain (Chen et al. 2013;de Pablo et al. 2009), but has been 
biologically linked to enhanced citrullination and so is a continuing area of research.   
 
1.1.2.3 Biological factors 
1.1.2.3.1 Age 
While RA can occur at any age, there is a low incidence in men under the age of 45 and 
the peak age of onset in women is 45 to 54 years of age using the 1987 ACR classification 
criteria and 55-64 years of age using the 2010 classification criteria (Humphreys et al. 
2013).  The incidence is generally much higher in women than men but over the age of 75 
the incidence is higher for men than women (Humphreys et al. 2013).  The prevalence 
rises with age and is highest over the age of 75.  The incidence rates are generally similar 
using the 1987 or the 2010 classification criteria (Humphreys et al. 2013) but men 
generally have much more severe disease than women (Symmons 2005) and the disease 
may be more severe with later onset (Van Der et al. 1991).  The reasons for this 
association with age are the subject of much debate.  For example, antioxidants are low in 
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the elderly (Hu et al. 2000) which may allow oxidative damage to accumulate in long lived 
cells such as lymphocytes.  Elderly humans have dysregulated immune responses with 
changes in both adaptive and innate immunity.  A shift in T cells to a predominantly 
memory phenotype may contribute to the decline in IL2 production, and an increased 
tendency to produce a Th2 profile of cytokines (Ely et al. 2007) which may explain the 
increased occurrence of autoantibody levels.  An increase in the basal level of CRP in the 
elderly suggests a low grade inflammatory process is present (Lisko et al. 2012) which 
may provide an environment conducive to the occurrence of the more overt inflammation 
seen in diseases such as RA.   
 
1.1.2.3.2 Hormones 
RA frequently remits during pregnancy and there is an increased incidence postpartum.  
Current oral contraceptive pill use has a protective effect and there is an association with 
miscarriage and termination of pregnancy of an increased risk of developing RA 
(Symmons 2005).  Oral contraceptive use in women seems to act early in the development 
of RA as it has been found to have an inverse relationship with rheumatoid factor in 
asymptomatic genetically susceptible women (Bhatia et al. 2007). What is still not clear is 
whether hormonal changes explain the gender differences seen in RA as it is well known 
that RA is more common in females than males.  As well as the hormone variation 
between females and males there is also a difference in body fat composition which may 
explain the gender differences seen.  Females have a higher body fat mass composition 
compared to males and high body fat mass has been shown to be linked with RA (Book et 
al. 2009).   
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1.1.2.4 Summary 
Several factors have been associated with the aetiology of RA but the main genetic factors 
(SE and PTNP22) and the most strongly associated environmental factor (smoking) seem 
only to be associated with ACPA positive RA.  Work involving these aetiological factors 
has given us insights into the pathogenesis of ACPA positive RA but there is still a lot of 
uncertainty regarding aetiology; in particular in the context of ACPA negative RA.  
1.1.3 Pathology 
The synovium is the primary site of inflammation in RA.  The synovial membrane is 
normally composed of a single cell lining layer of macrophages and fibroblasts.  The sub-
lining layer is composed of relatively acellular connective tissue and blood vessels.  In RA 
the synovial membrane becomes hyperplastic with macrophages and synovial fibroblasts 
infiltrating the lining layer and T cells, B cells, plasma cells and macrophages infiltrating 
the sub-lining layer (Bartok and Firestein 2010).   
 
In patients with RA, the sub-lining layer becomes oedematous and vascular.  The inflamed 
synovium forms a pannus lesion which invades the adjacent cartilage and bone promoting 
articular destruction by osteoclasts, chondrocytes and synovial fibroblasts (Karmakar et al. 
2010).   
 
Several types of immune cell are present in the synovium, which are very active 
metabolically.  During chronic inflammation leucocytes are recruited in response to 
changes in the expression of proinflammatory adhesion molecules and chemoattractant 
cytokines and they accumulate within the synovium (Raza et al. 2006).   
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I will discuss the role of synovial fibroblasts further as these are phenotypically unusual in 
RA and an important cell type that I have studied in my project.   
 
1.1.3.1 Synovial fibroblasts 
Inflammation and its persistence in RA result from complex interactions between 
haematopoietic and stromal cells (Buckley et al. 2001;Parsonage et al. 2005) but research 
into the pathogenesis of the disease has traditionally neglected the role of stromal cells. 
Fibroblasts are primarily responsible for the synthesis and remodelling of extracellular 
matrix components in tissues. However, their ability to produce and respond to growth 
factors enables the maintenance and homeostasis of the adjacent epithelial and endothelial 
cells (Naylor et al. 2013). Activated RA synovial fibroblasts (RASFs) have an important 
role in determining the site at which inflammation occurs and the persistence of 
inflammation in the joint microenvironment (Takemura et al. 2001).  Fibroblast activation 
causes survival and retention of leukocytes leading to accumulation at sites of 
inflammation (Iwamoto et al. 2008), hence preventing the resolution of chronic 
inflammation (Filer et al. 2006).  Fibroblasts have an important role in altering the 
behaviour of lymphocytes that accumulate within chronically inflamed joints by the 
production of the cytokines interferon-β, interleukin 6 (IL-6) and transforming growth 
factor-β and the chemokines stromal cell-derived factor-1 and CXCL12 (Buckley 2003). 
Fibroblasts also provide an environment which inhibits T-cell apoptosis, and type I 
interferons produced by fibroblasts and macrophages have been identified as the principal 
factor responsible for prolonged T-cell survival in the rheumatoid joint (Pilling et al. 
1999).  
14 
 
 
RASFs are characterised by a round, large pale nucleus with prominent nucleoli, indicating 
active RNA metabolism.  RASFs can be isolated from synovial tissue and expanded in cell 
culture over several passages without undergoing contact inhibition (Lafyatis et al. 1989) 
which is different from other cells such as macrophages.   
 
The mechanism underlying the expansion in numbers of RASFs in the lining layer of the 
synovial membrane is not fully understood.  In the joint, fibroblasts have limited access to 
nutrients and oxygen within the poorly vascularised synovium and yet expansion of 
fibroblast numbers still occurs.  This may be due to the migration of mesenchymal stem 
cells from the circulation or local expansion of a stem cell pool within the synovium.  
However, growth in the size of the RASFs population is most likely due to an imbalance 
between cell proliferation, survival and death (Bartok and Firestein 2010).  The synovial 
environment in RA promotes survival of RASFs.  RASFs are protected from apoptosis by 
the activity of NF-κβ.  NF-κβ is highly activated in RA and provides a strong pro-survival 
signal (Han et al. 1998).  Expression of the tumour suppressor gene p53 is induced by cell 
damage and leads to cell cycle arrest and if the damage is substantial p53 directs cells 
towards apoptosis.  There is an increase in p53 expression in the rheumatoid synovial 
lining but a lack of apoptosis.  Several mutations have been found in the p53 gene 
(Firestein et al. 1997) in RA synovium, potentially eliminating a key pathway that 
regulates cell survival which may explain the lack of apoptosis seen.  However, this 
observation has not been widely reproduced.   
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Cartilage and bone destruction are the hallmarks of RA.  Over a decade ago, RASFs were 
shown to attach to and invade normal human cartilage (Mueller-Ladner et al. 1996) and 
recent data suggest that RASFs are primarily responsible for cartilage damage (Bartok and 
Firestein 2010).  In situ hybridisation studies confirm that RASFs are the source of matrix 
metalloproteinases and cathepsins which destroy articular cartilage and bone (Tolboom et 
al. 2002).  RASFs are also involved in bone degradation through activation of osteoclasts 
and by producing RANKL (Bartok and Firestein 2010).   
 
RASFs are the dominant cell type in the hyperplastic synovial membrane.  It is possible 
that these cells may be a significant source of metabolites as it has been shown that 
administration of FGF 21 (a member of the fibroblast growth factor family) to mice, 
resulted in significant changes in plasma lipids and glucose (Li et al. 2009).  FGF 21 has 
significant effects on fibroblasts and adipocytes by regulating lipolysis (Li et al. 2012), 
which demonstrates a potential role for RASFs to be involved in the regulation of lipid 
related metabolites found in the blood.  Hence, RASFs are an important cell to study in the 
context of metabolomics. 
 
1.1.3.2 Inflammatory mediators 
Cytokines are important regulators of inflammation since some, such as TNFα, IL-6 and 
IL-1, promote inflammatory responses which induce cartilage degradation and promote a 
cell-mediated immune response (Lefebvre et al. 1990). Other cytokines such as IL-4, IL-10 
and IL-13 function mainly as anti-inflammatory molecules (Isomaki and Punnonen 1997).  
Key biological targets that have been identified as being involved in a destructive 
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inflammatory reaction are COX-2, pro-inflammatory interleukins, TNFα, migration 
inhibition factor, interferon gamma and matrix metalloproteinases (Ivanenkov et al. 2008).   
 
Several of the inflammatory mediators above have been shown to play a role in a broad 
range of inflammatory diseases.  This is true of CRP, a widely used marker of systemic 
inflammation which is secreted by several cell types and is capable of directly activating 
immune cells.  This suggests that CRP is an active inflammatory mediator which has 
systemic and local affects (Montecucco and Mach 2009).   
 
White adipose tissue has been shown to secrete several inflammatory mediators known as 
adipokines or adipocytokines.  They induce their effects by binding to selective 
transmembrane receptors.  Leptin is the most studied adipocytokine and is thought to have 
an important role in the inflammatory process (Montecucco and Mach 2009).   
 
1.1.4 Autoantibodies 
1.1.4.1 Rheumatoid factor  
RA is often referred to as an autoimmune disease due to the presence of self-reactive 
antibodies. Rheumatoid factor (RF), an antibody that binds to the Fc region of IgG is 
detectable in the serum of the majority of patients with RA (70% - 80%). However, RF is 
also found in up to 5% of normal individuals and in patients with other systemic diseases 
such as Sjogren’s syndrome and many systemic infections, suggesting its presence is a 
general consequence of immune activation rather than a RA-specific feature. RF can be 
detected many years prior to clinical onset (Aho et al. 1985;Rantapaa-Dahlqvist et al. 
2003) and levels of RF correlate with disease severity, with patients who are seropositive 
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having more aggressive disease and a worse prognosis (Symmons and Silman 2006;van et 
al. 1992). 
 
1.1.4.2. Anti-citrullinated protein antibodies  
Anti-citrullinated protein antibodies (ACPA) are highly specific for RA. The most 
frequently used assay in clinical practice is the CCP2 ELISA which captures ACPAs with 
a broad range of specificities (Ioan-Facsinay et al. 2011). ACPAs have been described in 
41-68% of patients with early RA (Kastbom et al. 2004;Nielen et al. 2004;Raza et al. 
2005a;van Gaalen et al. 2004) and in many cases ACPA emerge prior to the onset of 
symptoms (Berglin et al. 2004;Nielen et al. 2004). The presence of ACPA is associated 
with more severe joint destruction and greater disease activity, and seropositivity at 
diagnosis is an important predictor of a more aggressive disease course (Forslind et al. 
2004;Kastbom et al. 2004;Vallbracht et al. 2004). ACPA are specific for autoantigens 
modified by citrullination through deimination of arginine to citrulline, a post-translational 
modification which increases the affinity of potential autoantigens for the binding groove 
of the MHC class II β-chains (Hill et al. 2003). Although ACPA are specific and predictive 
for RA, the role for these antibodies in the disease pathogenesis is not clear. Kuhn et al 
have demonstrated that ACPA have a directly pathogenic role in the collagen-induced 
mouse model of arthritis, indicating an important role for citrullinated protein antigens in 
driving pathological events in RA (Kuhn et al. 2006). A recent study targeting citrullinated 
peptides from α-enolase, vimentin, fibrinogen and collagen type II demonstrated that 
HLA-DRB1 SE, PTNP22 and smoking are associated with the presence of specific ACPA 
reactivities rather than anti-CCP levels (Lundberg et al. 2013).  Current research does 
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suggest a role for citrullinated proteins in the presence of smoking in the pathogenesis of 
RA in a genetically susceptible population (Klareskog et al. 2008).  
 
There is also evidence of immunity to other posttransationally modified antigens including 
homocitrullination (carbamylation) (Klareskog et al. 2014;Mydel et al. 2010;Shi et al. 
2014). Carbamylation takes place at low levels in healthy individuals but at increased 
levels in people with RA. Anti-carbamylated fetal calf serum antibodies and anti 
carbamylated human fibrinogen antibodies have been identified in both ACPA positive 
and ACPA negative RA patients. The presence of anti-carbamylated antibodies (anti-CarP) 
in ACPA negative patients is associated with more severe joint damage. Anti-CarP 
antibodies are also found in patients with arthralgia and are associated with an increased 
risk of developing RA independent of ACPA (Shi et al. 2014). Anti-CarP may be a very 
useful tool in ACPA negative patients.  
 
1.2 Early Rheumatoid Arthritis 
1.2.1 Phases of rheumatoid arthritis 
Many of the characteristic features of RA described above are derived from studies of 
well-established disease. However, RA appears to develop clinically in several stages, 
usually beginning with swelling and pain in a limited number of joints, followed by a 
subsequent increase in the number of affected joints and severity of symptoms, and finally 
resulting in destruction and deformity (Deane et al. 2010b;Gerlag et al. 2012;Schaeverbeke 
et al. 2012).  
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Even following the development of clinical symptoms, evidence suggests that during the 
first few months, patients with early inflammatory arthritis who subsequently develop RA 
have a distinct but transient synovial fluid cytokine profile that is not seen in other early 
arthritides and not present in established RA.  Synovial fluid from patients with early RA 
contained elevated levels of T cell, macrophage and stromal cell related cytokines IL-2, 
IL-4, IL-15 and GM-CSF compared to those early arthritis patients who did not develop 
RA.  This cytokine profile is also not present in established RA (Raza et al. 2005b). 
However, evidence suggests that when looking at processes within the synovium, the same 
changes are seen within the first year of diagnosis of RA as seen in those with longer 
standing disease (Tak 2001).   
 
Synovial histology appears normal with no evidence of infiltrates in ACPA positive 
arthralgia patients without evidence of synovial inflammation (van de Sande et al. 2011) 
suggesting that the development of synovial inflammation occurs at the time of clinically 
apparent synovitis.  However, these biopsy samples were taken from the knee which is not 
the most common site of involvement in early RA.  
 
The serum of patients with very early RA (< 6 weeks duration) has a very distinct cytokine 
pattern which favours B cell activation and survival. The levels of APRIL and BAFF are 
significantly higher in patients with very early RA compared to other types of early 
arthritis, controls and established RA (Moura et al. 2011). Other serum cytokines such as 
IL-1, IL-6, IL-10, IL-12, IL-15, TNFα, GM-CSF and sTNFRII have been found to be 
elevated in the preclinical phases of RA but the results from several studies have been 
conflicting (Deane et al. 2010a;Deane et al. 2010b;Schaeverbeke et al. 2012;Sokolove et 
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al. 2012). This may be due to differences in the cohorts studied or due to the 
methodologies and cut offs of the assays used. Further research into pre clinical RA will 
lead to better understanding of the disease and preventive strategies for RA.  
 
1.2.2 Importance of treating rheumatoid arthritis early 
It is important to identify patients who will develop RA as early as possible as it is now 
known that a reduction in inflammation associated with early therapy limits the articular 
and extra-articular manifestations of RA (O'Dell 2002;Raza et al. 2006).  It has also been 
shown that aggressive early treatment in these patients leads to earlier functional 
improvement and less radiographic damage (Goekoop-Ruiterman et al. 2005).  Evidence 
suggests that if patients with RA are treated with DMARDs within 12 weeks of symptom 
onset they have less joint destruction and a greater chance of drug free remission (van der 
Linden et al. 2010).   
 
1.2.3 Predicting outcome in early rheumatoid arthritis 
Identifying patients that will go on to develop RA can be difficult. Algorithms have been 
developed to try and identify those patients with undifferentiated arthritis who will go on 
to develop RA.  These algorithms have used a combination of clinical symptoms, joint 
counts and the presence of antibodies such as RF and ACPA.  The Leiden group have 
introduced a prediction rule which includes 9 variables: sex, age, localisation of symptoms, 
morning stiffness, tender joint count, swollen joint count, CRP, RF and ACPA (van der 
Helm-van Mil et al. 2007).  The positive and negative predictive values of this score were 
good for the high and low levels but a large proportion of patients (25%) had an 
intermediate score for whom it was still difficult to predict outcome.  Hence, there are still 
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many patients that it is difficult to predict outcome for (Raza and Filer 2009) and there is a 
need for better methods of prediction in these patients.   
 
1.2.4 Predicting response to treatment in rheumatoid arthritis 
Treatments for RA have advanced significantly over the last decade but despite the 
availability of several specific therapies the process of selecting a treatment for an 
individual patient remains empirical.  However, there has been some progress towards 
personalised treatment of RA.   
 
Methotrexate is the most commonly used disease-modifying anti-rheumatic drug 
(DMARD) to be used in the treatment of RA and progress towards personalisation of 
therapy in RA has been more successful for methotrexate than for any other drug, though 
studies have not yielded consistent results.  Several demographic and clinical factors such 
as male sex, young age, late-onset RA, low disease activity, RF and ACPA status, non 
smoker, short disease duration, mild functional impairment and low level of radiological 
damage have been found to correlate with higher rates of remission in RA for patients 
treated with methotrexate (Katchamart et al. 2010).  However, a study from the NOAR 
register found that clinical and laboratory factors such as age, gender, age at disease onset, 
baseline RF and CRP were poor predictors of response to treatment with methotrexate 
(Hider et al. 2009).  Several inflammatory cytokines have been evaluated for their potential 
to predict response to methotrexate therapy. It has been shown that patients who had a 
good response to methotrexate therapy had a significantly lower ratio of IL-1ra/IL-1 beta, 
cytokines which are produced by peripheral blood mononuclear cells (Seitz et al. 2003).  
High serum TNF levels have also been found to be negatively correlated to treatment 
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responses to methotrexate in patients with RA (Maillefert et al. 2010).  Red blood cell 
methotrexate polyglutamate concentrations have also been proposed as biomarkers of 
response to treatment in RA (Dervieux et al. 2006) but more research is needed as studies 
have demonstrated conflicting results (Stamp et al. 2010). 
 
There have been several studies looking into the genetic factors governing responses to 
treatment with methotrexate.  The presence of the 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) SNP has 
been shown to be associated with a better response to treatment with methotrexate (Keith 
et al. 2012).  Multivariate analysis has demonstrated that four SNPs are associated with 
favourable treatment responses to methotrexate treatment when these data are combined 
with clinical data (Keith et al. 2012). Assessment for the presence of these SNPs is not 
used in clinical practice and this may be due to lack of statistical power in the studies and 
racial variation.  NMR based metabolomics has also been used to predict responses to 
treatment to methotrexate in RA (Wang et al. 2012). A recent study demonstrated that 
serum metabolites correlated with an effective response to methotrexate in patients with 
early RA (Wang et al. 2012).   
 
Following the introduction of biological treatment in RA the ability to predict response to 
therapy is even more important due to the different modes of actions and cost of these 
drugs.  Several clinical factors have been shown to be associated with a poor response to 
TNF antagonists such as smoking and a high level of disability at baseline (Hyrich et al. 
2006).  Lower levels of disease activity and concurrent use of DMARDs, particularly 
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methotrexate have been shown to be associated with a better response to TNF antagonists 
(Hyrich et al. 2006).  
 
Several genetic susceptibility markers such as the shared epitope have been investigated to 
determine if they can predict response to biological therapy but there has been no 
convincing evidence (Emery and Doerner 2011). A meta-analysis assessed the association 
between TNF gene polymorphisms and response to TNF antagonists in RA but found no 
association (Potter et al. 2009). A genome-wide association approach has also been 
conducted to try and identify genetic factors predicting response to TNF antagonists in RA 
(Umicevic et al. 2013). They were unable to replicate any markers that have been 
previously reported but did identify eight new genetic loci, which will need validation in 
an independent cohort (Umicevic et al. 2013).  
 
There have also been several proteomic studies investigating response to TNF antagonists.  
One study identified a combination of 24 biomarkers comprising autoantibodies and 
cytokines which enabled prediction to TNF antagonists (Hueber et al. 2009). Another 
study has identified the cytokines monocyte chemoattractant protein and epidermal growth 
factor to be associated with a good response to TNF antagonists (Fabre et al. 2008). 
However, these studies are limited by small sample size.  
 
Baseline TNF levels have also been investigated in the plasma and the synovium to 
determine if they have a role in the prediction of response in TNF antagonists (Marotte and 
Miossec 2010). A study using plasma levels of TNF demonstrated that the clinical 
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response of patients with high levels of plasma TNF significantly improved with higher 
levels of TNF antagonists (Takeuchi et al. 2011). In general, high local and systemic levels 
of TNF prior to treatment with TNF antagonists have been found to be associated with a 
good response (Marotte and Miossec 2010).  
 
A recent study has investigated the association between central nervous system activity 
and response to TNF antagonists. This study found that responders to TNF antagonists had 
higher baseline activation in thalamic, limbic and associative areas of the brain using MRI 
scanning (Rech et al. 2013). Cytokine concentrations in synovial fluid have also been 
analysed to determine any prediction of response to TNF antagonists. A study found that 
synovial fluid levels of IL-6, IL-2 and G-CSF may predict responses to TNF antagonists 
(Wright et al. 2012). Again, all these studies have small sample sizes.  
 
Several studies have been conducted to try and predict responses to another biological 
therapy, rituximab.  Studies have demonstrated that the presence of antibodies (RF) and 
ACPA) are associated with better responses to rituximab (Emery and Doerner 
2011;Narvaez et al. 2011). A protein biomarker, the interferon signature has been shown to 
be related to response to rituximab therapy in RA. A study found that patients with a type I 
interferon low signature had much better responses to rituximab than those with a high 
signature (Thurlings et al. 2010).  
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In summary, several studies have attempted to predict response to biological treatments in 
RA but they have given conflicting results and are limited by small sample size so further 
studies are still needed. 
 
1.3 Metabolism in inflammatory disease 
1.3.1 The inflammatory process 
An acute inflammatory reaction is characterised by the classic cardinal signs of 
inflammation: heat, redness, swelling and pain (Tracy 2006).  In experimental settings the 
temporal relationships between oedema, accumulation of leukocytes and accumulation of 
monocytes and macrophages are well established.  These events, in self-limited 
inflammatory reactions, are coupled with the release of local factors which prevent further 
release of leukocytes, which allows resolution (Serhan 2009).  The transition from acute 
inflammation to chronic inflammation is widely viewed as an excess of pro-inflammatory 
mediators (Burger and Dayer 1995).   
 
1.3.2 Metabolic consequences of inflammation 
Many factors contribute to the complex course of inflammatory reactions.  
Microbiological, immunological and toxic agents can initiate the inflammatory response 
by activating a variety of humoral and cellular mediators.  In the early phase of 
inflammation, excessive amounts of interleukins and lipid-mediators are released and play 
an important role in the pathogenesis of organ dysfunction (Heller et al. 1998).  
Arachidonic acid (AA) is released from membrane phospholipids during inflammatory 
activation and is metabolised to prostaglandins and leukotrienes.  Various strategies have 
been used to regulate the excessive production of lipid mediators on different levels of 
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biochemical pathways, such as inhibition of phospholipase A2, the trigger enzyme for 
release of AA, blockade of cyclooxygenase and lipoxygenase pathways and the 
development of receptor antagonists against platelet activating factor and leukotrienes 
(Heller et al. 1998).  Some of these agents exert protective effects in different 
inflammatory disorders such as septic organ failure, RA or asthma, whereas others fail to 
do so.  Encouraging results in cardiovascular morbidity have been obtained by dietary 
supplementation with long chain omega-3 fatty acids like eicosapentaenoic acid (EPA) 
(Calder and Yaqoob 2009).  In states of inflammation, EPA is released to compete with 
AA for enzymatic metabolism inducing the production of less inflammatory and 
chemotactic derivatives (Heller et al. 1998). 
 
When investigating inflammation it is important to take into account the many facets of the 
inflammatory environment that have the potential to play a role in pathology. Hypoxia is 
known to be prevalent in inflammatory environments such as those associated with 
wounds, malignant tumours, bacterial infections and autoimmunity (Eltzschig and 
Carmeliet 2011;Murdoch et al. 2005). Increasing hypoxia in the inflammatory site is 
associated with poorer disease outcome such as increased macroscopic synovitis in 
rheumatoid arthritis (Ng et al. 2010).  
 
Normal physiological oxygen levels are thought to range between 5-12% oxygen 
(compared to 21% atmospheric oxygen). However, hypoxic tissue oxygen levels in 
pathological environments can range from as little as 0.5% oxygen to around 2.5% oxygen 
(Biniecka et al. 2010). Local hypoxia develops as a result of either blood vessel occlusion 
by inflamed tissues, or when existing supply is insufficient for increased cellular density 
caused by infiltrating or proliferating inflammatory cells (Biniecka et al. 2010).  
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Additionally, circulating phagocytes can block blood vessels reducing blood flow into the 
inflammatory site (Sitkovsky and Lukashev 2005). Normal tissue structures can lend 
themselves to hypoxia where they are poorly perfused, such as the synovium or the cornea. 
Tissue alteration associated with inflammation can contribute to hypoxia by altering 
pressure within the blood vessels causing vessel occlusion and increasing distances 
between blood vessels (Jawed et al. 1997;Mapp et al. 1995).  
 
There is considerable evidence to support the fact that the inflamed synovium is a hypoxic 
environment. The tumour environment is known to be hypoxic and extensive angiogenesis 
reveals the requirement of the tissue to have a better oxygen supply. In RA, oxygen levels 
in synovial fluid have been directly measured revealing lower oxygen tensions compared 
with synovial fluid from osteoarthritic patients and patients with traumatic joint injuries 
(Lund-Olesen 1970).  
 
An elegant cellular oxygen detection system is used by cells to respond to changes in 
environmental oxygen. Reductions in environmental oxygen lead to the stabilisation of the 
transcription factor hypoxia-inducible factor (HIF) which is otherwise targeted for 
depletion in oxygen-rich environments. HIF consists of two subunits α and β and the 
stability of the α subunit is regulated in an oxygen-dependent manner. Under hypoxic 
conditions the HIF-α escapes degradation and dimerizes with HIF-β (Aro et al. 2012). HIF 
expression is therefore suggestive of hypoxic exposure, and has been detected in 
autoimmune diseases such as RA and multiple sclerosis (Gaber et al. 2009;Hollander et al. 
2001;Lassmann 2003).  HIF is known to be important in inflammatory development, for 
example loss of HIF-1a in macrophages is associated with impaired aggregation, motility, 
invasiveness and killing of bacteria (Cramer et al. 2003).  
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Hypoxia and HIF stabilisation has a large effect on cellular metabolism. HIF causes a 
preference for glycolytic metabolism over oxidative phosphorylation by inducing the 
expression of glycolytic enzymes. This allows ATP generation to continue in the absence 
of sufficient oxygen albeit at a much reduced efficiency per molecule of glucose. It also 
induces the upregulation of lactate dehydrogenase A therefore promoting the conversion of 
pyruvate to lactate (Wheaton and Chandel 2011).  Lactate has been detected in many 
chronic inflammatory conditions such as in inflamed joints (Chang and Wei 2011;Treuhaft 
and MCCarty 1971) multiple sclerosis, pulmonary inflammation (Serkova et al. 2008) and 
is thought to play a role in wound healing (Trabold et al. 2003). Conversely, the acidosis 
associated with increasing lactate concentrations is thought to play a pathogenic role in cell 
transformation and autoantigen development in some inflammatory environments (Chang 
and Wei 2011).  The detection of lactate in metabolomic studies of disease suggests 
therefore that there may be an inflammatory component to the disease being investigated 
which may aid future treatment and understanding. It is also generally accepted that the 
RA joint is hypoxic and this may cause metabolic changes which could aid our 
understanding of the disease pathogenesis. 
 
Systemic inflammation causes changes in metabolism.  An indication of the strong link 
between inflammation and metabolic processes is seen in cachexia, the loss of cellular 
mass associated with disease.  The discovery of the involvement of TNFα in this process 
earnt it the name ‘cachexin’.  While TNFα is now known more generally as a mediator of 
inflammatory responses, the ability of inflammatory cytokines to have such profound 
effects on cellular and metabolic processes is informative.  Rheumatoid cachexia is a result 
of chronic inflammation and this is characterised by the loss of muscle mass and 
29 
 
preservation of fat mass (Evans et al. 2008).  Classically cachexia is characterised by a low 
BMI.  Muscle wasting is a common feature of RA but low BMI is uncommon as the fat 
mass is preserved or even increased (Summers et al. 2008).  Hence, RA patients may 
present with either the classic low BMI cachexia (1-13% of RA population) (Munro and 
Capell 1997) or more frequently, the rheumatoid cachexia (10-20% of RA with controlled 
disease and 38% of patients with active RA) (Engvall et al. 2008;Metsios et al. 2009).   
 
The muscle loss that occurs in rheumatoid cachexia is thought to be due to 
proinflammatory cytokines such as TNF, IL-1 and IL-6.  TNF promotes proteolysis 
through the ubiquitin-proteasome pathway.  There is also some evidence that cytokines 
may prevent an increase in muscle protein synthesis in response to feeding (anabolic 
resistance) (Summers et al. 2010).  In rheumatoid cachexia the degree of muscle wasting is 
associated with the disease activity of RA (Summers et al. 2010).   
 
Low or normal levels of free testosterone are found in men and women with RA and this 
may contribute to rheumatoid cachexia.  Population studies have shown that obesity 
(particularly visceral fat accumulation) is associated with low testosterone levels.  Physical 
activity is reduced in patients with RA, though they have a normal diet.  Therefore patients 
with RA have a positive energy balance and tend to store fat (Metsios et al. 2008b).  This 
may be relevant in rheumatoid cachexia (Summers et al. 2010).   
 
Metabolism is complex and is influenced by genetics and environmental factors.  Systemic 
inflammation causes changes in metabolism and several studies have looked at individual 
metabolites in patients and animal models of inflammation.  We therefore need to look at 
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several metabolites together and the systemic analysis of metabolites known as 
metabolomics allows us to do this.  Using this approach a number of metabolites have 
been identified in inflammatory diseases which have provided insights into the 
mechanisms of disease and are also potential biomarkers.   
 
1.4 Metabolomics 
Given the profound systemic and localised changes in metabolism provoked by 
inflammation and inflammatory cytokines that have been outlined above, it is not 
surprising that the experimental approach known as metabolomics has been used to 
investigate several inflammatory diseases.   
1.4.1 The metabolome 
 
The metabolome is the name given to the complete set of small molecule chemicals found 
within a biological sample. The term metabolome has arisen as a combination of the words 
“metabolite” and “chromosome”. The reason for this term was to demonstrate that 
metabolites are indirectly encoded by genes. The term “metabolome” was first used in 
1998 and was designed to match with existing biological terms referring to the complete 
set of genes (the genome), the complete set of proteins (the proteome) and the complete set 
of transcripts (the transcriptome). The study of the metabolome is called metabolomics.  
 
Unlike proteomics and genomics we are presently unable to identify the complete set of 
metabolites in metabolomics as identification of metabolites is still difficult and metabolite 
libraries can not identify all metabolites that can presently be measured and we are 
presently unable to measure anything with a concentration below 5µM.  
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The metabolome reflects the interaction between an organism’s genome and its 
environment. As a result, the metabolome can act as an excellent probe of its phenotype 
(i.e. the product of its genotype and its environment). We are aware that genetic and 
environmental factors are involved in the aetiology of RA, hence metabolomics may be a 
useful tool in investigating the aetiology of RA. The rationale behind metabolomics is that 
changes in a disease will cause alterations in the levels of certain metabolites.  To qualify 
as a metabolite, or to be considered to be part of the metabolome, a small molecule must 
typically have a molecular weight <1500 Da eg. glycolipids, polysaccharides, short 
peptides and not proteins (measured by proteomics), RNA or DNA (measured by 
genomics). 
 
Metabolomics has been used to identify novel biomarkers and to look into the mechanisms 
of disease process. Metabolomics attempts to systematically identify and quantify 
metabolites from biological samples using approaches including mass spectrometry (MS) 
or nuclear magnetic resonance (NMR).  
 
1.4.2 Approaches to metabolomics 
Metabolomics attempts to systematically identify and quantify metabolites from biological 
samples. The small molecules represent the end result of complex biological processes in a 
given cell, tissue, or organ, and thus form attractive candidates to understand disease 
mechanisms. Metabolites represent a diverse group of low molecular weight structures 
including lipids, amino acids, peptides, nucleic acids, and organic acids, which makes 
32 
 
comprehensive analysis a difficult analytical challenge. The recent rapid development of a 
variety of analytical platforms based on mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) have enabled separation, characterization, detection, and quantification 
of such chemically diverse structures. 
 
Unlike transcriptomics and proteomics, the molecular identity of metabolites cannot be 
deduced from genomic information. Thus, the identification and quantification of 
metabolites must rely on sophisticated instrumentation such as MS and NMR 
spectroscopy. Each of these technologies has its own unique advantages and 
disadvantages. Optimal selection of a particular technology depends on the specific goals 
of a study and is usually a compromise amongst sensitivity, selectivity, and speed. 
1.4.2.1 Mass Spectrometry 
MS offers a good combination of sensitivity and selectivity. Modern MS provides highly 
specific chemical information that is directly related to the chemical and the high 
sensitivity of MS allows detection and measurement of very low levels of many primary 
and secondary metabolites. These unique advantages make MS an important tool in 
metabolomics (Lei et al. 2011). 
1.4.2.2 NMR spectroscopy 
NMR spectroscopy was developed in the 1940s but with the evolution of higher magnetic 
field strengths sensitivity has improved (Nicholson and Lindon 2008). NMR is highly 
selective and non-destructive and is generally accepted as the gold standard in metabolite 
structural elucidation, but it suffers from lower sensitivity than MS. NMR is the only 
detection technique which does not rely on separation of the analytes, and the sample can 
thus be recovered for further analyses (Nicholson and Lindon 2008). A wide range of 
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small molecule metabolites can be measured simultaneously hence, NMR is close to being 
a ‘universal detector’. The main advantages of NMR are high analytical reproducibility 
and simplicity of sample preparation (Beckonert et al. 2007).  NMR is also felt to be more 
reliable than MS for determining concentrations of molecules (Nicholson and Lindon 
2008). 
 
1.4.3 Metabolomics of inflammatory disease 
Metabolomics can be thought of as ‘systems medicine’ as it requires a thorough clinical 
assessment in combination with laboratory measurements to systematically and accurately 
identify metabolites in a meaningful manner from small quantities of biological sample. I 
will now discuss metabolomics in the context of inflammatory diseases in further detail.   
 
1.4.3.1 The Gut 
Crohn’s disease (CD) is a chronic debilitating inflammatory disease of the bowel.  The 
exact aetiology is unknown but is thought to be related to the deregulation of the immune 
response towards gut microflora (Strober et al. 2007).  Urinary metabolite profiling has 
been carried out on a mouse model of CD and five key metabolic differences were 
identified between the CD model and controls.  This suggested that there are alterations of 
tryptophan metabolism, fucosylation and fatty acid metabolism in CD mice and the authors 
concluded that fucose and xanthurenic acid could be useful markers of gut inflammation 
(Lin et al. 2009).   
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A further mouse model of inflammatory bowel disease (IBD) investigating urinary 
metabolites identified that there was an increase in trimethylamine (TMA) and fucose 
compared to controls.  The increase in TMA was parallel to the progression of IBD 
(Murdoch et al. 2008).  A mouse model of ulcerative colitis (UC) investigating serum and 
urinary metabolites (Schicho et al. 2010) found that both serum and urine samples were 
equally accurate for detecting colitis but the metabolites responsible for the differences 
were different for both biofluids.   
 
Faecal extracts have also been used to study IBD (Bezabeh et al. 2009).  It is sometimes 
difficult to distinguish CD from UC and earlier identification could aid treatment and 
prognostication.  Metabolomic analysis of faecal extracts of patients with both 
inflammatory diseases showed reduced levels of butyrate, acetate, methylamine and TMA 
compared to control (Marchesi et al. 2007).  Comparing the UC and CD samples glycerol, 
alanine, isoleucine, leucine, lysine and valine were present in higher quantities in CD 
compared to UC.  Acetate was lower in CD compared to UC (Marchesi et al. 2007).  
Metabolic differences were more marked in CD indicating that inflammation is more 
extensive in CD compared to UC.   
 
Urinary metabolites have also been used to distinguish CD and UC in humans (Williams et 
al. 2009).  They found that specific urinary metabolites related to gut metabolism differed 
between CD, UC and controls.  Hippurate was lowest in CD and differed significantly 
between CD, UC and controls.  Formate levels were higher in CD than in UC or controls 
and 4-cresol sulphate was lower in CD than in UC or controls (Williams et al. 2009).  
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Hippurate has been shown to be modulated according to gut microbes and this difference 
is likely to reflect changes in intestinal microbes.   
 
A recent study of IBD in humans used serum, plasma and urine samples to try and 
distinguish UC from CD and to distinguish IBD from controls (Schicho et al. 2012). The 
authors identified that all three biofluids could be used to distinguish between IBD and 
controls but different metabolites were more prominent in different biofluids (methanol, 
mannose, formate, isoleucine, urea and citrate for plasma and serum but mannitol, 
allantoin, xylose, carnitine, betaine and hippurate in urine). They felt that the metabolic 
differences were less pronounced between UC and CD.  
 
In summary, several studies have looked at metabolomics of IBD and have demonstrated 
that in mice and in humans TMA is an important marker of IBD (Marchesi et al. 
2007;Murdoch et al. 2008) using both urine samples or faecal extracts.  Hence, TMA may 
be a useful biomarker for IBD. Several different biofluids have also been used in the 
metabolomics of IBD and though they all yield important distinguishing metabolites the 
metabolites are different between the biofluids suggesting that different biofluids may give 
us different input into the aetiology of disease.  
 
1.4.3.2 The Eye 
As a closed and immunopriveleged site, the eye provides an ideal system for metabolic 
analysis.  Metabolic products of inflammatory infiltrates accumulate in the vitreous fluid 
of the eye and may be extracted during ocular corrective surgery.  Metabolomics has been 
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used to look at vitreous humour in order to differentiate ocular inflammatory diseases 
(Young et al. 2009).  Vitreous fluid samples were taken from patients undergoing retinal 
surgery and analysed using NMR.  Patients had various retinal disorders including chronic 
non-infectious uveitis (CU), acute lens-induced uveitis (LIU), proliferative diabetic 
retinopathy, proliferative vitreoretinopathy, rhegmatogenous retinal detachment, candida 
endopthalmitis and varicella zoster virus acute retinal necrosis.  The different disease 
groups showed clear separation using principle component analysis (PCA) and partial least 
squared discriminate analysis (PLSDA).  The majority of the patients had LIU and CU.  
When looking at LIU and CU specifically there was clear separation and urea, 
oxaloacetate and glucose were all raised in LIU compared to CU.  As urea and 
oxaloacetate are both involved in the urea cycle it suggests that there is more active 
inflammation in the LIU patients (Young et al. 2009).   
 
NMR has also been used to determine ocular metabolism in porcine eyes (Greiner et al. 
1985).  Using phosphorous NMR they found phosphorous containing metabolites in 
aqueous and vitreous fluids (Greiner et al. 1985).  In addition to quantifying metabolites, 
phosphorous NMR can be used to monitor the rate of metabolic change in a specific 
biochemical reaction and the rate of change in the concentration of a particular metabolite 
(Greiner et al. 1985).  Phosphorous NMR provides a non-invasive method to analyse 
ocular tissues metabolically and detect subtle biochemical changes that precede 
manifestations of disease.  Such detection may allow for early and more effective 
therapeutic intervention. 
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1.4.3.3 Neurological disease 
Multiple sclerosis is a chronic inflammatory disease affecting the nervous system.  Its 
aetiology is still not completely understood (Ibrahim and Gold 2005) but it is characterised 
by demyelination, axonal loss and breakdown of the blood-brain barrier (Trapp et al. 
1999).  It is a heterogeneous, relapsing and remitting disease and different treatments have 
been shown to work at different stages of disease (Rieckmann and Smith 2001), so it is 
important to identify biomarkers that enable identification of different phases.   
 
IL-1β and TNF-α have been found to be associated with a broad spectrum of neurological 
diseases including multiple sclerosis. Griffin et al investigated rat urine samples to 
determine whether NMR spectroscopy could detect the presence of IL-1β and TNF-α 
induced lesions and distinguish between the pathology caused by the cytokines (Griffin et 
al. 2004).  They used an adenoviral vector to induce chronic endogenous expression of 
either IL-1β or TNF-α and found significant differences between the groups, with the IL-
1β treated group showing increases in leucine, isoleucine, valine, n-butyrate and glucose 
whilst the TNF-α treated group showed increases of citrate, 2-oxoglutarate and succinate 
(Griffin et al. 2004).   
 
NMR spectroscopy has also been used to analyse cerebrospinal fluid (CSF) in patients 
with multiple sclerosis and evidence suggests that there are increased CSF levels of lactate, 
creatinine and fructose in multiple sclerosis compared to control patients (Nicoli et al. 
1996).  Two additional unidentified signals were found to be elevated in multiple sclerosis 
and the compound responsible for both these signals has now been identified as B-
hydroxyisobutyrate (Lutz et al. 2007).  This is a typical partial degradation product of 
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branched-chain amino acids and increased B-hydroxyisobutyrate in urine samples is 
thought to be due to respiratory-chain deficiency leading to impaired oxidation of NADH 
(Chitayat et al. 1992).  However the level of B-hydroxyisobutyrate in these experiments 
was much higher than the level found in multiple sclerosis patients.  The precise role of B-
hydroxyisobutyrate in multiple sclerosis needs further investigation.   
 
Using a rat model of multiple sclerosis, metabolomics of CSF has revealed changes in 
metabolite levels over the course of the disease suggesting profound changes in central 
nervous system metabolism over the course of disease (Noga et al. 2012). The pathways 
that were altered included nitric oxide synthesis, energy metabolism, polyamine synthesis 
and levels of endogenous antioxidants.  
 
1.4.3.4 Lung disease 
Pulmonary inflammation contributes to the pathogenesis of a number of lung diseases and 
there is a growing need for validated experimental models that can help our understanding 
of disease pathogenesis and therapeutic intervention.  Traditionally animal models have 
been used but they have their own problems in representing human disease.  Genetic 
manipulation can greatly enhance animal models.  NMR has had some application in the 
quantification of experimental lung injury.   
 
Serkova et al used Magnetic Resonance Imaging and NMR to try and detect and quantify 
injury in mice following intratracheal administration of inflammatory cytokines (Serkova 
et al. 2008).  Pulmonary inflammation was induced by intratracheal administration of IL-
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1β and TNF-α.  Lung tissue was used for the NMR metabolomics and they demonstrated 
that with pulmonary inflammation there was a 50% depletion of ATP and a corresponding 
elevation of the lactate to glucose ratio suggesting a shift to anaerobic metabolism during 
inflammation.  These returned to control levels at 24 hours (Serkova et al. 2008) 
illustrating that intratracheal administration of IL-1β and TNF-α leads to profound but 
reversible pulmonary inflammation which is detectable by NMR.   
 
1.4.3.5 Osteoarthritis 
Osteoarthritis (OA) is a complex disease and has a multifactorial pathogenesis.  It has 
many known risk factors such as age, sex, obesity, activity level, prior joint damage and 
genetic susceptibility but is not classically thought of as an inflammatory disease, though it 
may have an inflammatory element.  There are currently no disease-modifying drugs for 
OA and very few in development.   
 
Synovial fluid (SF) has been used to investigate OA via NMR.  SF is widely regarded to 
be a good medium to study as the SF is the first place where the degradation products, 
enzymes and signal transduction molecules involved in OA are released from the cartilage 
matrix.  The SF should therefore have a higher concentration of metabolites compared to 
blood, lymph or urine.   
 
Damayanovich et al used SF from a canine model of OA to look at metabolic profiles 
using NMR (Damyanovich et al. 1999a).  They compared metabolites from experimentally 
induced canine knee OA SF to metabolites from SF of normal canine knees and found 
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large increases in lactate and decreases of glucose in OA SF compared to normal SF 
suggesting that the intraarticular environment of an OA joint is more hypoxic and acidic 
than a healthy joint. They also found increased levels of pyruvate, lipoprotein associated 
fatty acids, glycerol and ketones in OA SF suggesting that lipolysis may be an important 
source of energy in OA.  There were also elevated levels of N-acetylglycoproteins, acetate 
and acetamide in OA SF especially with progressive OA (Damyanovich et al. 1999a).   
 
In order to try and investigate further the mechanisms underlying OA progression, 
Damayanovich et al looked at the effect of joint afferent nerve injury (Damyanovich et al. 
1999b) using a bilateral canine model of OA.  Paired SF samples were taken from dogs 
which had undergone bilateral anterior cruciate ligament transaction, unilateral knee 
denervation and contralateral sham nerve exposure. Increases in glycerol, hydroxybutyrate, 
glutamine, creatinine, acetate and N-acetyl-glycoprotein were seen in the SF from 
denervated compared to control knees.  This suggested that the metabolite differences seen 
in the denervated knees was due to the aggravation of OA caused by joint denervation 
(Damyanovich et al. 1999b).  Hydroxybutyrate is also found in SF of RA patients 
(Naughton et al. 1993a) suggesting that it is more of a marker of joint destruction rather 
than being specific for any joint disease.   
 
Another group used guinea pigs to look at OA (Lamers et al. 2003) as they develop 
spontaneous progressive knee OA with features similar to human disease.  The earliest 
histological features appear at 3 months but this progresses to extensive cartilage 
degeneration after 12 months.  Urine samples were collected from these OA pigs and from 
healthy pigs at 10 and 12 months of age.  They identified a metabolic fingerprint that 
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reflected OA changes in the pigs composing of lactic acid, malic acid, hypoxanthine and 
alanine suggesting their involvement in OA (Lamers et al. 2003). The presence of 
hypoxanthine suggests that OA may be an inflammatory disease due to the increased 
oxygen demand and altered purine metabolism.   
 
Mass spectroscopy has also been used to look for novel biomarkers of knee OA (Zhai et al. 
2010).  They looked at serum samples of unrelated Caucasian females with and without 
knee OA where knee OA was defined as radiographic, medically diagnosed or total knee 
replacement due to primary OA.  They found that the ratio of valine to histidine and the 
ratio of xleucine to histidine was significantly associated with knee OA in humans (Zhai et 
al. 2010).  These ratios have potential clinical use as an OA biomarker.  OA branched 
chain amino acids (BCAA) are raised which may drive the release of acetoacetate and 3-
hydroxybutyrate and these can result from the partial oxidation of leucine.  BCAA are 
essential amino acids and therefore cannot be synthesised within the body.  An increased 
level of BCAA may suggest an increased rate of protein breakdown or be secondary to 
collagen degradation.  BCAA increase production of the cytokines IL-1, IL-2, TNF and 
interferon (Bassit et al. 2000) which could drive the collagen degradation.   
 
1.4.3.6 Rheumatoid arthritis 
Hyaluronic acid is a major component of the proteoglycan aggregate of articular cartilage 
which is required for the functional integrity of extracellular matrix.  In RA, SF 
hyaluronate is depolymerised by the action of reactive oxygen radical species (Parkes et al. 
1991) and hyaluronidase activity is absent in both normal and inflamed SF.  Generation of 
reactive oxygen species plays a principal part in synovial hypoxic reperfusion injury 
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(Farrell et al. 1992).  This occurs as increased intra-articular pressure during exercise 
exceeds synovial capillary perfusion pressure leading to impaired blood flow (Mapp et al. 
1995).   
 
In 1993, the Inflammation Research Group at the London Hospital Medical College looked 
at the NMR profiles of RA SF and matched serum samples (Naughton et al. 1993a).  The 
NMR profiles of SF were markedly different from their matched serum samples and there 
were high levels of lactate in the SF compared to the serum and low levels of glucose in 
the SF compared to the serum.  These changes are consistent with the hypoxic status of the 
rheumatoid joint (Naughton et al. 1993a).  All the SF samples (RA and control) had lower 
levels of chylomicron and very-low-density-lipoprotein associated triglycerides compared 
to their matched serum samples.  The SF samples also had high levels of ketone bodies 
compared to their matched serum samples.  These results suggest that the intra-articular 
environment has an increased utilisation of fats for energy even though it is hypoxic 
(Naughton et al. 1993a;Naughton et al. 1993b).  They were unable to compare the control 
SF to the rheumatoid SF due to the low levels of SF aspirated.   
 
Serum from mice has been used to identify a metabolite biomarker pattern associated with 
RA (Weljie et al. 2007).  Using NMR they found that uracil, xanthine and glycine could be 
used to distinguish arthritic from control animals (Weljie et al. 2007).  The presence of the 
metabolites suggests that nucleic acid metabolism may be highly affected in RA and there 
may be an association with oxidative stress.   
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More recently, a group in Denmark have looked at the plasma of patients with RA 
(Lauridsen et al. 2010).  They found differences in the metabolic profiles between patients 
with RA and healthy controls and differences between patients with active RA and RA in 
remission.  The metabolites that they identified which discriminated between the patients 
with active RA and healthy controls were cholesterol, lactate, acetylated glycoprotein and 
lipids.  The lactate levels represented oxidative damage and thus indirectly reflected active 
inflammation.  This suggests that the underlying inflammatory processes drive significant 
changes in metabolism that can be measured in the peripheral blood and metabolomics 
may prove useful as a measure of the extent of disease, potentially separating low disease 
activity states from patients in true remission. 
 
A recent clinical study has used synovial fluid from patients with RA to investigate lipid 
profiles (Giera et al. 2012). They identified almost 70 different lipid components; some 
with anti-inflammatory and some with pro-resolving properties. Traditional Chinese 
medicine has also been used in combination with metabolomics to further categorise 
different types of patients with RA (van Wietmarschen et al. 2012). They investigated the 
clinical chemistry, metabolomics of urine and plasma samples and symptom profiles of 39 
patients with RA. They combined this with traditional Chinese medicine (using Cold and 
Heat type methodology) and demonstrated significant biochemical differences between 
different subgroups of patients with RA suggesting that there are different mechanisms of 
disease progression and that treatments could be tailored accordingly. Metabolomic studies 
in RA have also illustrated that they can predict the response to a particular treatment 
(Wang et al. 2012). In a study of 38 patients with active RA there was a significant 
difference in the serum levels of certain metabolites between those who demonstrated a 
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clinical response to methotrexate monotherapy compared to those who did not respond 
(Wang et al. 2012).  
 
1.4.3.7 Inflammatory changes in metabolites 
As summarised above there is now a growing body of literature describing metabolomic 
changes in inflammatory diseases, both in humans and animal models.  There have been 
few studies looking at metabolomics in RA.  The studies looking at metabolomics in other 
inflammatory disease may help with our study in RA as there appears to be several 
common metabolic features of inflammation.  Multiple metabolites have been identified in 
the other inflammatory disorders using various biofluids but there is a theme of increased 
energy requirement with inflammation.  Studies in RA demonstrate that patients with RA 
have an increased energy requirement mainly due to the increased production of TNF 
(Metsios et al. 2008a). The studies in multiple sclerosis (Nicoli et al. 1996), OA 
(Damyanovich et al. 1999a) and inflammatory lung disease (Serkova et al. 2008) have 
found an increase in lactate and the studies in inflammatory eye disease (Young et al. 
2009) and inflammatory lung disease (Serkova et al. 2008) have shown a reduction in 
glucose.  The studies in RA point to the joint having a hypoxic environment (Naughton et 
al. 1993a;Naughton et al. 1993b) and an association with oxidative stress (Weljie et al. 
2007).  Xanthine has been shown to distinguish RA from controls in mice (Weljie et al. 
2007) and this has also been shown in inflammatory bowel disease (Schicho et al. 2012).   
 
Though there are several metabolites which have been identified in many inflammatory 
conditions there are unique metabolites associated with individual disease suggesting that 
there may be some distinctive features within the metabolic profiles of arthritis patients 
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which may be identifiable from a metabolomic analysis and enable us to gain insights into 
the aetiology and pathogenesis of RA. 
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1.5 Summary 
RA involves a complex interaction between genes and the environment with a significant 
effect on systemic metabolism.  As metabolism is influenced by both genetics and lifestyle 
analysis of metabolites may provide novel insights into the early stages of inflammatory 
disease.  
 
1.6 Aims and hypothesis 
The central aims for this project are: 
1. To test the hypothesis that chronic synovial inflammation alters metabolism. 
2. To test the hypothesis that the metabolic profile expressed by an individual patient 
in the earliest stage of inflammatory arthritis predicts the subsequent course of the 
disease.  I will test whether we can use metabolomics to generate a ‘fingerprint’ 
characteristic of arthritis-dependent changes in blood and in vitro cultured synovial 
fibroblasts.   
3. To test the relationship between disease outcome and the metabolic profile to 
identify novel biomarkers for RA and inflammatory disease.   
  
47 
 
2.0 Materials and methods 
2.1 Samples 
2.1.1 Serum 
Blood was collected in vacutainer tubes containing clotting accelerator (Greiner Bio-one) 
at the first visit to the early arthritis clinic at Sandwell and West Birmingham Hospitals 
NHS Trust.  Samples were then transferred to the University of Birmingham where they 
were centrifuged at 600g for 10 minutes, serum removed and then stored at minus 800C 
until analysis.  Samples were also collected at follow up visits.   
 
2.1.2 Urine 
Mid-stream urine samples were collected at the first visit to the clinic, centrifuged as above 
and stored at minus 800C.   
 
2.1.3 Fibroblasts 
Synovial fibroblasts from the early arthritis patients and established RA (DMARD naive) 
were grown from the biopsy material taken using ultrasound guidance (de Sande et al. 
2011) via explant culture.  Tissue was collected from multiple regions within the knee, 
ankle or metacarpopharyngeal (MCP) joints in which there was evidence of grey scale 
synovitis. Ultrasound guidance was used to introduce a single port through which tissue 
was sampled using custom manufactured 2.0mm cutting edge forceps (knee and ankle) or 
a 16g core biopsy needle (MCP joint). Each assessment was carried out using multiple 
biopsy samples taken systematically from different locations in the joint in order to 
overcome synovial heterogeneity (Scire et al. 2007). Normal synovial fibroblasts were 
obtained from patients presenting with knee pain for arthroscopy, who had no macroscopic 
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or clinical evidence of inflammation.  For the longstanding established RA control 
experiments tissue was obtained from the Royal Orthopaedic hospital and fibroblasts were 
cultured from these.  All samples were kept on ice until they could be processed at the 
university. Synovial tissue was cut into 1mm sections to allow more efficient breakdown 
of extracellular matrix components and subsequent growth of cells and collected into 10 
ml of wash buffer (RPMI, 20mMHEPES). Resulting cell suspension was washed twice 
and cultured in fibroblast medium.  Cultures were incubated in 0.2% collagenase at 37oC 
(Salmon et al. 1997) allowing adherent cells to become attached to the plastic.  All cells at 
passage four were run through a flow cytometer under basic single colour staining panel 
for quality control to ensure that all cells were fibroblasts. Panel included fibroblast marker 
(CD90) for conformation plus a macrophage (CD68) and an endothelial cell marker 
(CD31) for exclusion. 
 
2.2 Fibroblast cell culture 
2.2.1 General culture guidelines 
Fibroblast cultures were supplemented with fresh culture medium once weekly by 
replacing two thirds of the old culture medium with new culture medium.   
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2.2.1.1 Fresh complete fibroblast medium 
This was composed of: 
RPMI 1640 (Sigma R0883) (for full list of components see appendix) 
10% Foetal calf serum 
1% (100X) MEM Non-essential amino acids (Sigma M7145) 
1% (100mM) Sodium Orthopyruvate (Sigma S8636) 
2mM glutamine 
100U/ml penicillin 
100micrograms/ml streptomycin 
 
2.2.1.2 Phosphate buffered saline 
Phosphate buffered saline (PBS) was prepared from tablets purchased from Oxoid 
(BR14A) by dissolving 1 tablet in 100ml of water and autoclaving before use. 
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2.2.2 Trypsinisation of cells (splitting) 
When the fibroblasts were visually confluent they were split (i.e. cells were trypsinised and 
reseeded into new flasks at a lower density).  By convention, every time a culture is split 
its ‘passage number’ rises by 1.  The reagents used were complete fibroblast medium, 
(10X) Trypsin-EDTA solution (Sigma T4174) and PBS. 
1. A bottle of fresh complete fibroblast medium was pre-warmed to 37OC.   
2. (2X) trypsin-EDTA solution was prepared by diluting the stock solution 1:4 in 
PBS. 
3. Conditioned medium was collected from the flask and kept for the new flasks. 
4. The cells were washed with PBS once to remove excess medium. 
5. (2X) trypsin-EDTA solution was added to the flask to cover the cells.  Flasks were 
incubated at 370C for five minutes.   
6. Microscopy was used to check that the cells had detached. 
7. 8mls of fresh complete fibroblast medium were added to the flask and the cells 
were collected into a polypropylene tube.   
8. Tube was centrifuged at 300g for 6 minutes.  Supernatant was discarded.   
9. Cells were resuspended in 1ml of complete fibroblast medium and cell numbers 
and viability assessed using a Neubauer counting chamber following staining with 
Trypan blue.   
10. 33% conditioned medium was prepared by diluting conditioned medium1:2 in 
fresh complete fibroblast medium.   
11. The pellet was resuspended in 33% conditioned fibroblast medium and seeded into 
flasks as required.   
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2.2.3 Cell quenching and extraction protocol: 
Fibroblasts were trypsinised between passages once cells had reached confluence but when 
adequate number of fibroblasts for NMR experiments had been obtained metabolites were 
extracted using methanol, since trypsinisation has been shown to affect NMR results (Teng 
et al. 2009). 
1. Media was aspirated (2x1ml was kept for NMR and cytokine analysis and frozen at 
-80°C) 
2. 1x wash with 10ml PBS at room temperature and fluid aspirated 
3. 1x wash with 10ml 60% methanol at -48°C (by placing the methanol on dry ice) 
and fluid aspirated 
4. 3.5 ml -48°C methanol added and flask placed on dry ice 
5. cells scraped into methanol with a cell scraper 
6. cell extract transferred into two 2ml microcentrifuge tubes and snap frozen in 
liquid nitrogen 
7. 3x freeze/thaw cycle (liquid nitrogen/dry ice) 
8. Samples dried under vacuum using a Speedvac centrifugal drier overnight and 
stored at -80°C prior to liquid/liquid extraction 
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2.3 Cell extraction procedure to produce samples for NMR 
Once the fibroblasts were extracted, a methanol-chloroform liquid cell extraction 
procedure was used to precipitate the proteins and remove lipids to leave the water 
soluble metabolites in the extract.   
1. all four 1.5ml polypropylene microcentrifuge tubes (two from each of the two T75 
flasks) in succession were re-suspended in methanol:water (600μl:540μl)** and 
pooled into a glass vial containing 600μl chloroform 
2. glass vial was vortexed for 30seconds 
3. vial left to stand on ice for 10 minutes 
4. vial centrifuged at 4°C, 1500g for 10 minutes 
5. vial left to stand on bench for 5 minutes 
6. upper polar layer removed and placed into an polypropylene microcentrifuge tube  
7. polar fraction dried in speedvac overnight and stored in -80°C prior to NMR 
analysis - **300µl methanol and 300µl water were added to the 2nd polypropylene 
microcentrifuge tube, vortexed for 30seconds, etc. until the supernatant was 
transferred to the 4th polypropylene microcentrifuge tube. The supernatant was then 
transferred to the glass vial with 600µl chloraform. 300µl methanol and 240µl 
water were added to the 1st polypropylene microcentrifuge tube (in order to recover 
as much as possible), vortexed for 30seconds and spun for 30seconds at 16000g, 
transferred to 2nd polypropylene microcentrifuge tube and repeat vortexed and 
spun, etc. until the supernatant was transferred, vortexed and spun into the 4th 
polypropylene microcentrifuge tube, then pooled into the glass vial with the first 
supernatant and chloroform. 
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2.4 Sample preparation for NMR 
2.4.1 Materials 
3-trimethylsilyl 2,2,3,3-tetradeuteropropionic acid (TMSP), Isotec. 
NMR tubes:standard series 5mm NMR tubes, Norell. 
NMR tubes standard series 1.7mm, Bruker. 
Filters: Nanosep 3K omega, Pall.  
Deuterium oxide (D2O) 99.9%, Aldrich. 
NaH2PO42H2O (S/3760/53, Fisons Scientific Equipment) 
Sodium azide (S8032-100G), Sigma 
 
2.4.2 Preparation of sodium phosphate buffer 
A phosphate buffer of pH 7 was prepared by mixing 0.624g NaH2PO42H2O, 40mg sodium 
azide, 3.44mg TMSP and 4mls of D2O to give a final concentration of D2O of 10%. Final 
volume of 10mls was made using distilled water and pH was adjusted to pH7 using 2M 
NaOH.  
 
2.4.3 Serum samples 
After thawing, some serum (unfiltered) was diluted 1:1 with D2O/H2O containing NaCl 
(150mM) TMSP and sodium phosphate (20mM) pH 7.  Filters were washed 6 times using 
warm water (380C) (0.5ml) and each time centrifuged at 3 000g for 15minutes to remove 
preservative glycerol (Tiziani et al. 2008).  After thawing some sera was filtered and 
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centrifuged at 40C for 15 minutes at 10 000g.  Filtered sera (50µl) were diluted with 16.7µl 
of buffer containing D2O, TMSP, sodium azide and sodium phosphate.   
 
2.4.4 Urine samples 
After thawing, urine samples (1ml) were centrifuged at 16000g for 5minutes.  Samples 
were prepared using a standard protocol that has been used in other studies of urine (Viant 
et al. 2007).  Urine samples were buffered with phosphate buffer (100mM), made 10% 
with D2O and 0.5mM with TMSP and the pH adjusted (twice over 30minutes) to pH 7.0.  
The samples were centrifuged at 15700g for 2 minutes and the pH of the samples was 
adjusted again to obtain a pH of 7-7.05.  0.6ml of sample was placed into a standard 5mm 
NMR tube for spectroscopy.   
 
2.4.5 Fibroblast medium samples 
Filters were washed 6 times using warm water (380C) (0.5ml) and each time centrifuged at 
3 000g for 15minutes to remove preservative glycerol (Tiziani et al. 2008).  Fibroblast 
medium was then filtered and centrifuged at 40C for 15 minutes at 10 000g.  Samples 
(50µl) were diluted with 16.7µl of buffer containing D2O, TMSP, sodium azide and 
sodium phosphate.   
 
2.4.6 Fibroblast cells 
Once the sample had been dried in the Speed-vac, 50µl of water and 16.7µl of buffer 
containing D2O, TMSP, sodium azide and sodium phosphate was added to each sample.   
55 
 
2.5 Metabolomic analysis 
One-dimensional 1H spectra were acquired at 300K using a standard spin-echo pulse 
sequence with water suppression using excitation sculpting on a Bruker DRX 500MHz 
NMR spectrometer equipped with a cryoprobe or using a standard NOESY sequence on a 
Bruker 600MHz NMR spectrometer.  Excitation sculpting makes use of pulsed field 
gradients and generally produces much flatter baselines (Jerschow 1999).  It is useful in 
samples which contain large amounts of protein, which will distort the baseline.  
Excitation sculpting was not required on the Bruker 600 as all samples were filtered.  Two-
dimensional 1H J-resolved (JRES) spectra were also acquired to aid metabolite 
identification (Ludwig and Viant 2010).  
 
Samples were processed and data normalised with respect to the TMSP signal.  Spectra 
were read into Prometab (Viant 2003) which is custom written software in Matlab (version 
7, The Math Works, Natick, MA), and were truncated to a 0.8-10.0 ppm (parts per million) 
range.  Spectra were segmented into 0.005 ppm (2.5Hz) chemical shift ‘bins’ and the 
spectral areas within each bin were integrated.  In many metabolomics studies, NMR 
spectra are divided into bins of fixed width.  This spectral quantification technique is used 
to reduce the number of variables for pattern recognition techniques and to mitigate effects 
from variations in peak positions.  Spectra were corrected for baseline offset and then 
normalised to a total spectral area of unity and a generalised log transformation was 
applied, which stabilises the variance of the data effectively making the data more suitable 
for multivariate analysis (Viant 2003).  Binned data were then compiled into a matrix, with 
each row representing an individual sample.  
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2.6 Statistical analyses 
2.6.1 Principal components analysis (PCA) 
The data bins from groups of spectra were mean centred and then assessed by PCA using 
the PLS_Toolbox (version 5.8) (Eigenvector Research) in Matlab (release 2009a) 
(Mathworks). PCA analysis identifies regions of the spectrum which allow segregation in 
order to identify metabolites.   
 
PCA is a mathematical technique that yields patterns and relationships in multivariate 
datasets, enabling an understanding into the causes and effects behind these relationships. 
The basis of this method is the generation of a new coordinate system where the new 
variables are independent linear combinations of the original variables and also capture 
some features in the original data. A feature illustrates some aspect of the data, described 
as numerical values for each object. The fundamental basis behind PCA is the relationship 
between the numerical values for each object (Webb-Robertson et al. 2005). 
 
PCA is a mathematical procedure which transforms a number of possibly correlated 
variables in a large multivariate dataset into a smaller number of uncorrelated variables 
called principal components, with little information loss.  The first principal component 
accounts for as much of the variability in data as possible and each succeeding component 
accounts for as much of the remaining variability as possible.  PCA simply describes the 
data. 
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2.6.2 Partial least square discriminant analysis (PLS-DA) 
PLS-DA was used to perform supervised clustering of samples (Chauchard et al. 2004;De 
Jong 1990) and on some occasions an orthogonal signal correction was applied (OPLS-
DA) to enhance the separation of groups and to achieve better models in multivariate 
calibration (Gavaghan et al. 2002). The PLS-DA models were cross-validated using 
Venetian blinds (Chauchard et al. 2004;De Jong 1990), a method which re-assigns 
randomly selected blocks of data to the PLS-DA model to determine the accuracy of the 
model in correctly assigning class membership.  
 
2.6.3 GALGO 
GALGO (Genetic ALGOrithm), a statistical package available in the statistical 
environment R, uses a genetic algorithm search procedure coupled to statistical modelling 
methods for supervised classification (Trevino and Falciani 2006).  The results of GALGO 
analyses are presented as principle component analysis (PCA) plots where the X and Y 
axes represent first and second principle components providing the greatest variation 
between samples, and the next largest unrelated variation respectively.  GALGO analysis 
was cross validated using K-fold cross validation where the original sample is randomly 
partitioned into subsamples and each observation is used for both training and validation.  
 
GALGO, like any genetic algorithm, is based on randomly generated data whereas the 
fundamental principle behind PCA and PLSDA are the correlation of different components 
within the data. GALGO undergoes several ‘generations’ of analysis and in each 
generation the fitness of each individual within the data is evaluated.  The individuals 
which fit best are then selected and the next generation of analysis begins.  The algorithm 
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is complete when the maximum number of generations has been produced or a satisfactory 
fitness level has been achieved for all the individuals. It has been shown that genetic 
algorithms optimise the results of other models by removing irrelevant variables, which 
dramatically improves the classification ability of the model (Ramadan et al. 2006).  
 
2.6.4 Partial least squares regression analysis (PLS-R) 
PLS-R is a regression method that identifies which metabolites can predict a continuous 
variable and enables the correlation of complex metabolomic data with a relatively simple 
clinical parameter. This analysis yields r2, a measure of the cross-validated goodness-of fit 
of the linear regression, while permutation testing (multiple analyses using random data 
subsets) assessed the significance of this prediction (McLeod et al. 2009).   
 
2.6.5 Identification of metabolites 
Lists of metabolites providing the greatest discrimination between groups were then 
identified for each technique. Using multivariate analyses, peaks with large loadings (for 
PCA), weightings (for PLS-DA) or regression coefficients (for PLS-R) were identified. 
For the PLS-DA models variable importance for projection (VIP) were calculated to 
produce a summary of how important each variable was in the data for predicting the 
classification. NMR databases (Human Metabolome Database version 2.5) and Chenomx 
NMR suite (Chenomx, professional version 4.0) (Weljie et al. 2006) were used to identify 
the metabolites (Figure 2.1). The two dimensional JRES were also used to identify 
metabolites using the FIMA software (Ludwig et al. 2012).   
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Figure 2.1 Chenomx profiler identifying metabolites in a spectrum. A spectrum is 
uploaded into chenomx and the chenomx profiler uses its library to identify metabolites in 
the spectra. The metabolite citrate is matched by the profiler as the peaks of the metabolite 
citrate (2.7, 2.5) match that in the spectrum. 
 
2.7 Enzyme-linked immune-sorbent assays (ELISAs) 
Levels of IL-6 in supernatants (in duplicate) of cultured fibroblasts were measured by 
ELISA according to the manufacturer’s instructions (eBioscience: human IL-6). Plates 
were washed using the Bio-red Bioplex Pro plate washer. The assay was read using the 
Anthos htIII spectrophotometric plate reader and Stingray software. Wash buffer used was 
1 x PBS, 0.05% Tween-20 and stop solution was sulphuric acid. 
1. ELISA plate coated with 100µl/well of capture antibody in Coating Buffer. Plate 
sealed and incubated over night at 40C. 
60 
 
2. Wells aspirated and washed five times with >250µl/well of wash buffer. 
3. Wells blocked with 200µl/well of Assay Dilutent. Incubated at room temperature 
for one hour. 
4. Wells aspirated and washed five times with >250µl/well of wash buffer. 
5. 100µl/well of standard and 100µl/well of sample added to the appropriate well.  
Plate sealed and incubated at room temperature for two hours. 
6. Wells aspirated and washed five times with >250µl/well of wash buffer. 
7. 100µl/well of detection antibody added. Plate sealed and incubated at room 
temperature for one hour. 
8. Wells aspirated and washed five times with >250µl/well of wash buffer. 
9. 100µl/well of the enzyme Avidin-HRP added. Plate sealed and incubated at room 
temperature for 30 minutes. 
10. Wells aspirated and washed seven times with >250µl/well of wash buffer. 
11. 100µl/well of substrate solution added to each well. Plate incubated at room 
temperature for 15 minutes. 
12. 50µl of stop solution added to each well. 
13. Plate read at 450nm. 
 
2.8 Multiplex analysis 
Supernatants (in duplicate) of cultured fibroblasts were used for the multiplex analyses.  
The assay was performed according to manufacturer’s instructions using the following 
VersaMAPTM  Custom Premixed Multiplex (R&D systems): 
MMP-9, IL-8, IL-10, VEGF, MIP-1 alpha, IL-4, MMP-3, MMP-1, MCP-1, MMP-13, 
RANTES, IP-10 
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Plates were washed using the Bio-rad Bioplex Pro plate washer and the assay was read 
using the LUMINEX 100 TM System. 
1. 100 µl of wash buffer added to each well. Liquid removed through the filter at the 
bottom of the plate using a vacuum manifold. 
2. 50 µl of the Microparticle Cocktail added to each well. 
3. 50 µl of standard or sample added to each well. Plate sealed and incubated at room 
temperature on a horizontal microplate shaker for two hours. 
4. Vacuum manifold used to wash the plate by removing the liquid.  100µl of wash 
buffer added to each well and liquid removed again. 
5. 50 µl of diluted Biotin Antibody Cocktail added to all the wells. Plate sealed and 
incubated at room temperature on a horizontal microplate shaker for one hour. 
6. Vacuum manifold used to wash the plate by removing the liquid.  100µl of wash 
buffer added to each well and liquid removed again. 
7. 50 µl of diluted Stretavidin-PE added to each well. Plate sealed and incubated at 
room temperature on a horizontal microplate shaker for 30 minutes. 
8. Vacuum manifold used to wash the plate by removing the liquid.  100µl of wash 
buffer added to each well and liquid removed again. 
9. 100µl of wash buffer added to each well to resuspend the microparticles. Plate 
sealed and incubated at room temperature on a horizontal microplate shaker for 2 
minutes. 
10. Plate read and double discriminator gates set at 7500 and 15 500. 
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3.0 Quality Control of the biofluids used 
3.1 Blood 
3.1.1 Introduction 
The ready accessibility of blood from most patients means that blood cells, plasma and 
serum are often used in metabolomic studies. Blood is a useful biofluid in metabolomic 
studies as it contains a broad complement of metabolites (Zhang et al. 2010) but a lack of 
standardization for collection protocols may impact on the validity and reproducibility of 
results.  Sample quality control can be an issue, particularly when samples are collected in 
a routine clinical setting, where variation in sample handling can significantly impact on 
the quality of the sample and hence the data derived from it. This has also been identified 
as an important issue in assessment of RNA in transcriptomic studies (van der Veen et al. 
2009).  Metabolites may be susceptible to variation since they may be subject to enzymatic 
or chemical conversion after sample collection. Subsequent storage conditions may also 
have an effect, for example, the number of freeze-thaw cycles the sample has gone through 
and the storage temperature (Teahan et al. 2006).  Causes of such biases are not always 
obvious but can result from the type of tube in which the sample was collected and the 
length of time the sample was left at room temperature before being processed, cooled or 
frozen for storage.  
 
A number of groups have investigated the stability of components of human plasma and 
serum over time but the majority of analytes targeted in these studies have been proteins, 
enzymes and metal ions (Boyanton and Blick 2002;Zhang et al. 1998).  There are 
relatively few studies of the effects of variations in sample handling for metabolomics 
analyses.  Plasma or serum metabolites are subject to constant flux as long as catalytically 
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active enzymes or interacting proteins are present and so removal of proteins is desirable 
to enhance the consistency of metabolite content prior to analysis. One disadvantage of 
removing proteins is that metabolites bound to proteins are removed. However, this has 
little impact on NMR spectra of metabolites since when these molecules are tightly bound 
to proteins; they would have large line widths and so are unlikely to be resolved in NMR 
spectra. Some small molecules with an intermediate affinity for proteins (KD μM to mM) 
would show altered intensities. This potential minor loss has to be balanced against the 
increased reproducibility of deproteinised samples and, of the various methods used to 
remove proteins from blood samples, ultrafiltration (using nanosep centrifugal filters) was 
found to be superior to precipitation (acetone extraction, acetonitrile extraction, perchloric 
acid precipitation and methanol/chloroform extraction) in retaining metabolite 
concentration and offering reproducibility (Tiziani et al. 2008).   
 
Metabolomic studies have demonstrated good reproducibility of metabolite concentrations 
over variable time periods of sample handling in both plasma and serum (Yu et al. 2011).  
However, studies of the relative benefits of using these fluids have given conflicting 
results with one study showing that reproducibility over time (approximately one hour) 
was significantly better for plasma than for serum (Yu et al. 2011) and another study 
illustrating that human serum metabolite profiles were more reproducible (i.e. clustered 
more closely) than those from human plasma (Liu et al. 2010).  
 
In order to minimize the artefactual variability in data derived from either serum or plasma 
it important to use a highly reproducible standard operating procedure for collection and 
preparation of blood samples for metabolomics.  However, in bringing metabolomic 
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analyses into the mainstream of clinical practice in the routine hospital clinic, one of the 
least controllable variables is the time taken between the taking of the blood and storage, at 
low temperature, of the plasma or serum.  A previous study assessed the effects of delays 
of up to 3 hours on the metabolites (Teahan 2006). However, in a routine clinic, delays of 
longer than this can occur. Furthermore Teahan et al only assessed the impact of sampling 
handling variables on whole serum/plasma NMR spectra, whereas in more recent studies 
the strong preference is to remove proteins prior to analysis. 
 
In order to further investigate the factors which impact on the variability of metabolite 
analysis that might impinge on samples collected in a routine clinical environment, we 
have assessed the effects of time delays of up to 6 hours, on the stability of metabolite 
profiles derived from deproteinised serum and plasma collected from healthy donors. We 
have also assessed the cooling of samples on ice and an initial centrifugation to sediment 
cells, prior to further processing in these donors.  
 
3.1.2 Materials and methods 
3.1.2.1 Patients 
3 healthy individuals (males 42, 48 and 59 years of age) were recruited from staff at the 
University of Birmingham.  The local ethics committee approved the study and all donors 
gave written informed consent (see appendix).  None of the subjects had a current infection 
and had had no infections within the previous month.  They also had none of the 
following: inflammatory arthritis, inflammatory bowel disease, psoriasis, liver disease, 
inflammatory lung disease or asthma, kidney disease or multiple sclerosis.   
65 
 
3.1.2.2 Experimental plan 
We aimed to investigate the stability of components of human plasma and serum over time 
ex vivo, assessing whether placing blood samples on ice immediately after collection and 
prior to processing and whether rapid versus delayed separation of cells from serum and 
plasma affected the metabolic profiles measured in serum and plasma.  We also aimed to 
compare these different conditions for filtered and non-filtered serum and plasma.  Seven 
tubes of serum (containing clotting accelerator (Greiner Bio-one)) and eight tubes of 
plasma (containing lithium heparin (Greiner Bio-one)) were taken from the 3 donors. The 
pathway that was followed for sample handling is shown in Figure 3.1.  The addition of 
anticoagulants such as lithium heparin or EDTA to whole blood inhibits clot formation and 
reduces the loss of blood proteins and their bound substrates.  It has been shown that 
EDTA produces strong signals for CaEDTA and MgEDTA complexes as well as free 
EDTA in 1H NMR spectra (Nicholson et al. 1983) and so plasma was collected using 
lithium heparin.   
 
The earliest post collection processing time chosen for the serum samples was 30 minutes 
– the length of time it takes for blood to consistently clot in the presence of clot 
accelerator.  The other time points were chosen to reflect clinical practice.  Final serum 
and plasma samples were stored at minus 80°C until NMR analysis.  Samples were 
prepared as 2.4.3 and NMR spectra acquired.   
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Figure 3.1: Experimental plan for investigating the effect of different sample 
collection methods on metabolomic analysis of blood (plasma and serum).  Plasma was 
investigated at all time points but serum was not spun until 30minutes.  Centrifugation was 
at 600g for 10 minutes.    
 
3.1.3 Results 
3.1.3.1 Unfiltered plasma and serum 
NMR spectra of plasma and serum are shown in Figure 3.2. Here we assessed a number of 
sample collection and processing variables that may impact on the use of metabolomics 
within a clinical setting. These included time post blood collection and prior to 
centrifugation to separate the clot from serum and cells from plasma.  When data from all 
the different sampling conditions used to produce the unfiltered plasma were aggregated 
from the 3 donors, and subjected to non-supervised analysis (Figure 3.3A), this 
demonstrated a clear separation of donor 2 but some overlap between donors 1 and 3 
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(p<0.0001 when comparing the PC1 values using one-way analysis of variance 
(ANOVA)).  Non-supervised analysis of unfiltered serum (Figure 3.3C) produced a clear 
separation of all the donors regardless of the sampling conditions (p<0.0001 for the PC1 
values using ANOVA).  Supervised analyses (Figure 3.3B and 3.3D) enhanced the 
separation for unfiltered plasma and serum with good sensitivity and specificity.   
 
B 
A 
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Figure 3.2: NMR spectra of plasma (A) and serum (B) from the same individual. 
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Figure 3.3: 1D 1H NMR spectra of non-filtered plasma and serum from all 3 control 
donors for all conditions combined (time points, ice/no ice and initial centrifugation). 
The values on the axis labels indicate the proportion of the variance captured by each 
principal component.  ▼=control 1 ●=control 2 and ■=control 3. PCA of plasma samples 
(A) and supervised analysis (PLS-DA) of plasma samples (B) separate with a sensitivity of 
100% and specificity of 96.7%. PCA of serum samples (C) and supervised analysis (PLS-
DA) of serum samples separate with a sensitivity of 92.9% and specificity of 100% (D). 
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3.1.3.2 Filtered plasma and serum 
Non-supervised analysis of filtered plasma (Figure 3.4A) demonstrated that there was 
separation of donors 1 and 3 but some overlap with donor 2 when combining all the 
sampling conditions for each donor (p<0.0001 for the PC1 values using ANOVA). Non-
supervised analysis of filtered serum (Figure 3.4C) illustrated that there was some overlap 
of all the donors (p=0.0219 for the PC1 values using ANOVA).  Supervised analyses 
(Figure 3.4B and 3.4D) enhanced the separation for filtered plasma and serum for all 3 
donors regardless of the sampling conditions with good sensitivity and specificity.   
 
These data demonstrate that the main variance in the metabolic profiles of collected 
biofluids resulted from differences between individuals and not from the effect of the 
different sampling handling protocols.  This implies that the metabolic differences between 
individuals may still be detected where samples are not collected in a strictly controlled 
manner (e.g. differing time periods between collection and freezing of serum or plasma 
derived from the blood) or whether serum or plasma is collected.   
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Figure 3.4: 1D 1H NMR spectra of filtered plasma and serum from all 3 control 
donors for all conditions combined (time points, ice/no ice and initial centrifugation). 
The values on the axis labels indicate the proportion of the variance captured by each 
principal component.  ▼=control 1 ●=control 2 and ■=control 3. PCA of plasma samples 
(A) and supervised analysis (PLS-DA) of plasma samples (B) separate with a sensitivity of 
92.9% and specificity of 93.1%. PCA of serum samples (C) and supervised analysis (PLS-
DA) of serum samples (D) separate with a sensitivity of 92.3%and specificity of 96.3%. 
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3.1.3.3 Stability of metabolites over time 
Metabolic profiles of both plasma and serum displayed good stability of metabolites and 
concentrations (over 6 hours) regardless of the sampling conditions. Inter-donor variability 
was much greater than the intra-donor variability for both filtered and non filtered blood 
(Figures 3.3 and 3.4).  Interestingly, inter-donor variability was more pronounced for non-
filtered blood than for filtered blood, perhaps deriving from the presence of lipids or 
lipoproteins in non-filtered blood, which may differ significantly between individuals.  
Using the PLSDA models for serum and plasma separately, peaks with a VIP of >1 were 
identified which were responsible for the separation between samples taken at baseline and 
those taken at 360 minutes (Table 3.1).  Lactate (p=0.0174) and pyruvate (p=0.0017) were 
the only metabolites for which concentrations altered significantly when plasma remained 
in contact with cells and similarly lactate (p=0.0417) and pyruvate (p=0.0278) altered 
significantly when serum was in contact with cells and clot (Figure 3.5).  Variation due to 
sample collection time was minimized by incubation of blood on ice prior to separation 
into serum or plasma or by an initial centrifugation to minimise cell to supernatant contact. 
Both approaches successfully mitigated the effects of cellular contact on lactate 
concentrations. In contrast, pyruvate still altered significantly in the serum on ice 
(p=0.0174) but did not alter significantly if there was an initial centrifugation (Figure 3.5).  
 
Significant differences in metabolic profiles were found between the blood samples that 
had been left for different time periods prior to centrifugation and these were similar for 
plasma and serum.   
  
73 
 
Peaks 
(ppm)in 
plasma 
which 
had a 
VIP>1 
Peaks 
(ppm)in 
serum 
which 
had a 
VIP>1 
8.46 7.83 
4.66 4.14 
4.14 4.13 
4.13 4.12 
4.12 4.11 
4.10 3.92 
3.92 3.90 
3.90 3.86 
3.86 3.83 
3.84 3.75 
3.80 3.72 
3.72 3.56 
3.70 3.52 
3.57 3.50 
3.55 3.46 
3.54 3.43 
3.51 3.36 
3.50 3.24 
3.48 3.03 
3.41 2.83 
3.39 2.43 
3.27 2.42 
3.25 2.38 
3.24 2.07 
3.23 2.06 
2.45 2.04 
2.38 2.03 
1.93 1.49 
1.48 1.47 
1.33 1.34 
1.32 1.33 
1.05 1.04 
1.00 0.98 
0.94 0.95 
Table 3.1 Peaks in ppm from the PLSDA weightings plot of serum and plasma over 
time which had a Variable Importance of Projection (VIP) of >1. 
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Figure 3.5: Filtered blood from control samples at different time points highlights 
differences in the metabolite lactate in the plasma (A) and in the serum (B) and 
pyruvate in the plasma (C) and in the serum (D) with time. Friedman test; p*<0.05, 
p**<0.01, NS=not significant.   
 
3.1.4 Discussion 
Others have studied the effect of varying sample collection times on metabolomic data 
(Teahan et al. 2006).  Teahan et al investigated the effect of storage on ice or not, post 
collection and prior to further processing, for both plasma and serum and a range of time 
delays in sample processing.  In this study we extended the time course to include a 6 hour 
time point to reflect the longest time delay likely to be experienced in most routine clinical 
settings. Here we have demonstrated a gradual increase in lactate up to 3 hours but a larger 
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increase after this point. We have also demonstrated that the increase in the concentration 
of pyruvate parallels that for lactate. Teahan et al also found variation in lactate arising 
from the serum-clot time, with the largest variation being with the longest delay in 
processing, though clotting on ice seemed to reduce this variation (Teahan et al. 2006). 
This was based on the analysis of whole serum and plasma, which are not ideal samples 
for metabolomic analysis due to the potential for protein-dependent distortion of the 
spectra.  However, our data demonstrate in both filtered (deproteinised) and whole plasma 
and serum that only lactate and pyruvate change significantly and that no other 
confounding metabolites were revealed by the filtration process. 
 
This study demonstrates that significant variation in levels of lactate and pyruvate may 
result over time following sample collection, and that this may be affected by sampling 
conditions for both plasma and serum (Figure 3.5).  Pyruvate and lactate are intimately 
linked in the glycolytic pathway.  This variation in pyruvate and lactate concentration may 
be mitigated by initial centrifugation of the sample and likely reflect the pyruvate 
consumption and lactate production by red blood cells (Wiback and Palsson 2002).  
Ideally, time prior to centrifugation should be kept to a minimum and samples should be 
collected on ice to reduce variation.  However, if centrifugation or ice are not available in 
the clinical setting and sample processing cannot be performed in a timely manner; we 
suggest it may be important to exclude lactate and pyruvate in subsequent analyses. This 
work demonstrates that there is very little variation in the concentration of other 
metabolites and indicates that, with the above caveats, blood samples from routine clinical 
practice can confidently be used in metabolomic studies.  
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3.2 Urine 
3.2.1 First void or random urine 
Several studies have used urine samples for metabolomic analysis (Lin et al. 
2010;Williams et al. 2009).  We are aware that it is important for samples to be collected 
in a controlled manner to obtain consistent and accurate NMR results.  We wished to 
ascertain the reproducibility of different forms of urine samples. A first void urine sample 
and a random urine sample were collected on three different occasions from eight control 
subjects.  Triplicates of each sample were analysed by NMR. 
 
The PCA data are shown in Figure 3.6 and the PLSDA data are shown in Figure 3.7 and 
3.8.  There are marked differences between the First Void and the Random urine samples 
of each individual control.  However, it is still possible to distinguish each individual 
control subject very well from the other controls.  The three separate urine samples for 
each collection type from each individual are very reproducible. For example samples 1, 2 
and 3 are very similar and samples 4, 5 and 6 are very similar but 1, 2 and 3 are very 
different from 4, 5 and 6.   
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Figure3.6: 1D 1H NMR spectra of First Void (●) and Random (○) urine samples were 
subjected to PCA. The values on the axis labels indicate the proportion of the variance 
captured by each principal component. This demonstrates marked differences between first 
void and random urine samples.
 
Figure 3.7: 1D 1H NMR spectra of First Void (●) and Random urine samples (○) 
were subjected to supervised analysis (PLS-DA). The values on the y axis label indicate 
the proportion of the variance captured by each principal component.  The first 3 first void 
urine samples (●) are from the same control.  The three random urine (○) samples for the 
same control donor follow the 3 first void (●) samples. First void urine samples are very 
different from random urine samples for each individual. 
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Figure 3.8: 1D 1H NMR spectra of First Void (●) and Random urine samples (○) 
were subjected to supervised analysis (PLS-DA). The values on the axis labels indicate 
the proportion of the variance captured by each latent variable.  Urine samples of the same 
sampling type are very reproducible. 
 
3.2.2 Discussion: urine 
Urine is a very important and useful biofluid for investigating metabolites.  It is easily 
accessible and requires little preparation for NMR as it only contains small amounts of 
protein so there is little interference or need for filtration.  NMR analysis is strongly 
influenced by pH and as the pH of urine can be extremely variable samples need a higher 
concentration of phosphate buffer (Lindon et al. 1999;Miyataka et al. 2007).  There has 
been no previous work using urine samples in the metabolomics of RA as most studies 
have used serum, plasma or synovial fluid (Lauridsen et al. 2010;Naughton et al. 
1993a;Parkes et al. 1991;Weljie et al. 2007).  Urine samples have been used for 
metabolomic studies quite widely in other inflammatory conditions including 
inflammatory bowel disease (Lin et al. 2009;Lin et al. 2010;Williams et al. 2009) and have 
produced interesting and useful findings.   
 
-4 -2 0 2 4 6
-5
0
5
Scores on LV 2 (23.50%)
Sc
or
es
 o
n 
LV
 1
 (2
6.
99
%
)
79 
 
We found large differences between the first void and random urine samples for each 
individual but the individuals could be easily identified from each other and the samples 
were very reproducible.  Previous work looking at urine sample collection has shown that 
normal urine is metabolically stable for 24 hours post collection at room temperature 
(Maher et al. 2007).  However, differences in the NMR spectra have been seen with the 
different methods of urine collection e.g. 24hour urine, first void urine and random urine 
samples.  Previous work has demonstrated that the inter-donor variability is the greatest 
factor but the time of day that a sample is collected does play a part.  Others have found 
that first void urine was the least reliable method of collecting urine in terms of 
reproducibility and that samples taken later in the afternoon were more reliable (Lenz et al. 
2003;Maher et al. 2007).  This is thought to be the effect of creatinine being most 
concentrated in the morning.  Therefore, in view of reproducibility and ease of sample 
collection we concluded like others that the use of random urine samples was appropriate 
for our metabolomic studies in RA (Assfalg et al. 2008). 
 
3.3 Number of fibroblasts required to produce a NMR spectrum 
3.3.1 Introduction 
No previous published work has been done using fibroblast cells in NMR based 
metabolomics although there is a significant body of work using NMR in cancer cells.  
Cancer cells grow very rapidly and the number of cells used in these experiments has been 
approximately 50 million (Musacchio et al. 2009).  Fibroblast cells grow much slower so 
we wanted to define the minimum number of cells we could use to produce a NMR 
spectrum which could be used to potentially distinguish between fibroblasts in different 
metabolically active states.   
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3.3.2 Materials and methods 
Samples were produced using 1 x 106 synovial fibroblast cells.  A representative spectrum 
produced is shown in Figure 3.9.   
 
Figure 3.9: Spectrum produced using 1 x 106 synovial fibroblast cells demonstrating 
several metabolites 
 
Extracts from one million cells produced a spectrum with good resolution (peaks in close 
proximity could be easily distinguished) but we wished to ascertain if spectra of fibroblasts 
could be used to assess potential differences between early inflammatory arthritis that 
resolves and early arthritis that persists.  We therefore compared one, two and three T75 
flasks of synovial and dermal fibroblasts (as these sites can be distinguished in terms of T 
cell and neutrophil accumulation) from two different patients with established RA to see if 
the two sites could be distinguished metabolically.  Each T75 flask usually contains 
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between half a million and one million fibroblasts at confluence.  It is well known that 
fibroblasts from different anatomical regions display characteristic phenotypes that are 
maintained after prolonged culture in vitro, suggesting that many fibroblasts have an 
imprinted phenotype that is stable (Buckley et al. 2001).  Fibroblasts from patients with 
established RA were fed as per section 2.2.1.  Two or three flasks were combined and the 
cells were extracted as per section 2.2.3 and 2.3.   
 
3.3.3 Results 
The PCA data shown in Figure 3.10 demonstrates the differences between the fibroblasts 
of the 2 different RA patients and the differences between synovial and dermal fibroblasts.  
We then overlaid the spectra for 1, 2 and 3 flasks for each cell line to identify the 
differences in metabolites due to the different numbers (Figure 3.11).   
  
82 
 
 
Figure 3.10: 1D 1H NMR spectra of RA synovial and dermal fibroblasts were 
subjected to PCA. The values on the axis labels indicate the proportion of the variance 
captured by each principal component.  The synovial fibroblasts (●) and the dermal 
fibroblasts (○) represent fibroblasts from the same patient.  The synovial fibroblasts (■) 
and the dermal fibroblasts (∆) represent fibroblasts from the same patient.  Samples 1, 4, 7 
and 10 represent one T75 flask, samples 2, 6, 8 and 11 represent two T75 flasks and 
samples 3, 5, 9 and 12 represent three T75 flasks.  
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Figure 3.11 1D 1H NMR spectra from one, two and three T75 flasks of RA synovial 
and dermal fibroblasts from two different established RA patients.  
A and B illustrate the synovial fibroblasts and C illustrates the dermal fibroblasts from the 
same RA patient. D illustrates the synovial fibroblasts and E illustrates the dermal 
fibroblasts from the other RA patient. One T75 flask is depicted in blue, two T75 flasks are 
depicted in red and three T75 flasks are depicted in green. 
  
On overlying the spectra no peaks were visibly lost but the peak heights of the metabolites 
were much smaller for one flask compared to two or three flasks.  The peak heights were 
similar for two and three T75 flasks particularly for synovial and dermal fibroblasts of cell 
line 22 (Figure 3.11 A, B and C).   
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3.4 Fibroblast medium 
3.4.1 Introduction 
Fibroblasts are grown in complete fibroblast medium.  Metabolites are used by the cells 
from this medium and are also extruded from the cells into this medium.  We envisaged 
that this conditioned medium may be a good source for studying the metabolic activity of 
fibroblasts.   
 
The medium of cells has not been used for NMR previously but we were interested to 
explore whether it might give us a significant amount of useful information.  When 
fibroblasts are split the passage number increases by one and this is done when the cells 
appear visually confluent which is very subjective.  How confluent the cells are may affect 
metabolism, although it is felt that synovial fibroblasts do not undergo contact inhibition 
(Lafyatis et al. 1989).  The number of fibroblasts present, and the quantity of metabolites 
extracted, may also affect metabolism, though this should not affect our results, since the 
analysis of the NMR data involves a normalisation of the NMR spectra to correct for 
differences in overall concentration.   
 
In order to investigate the number of fibroblasts present, and the quantity of metabolites 
extracted, I collected fibroblast medium from cell lines at different weeks of growth. To 
investigate the effect of different passages on metabolic profiles I examined the fibroblast 
medium of a cell line and compared the different passages (P2 to P10) to see how different 
their NMR spectra were.  Most researchers use synovial fibroblasts in the range of P2 to 
P5 as at higher passages there is a reduction in proliferation rate and senescence 
(Zimmermann et al. 2001).  Though cells either differentiate or we select different 
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subpopulations over time, central pathological characteristics which appear to be imprinted 
such as IL-6 expression and invasiveness in the SCID mouse model remain present over 
many passages (Hirth et al. 2002;Mueller-Ladner et al. 1996).  A recent study has looked 
at the effect of different passages in RASF and gene expression and they found that there 
was little change in gene expression using P2-P4 but there were alterations in gene 
expression in passages above this (Neumann et al. 2010).  However, we were not aware if 
higher passages affect metabolites and we aimed to determine this by analysing our 
samples.   
 
3.4.2 Materials and methods 
The conditioned medium of established RA synovial fibroblasts was kept and stored 
during the feeding process.  The samples were prepared as section 2.4.5 and were 
compared to normal fresh complete fibroblast medium.  Conditioned medium was also 
taken from the same synovial fibroblasts one week after each split to represent medium 
from different passages.  To try and standardise the process as much as possible these 
samples were collected from a set number of cells (10 000) one week after splitting.  
Fibroblast medium was also collected from cell lines at different weeks of growth after this 
to represent different numbers of cells. Fibroblast cultures were supplemented with fresh 
culture medium once weekly by replacing two thirds of the old culture medium with new 
culture medium. The old culture medium was collected at weekly intervals. It was not 
possible to count the number of cells accurately during the growth period without splitting 
the cells but the increase in number of cells can be seen visually by microscopy without 
splitting.  The spectra from these samples were compared to determine the contribution of 
variability in cell numbers to the results of NMR experiments.   
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3.4.3 Results 
There are clear differences between fresh fibroblast medium and conditioned medium and 
this difference all seems to be on PC1 (Figure 3.12).   
 
 
Figure 3.12: 1D 1H NMR spectra of normal (●) and Conditioned (○) fibroblast 
medium were subjected to PCA. The values on the axis labels indicate the proportion of 
the variance captured by each principal component.  All the conditioned medium was 
taken from one established RA cell line.  There are marked differences between the normal 
and conditioned fibroblast media. 
 
There are clear differences between conditioned medium from synovial fibroblasts of 
different cell lines, regardless of passage by both PCA (Figure 3.13) and PLSDA (Figure 
3.14).   
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Figure 3.13 1D 1H NMR spectra of medium from fibroblasts at different passages (P2 
to P10) were subjected to PCA. The values on the axis labels indicate the proportion of 
the variance captured by each principal component.  The different symbols represent the 
three different cell lines.  The cell lines are easily distinguishable regardless of the passage. 
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Figure 3.14 1D 1H NMR spectra of medium from fibroblasts at different passages 
were subjected to supervised analysis (PLS-DA). The values on the axis labels indicate 
the proportion of the variance captured by each principal component.  The different 
symbols represent the different cell lines.  The cell lines are easily distinguishable 
regardless of the passage. 
 
There are clear differences between conditioned medium of different cell lines on both 
PCA (Figure 3.15) and PLSDA (Figure 3.16) regardless of the number of fibroblasts that 
have been growing in it.   
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Figure 3.15 1D 1H NMR spectra of fibroblast medium containing different numbers 
of fibroblasts were subjected to PCA. The values on the axis labels indicate the 
proportion of the variance captured by each principal component.  The different symbols 
represent the three different cell lines.  The cell lines are easily distinguishable regardless 
of the number of fibroblasts. 
 
Figure 3.16 1D 1H NMR spectra of fibroblast medium containing different numbers 
of fibroblasts were subjected to supervised analysis (PLS-DA). The values on the axis 
labels indicate the proportion of the variance captured by each principal component.  The 
different symbols represent the different cell lines.  The cell lines are easily distinguishable 
regardless of the number of fibroblasts and PLSDA enhances this separation. 
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3.5 Discussion: Fibroblasts and fibroblast medium 
There has been no published research using fibroblasts in NMR based metabolomics. The 
majority of research in NMR based metabolomics has used cancer cell lines (Teahan et al. 
2011) and this has been based on large number of cells, a position which is made feasible 
by the fact that the cell lines are fast growing.  As no previous research has used 
fibroblasts and they are much slower growing than cancer cells we wanted to determine 
the minimum number of fibroblast cells that we could use in our experiments.   
 
The study we did using approximately 1 million cells did produce a NMR spectrum but we 
were unsure whether this spectrum would give us sufficient information to detect any 
potential differences between the fibroblasts from patients with different types of 
inflammatory arthritis.  We compared spectra of dermal and synovial fibroblasts from two 
different patients as we hypothesised that there would be metabolic differences between 
these sites in view of the research demonstrating differences in the pattern of T cell and 
neutrophil accumulation between these sites (Filer et al. 2006).  The PCA results 
demonstrate differences (Figure 3.10) between the synovial and dermal fibroblasts for one, 
two and three T75 flasks.  We were unaware which metabolites may alter between 
fibroblasts from early arthritis that go on to develop persistent arthritis and fibroblasts from 
patients whose arthritis resolves.  Hence, we compared the spectrum from one, two and 
three flasks of the same cell type and line (Figure 3.11) to determine if any metabolites 
were lost by using fewer cells.  We did not identify any metabolites that were lost but we 
did find that the peak heights were much smaller when cells were used from one flask 
compared to two or three flasks.  Also, the cell lines that we used for this experiment grew 
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quite well compared to average synovial fibroblasts as the number of cells per flask varied 
from 0.7 million to 1.6 million.   
 
Our work in cell culture illustrates that dermal fibroblast grow more rapidly than synovial 
fibroblasts and the number of cells in a confluent flask are also greater. Hence, we 
hypothesised that the synovial fibroblasts from patients with early arthritis may not all 
grow as well as the fibroblasts in this experiment.  We also speculated that the metabolic 
differences between fibroblasts from different sites may be greater than the differences 
between fibroblast from the same site in different conditions.  Therefore we used two T75 
flasks for all our future experiments.   
 
The conditioned medium from fibroblasts from different cell lines could be distinguished 
regardless of the passage or the number of fibroblast that had been grown in it.  This 
suggests that NMR may be able to differentiate between the metabolic profiles of different 
RA patients using fibroblast medium as the investigating biofluid.   
 
3.6 Conclusions 
We have conducted quality control experiments for several different biofluids which can 
be used in NMR based metabolomics. We have demonstrated that both filtered and 
unfiltered serum and plasma can be used from routine clinical practice.  Blood samples 
should be processed in a timely manner as the metabolites lactate and pyruvate alter over 
time. However, there is very little variation in the concentration of other metabolites and 
indicates that, with the above caveats, blood samples from routine clinical practice can 
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confidently be used in metabolomic studies. Our work with urine samples illustrated 
marked differences between random urine sample and first void urine samples but good 
reproducibility for each collection type. Therefore, in view of reproducibility and ease of 
sample collection we concluded that the use of random urine samples was appropriate for 
our metabolomic studies in RA. 
 
Our work with fibroblast cells comparing the number of fibroblasts grown in one, two and 
three T75 flasks did not demonstrate any loss of metabolites between the three sampling 
conditions but we did find a difference in peak height between one flask compared to two 
or three. Therefore we chose to use two T75 flasks for all future experiments.  Our work 
using fibroblast media illustrated that normal fibroblast media could be easily 
distinguished from conditioned media and that different cell lines could be clearly 
identified regardless of the passage or number of fibroblasts. However, to minimise any 
confounding factors we planned to use media from cells with similar numbers and those 
that were passage matched. All this work suggests that these biofluids may give us 
interesting results using NMR based metabolomics.  
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4.0 DATA (Differentiating the mechanism of action of anti-TNF-α 
agents) study  
4.1 Introduction 
The introduction of anti-TNFα treatment has revolutionised the management of RA (Furst 
et al. 2011;Keystone et al. 2004;Maini et al. 1999;Spencer-Green 2000).  Several agents 
are available within this class but response rates are imperfect: only 26-42% of patients 
achieve a good EULAR response within 6 months (Bazzani et al. 2009;Bennett et al. 
2005;Rau 2005).  Given the high cost of these therapies, and implications for disease 
progression in non- responders waiting for 3 to 6 months for clinical reassessment, the 
ability to predict treatment responses at baseline is an important goal. Several approaches 
have been used to attempt to predict responses to TNF antagonists but most of these are 
relatively weak. Clinical factors such as smoking and high levels of disability at baseline 
are associated with a poor response to TNF antagonists (Hyrich et al. 2006) and concurrent 
use of methotrexate is associated with a better response to TNF antagonists (Hyrich et al. 
2006). Multiple genetic factors have been investigated for predicting responses to TNF 
antagonists in RA but there has been no convincing evidence (Emery and Doerner 
2011;Potter et al. 2009;Umicevic et al. 2013). Proteomic studies have also been used to 
investigate responses to TNF antagonists but these are limited due to small sample size 
(Fabre et al. 2008;Hueber et al. 2009). Hence, new approaches are needed.  
 
In addition to synovitis there are widespread systemic effects mediated by 
proinflammatory cytokines that impact upon metabolism.  Muscle wasting is a common 
feature of RA and its extent is associated with RA disease activity (Summers et al. 2010) 
but low BMI is uncommon, as fat mass is preserved or even increased (Summers et al. 
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2008).  The extent of the metabolic changes and the types of metabolites seen may 
therefore be good markers of cytokine mediated inflammatory processes in RA.  
 
Metabolomic analysis, based on nuclear magnetic resonance (NMR) spectroscopy of 
biofluids, can be used to identify a broad range of metabolites simultaneously.  Using this 
approach, the identification of several metabolites in cancer and cardiovascular disease has 
provided insights into disease mechanisms and has highlighted their potential as 
biomarkers of disease activity and response to therapy (Brindle et al. 2003;Pan et al. 
2011;Sreekumar et al. 2009).  
 
Systemic changes in many low molecular weight metabolites are reflected by their levels 
in urine and, indeed, metabolomic analysis of urine samples has been used in inflammatory 
conditions such as inflammatory bowel disease (IBD) (Murdoch et al. 2008;Schicho et al. 
2010;Williams et al. 2009) to successfully distinguish different types of IBD, and to 
identify the presence of ongoing intestinal inflammation.  Metabolomic profiles have also 
been shown to alter during therapy (Pan et al. 2011). Consequently, we sought to assess 
whether metabolomic profiles in the urine may have a role in predicting responses to TNF 
antagonists in patients with RA and PsA.   
 
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis.  RA and PsA 
are different diseases both clinically and pathologically.  However, clinically they can 
often be difficult to distinguish as it is possible for a patient with PsA to be classified as 
having RA using the 1987 ACR classification criteria (Arnett et al. 1988).  Pathologically 
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PsA is very different to RA in terms of the osteoclast and osteoblast progenitor numbers 
and the high levels of RANKL and osteoprotegerin in PsA (Veale et al. 2005).  The 
cytokines also vary between the synovial tissue of RA and PsA with the interferon gamma 
levels being significantly higher in RA patients (Canete et al. 2000).  Patients with PsA 
often have lower levels of inflammation, less deforming disease and less systemic 
involvement than patients with RA.  Recent data suggests that patients with PsA may not 
respond to the same treatments used in RA (Kingsley et al. 2010).  Hence, it is very 
important to predict responses to treatment in patients with RA and PsA and to distinguish 
between patients with RA and PsA.   
 
4.2 Patients 
Patients were part of a multicentre study (Glasgow Royal Infirmary (PsA patients only), 
Queen Elizabeth Hospital, Birmingham (PsA patients only), and Charing Cross Hospital, 
London (RA patients only) comparing responses to infliximab and etanercept.  All patients 
were aged 18 or over.  RA patients were required to fulfil 1987 ACR classification criteria 
(Arnett et al. 1988), to be positive for rheumatoid factor (RF) and/or anti-CCP antibodies, 
have a disease duration > 6 months and a DAS28 score > 4.0.  The PsA patients were 
required to have psoriasis at screening, >3 swollen and >3 tender peripheral joints, 
negativity for RF and anti-CCP antibodies and a disease duration > 6 months. All patients 
had failed treatment with at least one DMARD and were treated with methotrexate at a 
dose of at least 7.5mg weekly, stable for at least 4 weeks prior to commencing anti-TNFα 
therapy.  No other DMARDs were allowed within the 4 weeks prior to commencing 
treatment but prednisolone was allowed provided the dose remained stable and did not 
exceed 10mg daily.   
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Participants were randomised to either infliximab 3mg/kg at weeks 0, 2 and 6 and then 
every 8 weeks until week 46, or etanercept 25mg twice weekly for 52 weeks.  Therapy was 
kept stable for the first 3 months.  After 3 months, therapy could be changed as required, 
including escalation of methotrexate therapy to 25mg weekly in apparent non-responders.  
Clinical data, including ESR, DAS28 and HAQ scores, were collected at baseline and 
monthly up to week 52.  A good clinical response was defined as a DAS 28< 3.2 and a 
DAS 28 improvement> 1.2 after therapy (van Gestel et al. 1998) in RA.  A good response 
in PsA was defined as an improvement in 2 factors (with at least one being a joint score) 
with worsening in none of the following four factors: patient and physician global 
assessments, tender and swollen joint scores (Clegg et al. 1996).  Random urine samples 
were collected from the patients at baseline and at 12 weeks and were snap frozen and 
stored at -800C.  The study was conducted in compliance with the Helsinki declaration and 
ethical approval was obtained from the West Glasgow Ethics Committee.  All subjects 
gave written informed consent. 
 
Urine samples were prepared as described in section 2.4.4 and then subjected to NMR 
spectroscopy.  Glutamine levels were measured in the urine samples using high 
performance ion-exchange chromatography and xanthurenic acid levels were measured 
using a fluorometric method (Liu et al. 1996) which used a solid-phase extraction column.   
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4.3 Results 
Demographic data are shown in Table 4.1.   
 RA PsA 
Number of patients from whom baseline urine 
samples were available 
19 21 
Females 19 (100%) 10 (48%) 
Median age 49.9 years (IQR 
44.15-64.12) 
47.84 years (IQR 
35.24-58.49) 
Smokers 2 (11%) 4 (19%) 
Concomitant drug (Immunosuppressant) 8 (42%) 5 (24%) 
Concomitant drug (NSAID) 10 (53%) 12 (57%) 
Table 4.1: Table to compare the demographic details of the patients with established 
Rheumatoid arthritis and established Psoriatic arthritis included in the DATA study. 
 
4.3.1 RA and PsA at baseline 
To determine if systemic metabolic differences were observable between established RA 
and established PsA 1D NMR spectra of urine samples were acquired.  After normalising 
and binning, these data were analysed by PCA to generate an unbiased overview of the 
major metabolite differences between RA and PsA patients.  This is shown in Figure 4.1 
and there is no clear separation of the two groups.   
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Figure 4.1: 1D 1H NMR spectra of urine samples of patients with RA (●) and PsA (○) 
patients were subjected to PCA. The values on the axis labels indicate the proportion of 
the variance captured by each principal component.  There are 19 urine samples from 
patients with RA and 21 urine samples from patients with PsA. 
 
4.3.1.1 PLS-DA analysis 
The supervised analysis PLS-DA enhanced the separation of the two groups of samples 
(RA and PsA).  The optimised model comprised 7 latent variables (LV) which captured 
96.7% of the variance.  The major contribution to the separation was made by LV1 and 
LV2 (Figure 4.2).  This model was cross validated using Venetian blinds approach and 
was shown to identify samples with PsA with a sensitivity of 75% and specificity of 61% 
and samples with RA with a sensitivity of 61% and specificity of 75%.   
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Figure 4.2: 1D 1H NMR spectra of urine samples of patients with RA and PsA were 
subjected to supervised analysis (PLS-DA).  The values on the axis labels (LV 1 and 2) 
indicate the proportion of the variance captured by each principal component.  There are 
19 urine samples from patients with RA and 21 urine samples from patients with PsA. 
(sensitivity of 75% and specificity of 61%) 
 
4.3.1.2 Metabolite identification 
A weighting plot derived from the PLS-DA model is shown in figure 4.3.  The weightings 
provide an overall picture of the discriminating features.  Figure 4.4 and figure 4.5 show 
the prominent peaks which discriminate RA from PsA.   
 
In RA the prominent peaks may represent 2-phenylglycine and phenylacetic acid.  These 
are shown in Figure 4.4.  In PsA the prominent peaks may represent creatinine.  This is 
shown in Figure 4.5.   
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Figure 4.3: Entire weighting plot derived from PLS-DA of data from urine samples of 
patients with RA and PsA 
 
 
Figure 4.4: Weighting plot showing prominent peaks and their relevant ppm.  The 
doublet represents Phenylacetic acid and the triplet represents 2-phenylglycine.   
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Figure 4.5: Weighting plot showing prominent peaks and their relevant ppm.  The 
position of creatinine is shown on the weighting plot.   
 
4.3.1.3 Relationship between CRP levels and metabolites in RA and PsA 
patients 
My work using serum (chapter 5) has demonstrated a strong relationship between current 
inflammation (as tested by CRP) and the subsequent metabolic profile.  We wanted to 
determine whether the difference we had observed between the RA and PsA samples was 
due to a difference in inflammation (CRP levels) or something else.   
 
We used PLS-R (section 2.6.4) to investigate the relationship between CRP and the 
metabolites in RA and CRP and the metabolites in PsA separately.  We found no 
significant association between the CRP and RA metabolites (p=0.5) and no significant 
association between the CRP and PsA metabolites (p=0.56) suggesting that the difference 
seen on the PLSDA model is not simply due to inflammation.   
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Using an unpaired T-test there was no significant difference between the CRP levels of the 
RA and the PsA patients (p=0.945).   
 
4.3.1.4 Differences between males and females 
All our patients with RA were female and 48% of the patients with PsA were female.  We 
wished to ascertain whether these differences in gender were responsible for the changes 
that we were identifying between RA and PsA. 
 
I first investigated the patients with PsA and split these into females and males to see if 
there were any differences in their metabolic profiles.  The PCA data are shown in Figure 
4.6 and the PLSDA data are shown in Figure 4.7.  The PCA data show no clear differences 
between the females and males with PsA.  The supervised analysis PLS-DA enhances the 
separation of the two groups of samples (males and females) and clear differences were 
seen.  The optimised model comprised 8 latent variables (LV) which captured 99.7% of 
the variance.  The major contribution to the separation was made by LV1.  This model was 
cross validated using Venetian blinds approach and was shown to identify females with a 
sensitivity of 70% and specificity of 82% and males with a sensitivity of 91% and 
specificity of 50%.   
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Figure 4.6: 1D 1H NMR spectra of urine samples of the male (●) and female (○) 
patients with PsA were subjected to PCA. The values on the axis labels indicate the 
proportion of the variance captured by each principal component.   
 
Figure 4.7: 1D 1H NMR spectra of urine samples of the male (●) and female (○) 
patients with PsA were subjected to supervised analysis (PLS-DA). The values on the 
axis labels indicate the proportion of the variance captured by each principal component.   
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The RA and PsA baseline data were analysed again just using the female patients in order 
to remove the variation created by gender.  The PCA data are shown in Figure 4.8 and the 
PLSDA data are shown in Figure 4.9.  The PCA does show some differences between the 
RA and PsA patients and this is enhanced by the PLSDA model.  The optimised model 
comprised 4 latent variables (LV) which captured 69.1% of the variance.  The major 
contribution to the separation was made by LV1.  This model was cross validated using 
Venetian blinds approach and was shown to identify samples with RA with a sensitivity of 
60% and specificity of 57.9% and samples with PsA with a sensitivity of 57.9% and 
specificity of 60%.   
 
Figure 4.8: 1D 1H NMR spectra of urine samples of female patients with RA (●) and 
PsA (○) were subjected to PCA. The values on the axis labels indicate the proportion of 
the variance captured by each principal component.   
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Figure 4.9: 1D 1H NMR spectra of urine samples of female patients with RA (●) and 
PsA (○) were subjected to supervised analysis (PLS-DA). The values on the axis labels 
(LV1 and LV2) indicate the proportion of the variance captured by each principal 
component.   
 
Although, there are differences between the urine samples of female and male patients 
with PsA there are still differences between the urine samples of the RA and PsA patients 
when the variability of gender has been removed.   
 
4.3.2 RA and predictors of response to anti-TNFα therapy 
After 12 months of anti-TNF therapy RA patients were divided into two groups according 
to their response, as determined by EULAR criteria (Table 4.2).  Response to anti-TNF 
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respond to treatment with a TNF antagonist according to the predefined response criteria.  
It was therefore not possible to study prediction of response in PsA.   
 
 Good response to 
TNF antagonists 
(n=7) 
Not a good response 
to TNF antagonists 
(n=9)† 
P value 
Age (years);mean (SD) 50.0 (13.40) 52.67 (12.83) 0.69‡ 
Female (number (%)) 7 (100) 9 (100)  
BMI; mean (SD) 26.16 (3.75) 26.97 (5.64) 0.78‡ 
Prednisolone (patient 
number) 
1 2 1‡‡ 
NSAIDs (patient number) 4 4 1‡‡ 
Baseline methotrexate dose 
(mg/week); mean (SD) 
13.57 (4.76) 15.83 (6.12) 0.43‡ 
DAS28; mean (SD) 6.041 (1.06) 6.46 (0.91) 0.41‡ 
CRP (mg/ml); mean (SD) 21.31 (15.97) 7.02 (7.97) 0.03‡ 
Rheumatoid factor positive 
(patient number) 
6 8 1‡‡ 
Anti CCP antibody positive 
(patient number) 
6 8 1‡‡ 
Urinary albumin to 
creatinine ratio; mean (SD) 
1.60 (2.71) 0.29 (0.45) 0.17‡ 
Table 4.2: Baseline characteristics of RA patients divided according to response to 
anti-TNF therapy at 12 months. 
† “Not a good response” corresponds to moderate and poor response as determined by 
EULAR criteria. 
‡p value calculated using unpaired t test. 
‡‡p value calculated using Fishers exact test. 
 
NMR spectra of stored baseline urine samples were acquired and analysed in order to 
identify differences between the two groups as follows:  
Supervised PLS-DA analysis (Figure 4.10A) shows a clear distinction between patient 
groups segregated according to clinical response.  This model comprised 1 latent variable 
(LV) which captured 35.5% of the variance.  This model distinguished samples with or 
without a good response with a sensitivity of 66.7% and a specificity of 57.1%.  A 
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weightings plot, which indicates regions of the NMR spectra which contribute to this 
separation (Figure 4.10B), was used to identify the discriminatory metabolites responsible 
for the difference in response and these are shown in Table 4.3.  
 
The PLS-R model represents the 90 “bins” or regions of the spectra which had the greatest 
influence on the correlation with the change in DAS28.  The GALGO model identified the 
bins which had the greatest influence on the separation.  For the PLS-DA model the 
metabolites were identified from the weightings plot, which indicates regions of the NMR 
spectra which contribute to the separation.  From the bins identified using GALGO and 
PLS-R the metabolites were identified for the top 20 bins.  From the PLS-DA weightings 
plot the top 20 peaks were identified and the metabolites identified from these. 
 
GALGO analysis was then used to reanalyse the data, firstly in order to verify the results 
obtained using a further supervised analysis technique, but secondly to utilise the superior 
modelling power of the GALGO genetic algorithm, which more effectively removes 
irrelevant variables. The PCA plot yielded by Galgo analysis shows a clear distinction 
between RA patients segregated according to clinical response (Figure 4.10C).  The cross 
validation of this model was shown to distinguish samples from patients who would not 
have a good response and samples from patients who would have a good response with a 
greatly improved sensitivity of 88.9% and specificity of 85.7%.  GALGO analysis was 
further used to identify the discriminatory metabolites responsible for the difference in 
response as shown in Table 4.3.   
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Finally, the relationship between baseline metabolite profiles and the change in DAS28 
over 12 months was assessed using PLS-R.  This analysis was repeated 100 times with and 
without randomisation of the NMR bin data.  There was a significant association between 
the change in DAS28 and baseline RA metabolites (p=0.04).  Permutation testing with 90 
NMR bins included (as optimised by forward selection) demonstrated that the regression 
model was statistically valid (p<0.01).   
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Figure 4.14: Metabolic fingerprinting distinguishes between baseline urine samples f 
patients who go on to have good response or not at 12 months. 
A. . 
Figure 4.10:Metabolic fingerprinting distinguishes between baseline urine samples 
from RA patients who go on to have good response or not at 12 months. 
A. 1D 1H NMR spectra of baseline urine samples from RA patients who go on to 
have a good response (●) or not (○) to TNF antagonists at 12 months were 
subjected to supervised analysis (PLS-DA). The values on the axis labels indicate 
the proportion of the variance captured by each latent variable. 
B. Weightings plot of the PLS-DA model of spectral data from baseline urine 
samples of the RA patients who go on to have good response or not at 12 months 
highlight major regions of the spectra that distinguish between the sample groups.  
The values on the x axis indicate chemical shift (ppm) and the values on the y axis 
indicate the proportion of the variance captured by each latent variable. 
C. 1D 1H NMR spectra of baseline urine from RA patients who go on to have a good 
response (●) or not (○) to TNF antagonists at 12 months were subjected to PCA 
using GALGO. The values on the axis labels indicate the proportion of the 
variance captured by each principal component. 
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Rank Metabolite 
(chemical shift 
(ppm)) 
PLS-DA 
Variable 
Importan
ce of the 
Projectio
n (VIP) 
values 
Metabolite 
(chemical shift 
(ppm)) 
GALGO 
Metabolite 
(chemical shift 
(ppm)) 
PLSR 
1 ↑Histamine (7.15) 91.54 Trimethylamine 
(2.87) 
Citrate (2.67, 2.53, 
2.56) 
2 ↑Glutamine (2.16, 
2.34) 
87.72 Thiamine (7.41) Phosphocreatinine 
(3.04, 3.94) 
3 ↓p-
hydroxyphenylpyru
vic acid (4.06, 7.14, 
6.82, 7.12) 
72.72 Histamine (7.24, 
8.01, 8.00, 7.12) 
Ethanolamine (3.16, 
3.74) 
4 ↓Phosphocreatine 
(3.05, 3.94) 
60.58 Thymine (7.37, 
7.35, 1.86) 
Creatinine (4.05, 4.06, 
3.05) 
5 ↑Thymine (7.35, 
1.86) 
61.8 Ethanolamine 
(3.17, 3.80) 
Histamine (7.13, 3.28, 
7.15) 
6 ↑Creatinine (3.04, 
4.05) 
50.58 Phenylacetic 
acid (7.29, 7.39, 
7.30) 
Glutamine (2.16) 
7 ↑Xanthurenic acid 
(7.37, 7.13) 
36.71 Glutamine (2.12, 
2.13) 
P-
hydroxyphenylpyruvi
c acid (6.82, 6.8225, 
4.06, 7.12) 
8 ↑Phenylacetic acid 
(3.63, 7.44. 7.32) 
21.48 Xanthurenic 
acid (6.96) 
Dimethylamine (2.70) 
9 ↑Xanthine (7.82) 12.68 Xanthine (7.90) Xanthurenic acid 
(7.15) 
10 ↓Ethanolamine 
(3.80) 
7.59 Tartaric acid 
(4.38) 
 
11   3-
phosphoglyceric 
acid (4.14) 
 
Table 4.3 Baseline urinary metabolites most strongly correlated with response to 
anti-TNF therapy using PLSR, Galgo and PLSDA models. 
The top 20 bins (PLS-R and GALGO) and peaks (PLS-DA) were identified; their 
corresponding chemical shifts and the metabolites these represent are shown.  The 
metabolites which are underlined have been identified by all three methods and the 
metabolites in bold have been identified by two different methods.   
VIP values were calculated using PLS-DA. 
↑ up-regulation of metabolites in the urine samples of the patients that had a good response 
to TNF antagonists. 
↓ down- regulation of metabolites in the urine samples of the patients that had a good 
response to TNF antagonists. 
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There was a significant difference between the CRP level of those patients that responded 
to TNF antagonists compared to those that did not respond (p=0.03).  We therefore used 
PLS-R to further analyse the relationship between CRP and baseline metabolites in order 
to investigate potential confounding variables; this did not reveal any significant 
association (p=0.52), suggesting that the difference we have found is independent of the 
inflammatory processes reflected in the CRP levels.  Grouping the metabolite data into 
quartiles according to the CRP values also failed to separate patient groups on PCA or 
PLS-DA. Previous studies have shown that patients with RA have subclinical nephropathy 
(Niederstadt et al. 1999;Pedersen et al. 1995) and that the urinary albumin to creatinine 
ratio is a sensitive marker of disease activity in RA (Pedersen et al. 1995).  We measured 
the albumin to creatinine ratio in the urine samples and there was no significant difference 
between the albumin to creatinine ratio of those patients that responded to TNF antagonists 
compared to those that did not respond (p=0.17) (Table 4.2).  We also performed 
regression analysis for metabolic profiles at baseline against albumin to creatinine ratio 
and this was not significant (p= 0.31) suggesting that the relationship we have found 
between baseline urinary metabolic profiles and DAS28 is independent of micro-
albuminuria. 
 
4.3.3 Comparison of metabolites predicting response to therapy in RA 
Metabolites that are associated with a change in DAS28 are shown in Table 4.3. The 
metabolites histamine, glutamine, xanthurenic acid and ethanolamine were identified by all 
three analytical methods.  Furthermore, several metabolites were identified by at least two 
of the three different methods, including p-hydroxyphenylpyruvic acid, phosphocreatine, 
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thymine, creatinine, phenylacetic acid and xanthine.  These findings cross-validate the 
analyses used. We were also able to identify glutamine and xanthurenic acid in the urine 
samples that were used for NMR analysis using ion-exchange chromatography and a 
fluorometric method respectively. There was a good correlation between the NMR peaks 
heights and the assayed levels of xanthurenic acid (p=0.001, r=0.73 using the Spearman 
correlation test) and a strong trend in the results for the glutamine (p=0.07, r=0.46 using 
the Spearman correlation test), which help validate our interpretation of the NMR data. 
However, the assayed levels of glutamine and xanthurenic acid were not significantly 
higher in the urine samples of the patients who had a good response, which suggests that 
while these individual metabolites contribute strongly to the discrimination, the whole set 
of metabolites present in the fingerprints is needed to fully separate the groups. 
 
4.3.4 Effect of TNFα antagonists on metabolite profiles 
The details of the patients on etanercept and infliximab are shown in Table 4.4.  We 
investigated the effect of anti-TNF therapy on metabolic profiles longitudinally, comparing 
baseline and 12 week (during therapy) urine samples using supervised PLS-DA analysis 
(sensitivity 71.4% and specificity 57.1% in RA and sensitivity and specificity of 61.1% in 
PsA) and GALGO (sensitivity 100% and specificity 82.9% in RA and sensitivity 71.8% 
and specificity 69.5% in PsA).  Using the weightings plot we identified that in patients 
with RA who responded to TNF antagonists, there were high levels of glutamine, 
phenylacetic acid and histamine in the baseline urine samples and higher levels of 
methylamine and creatinine in the urine sample post anti-TNF therapy.  Similar changes in 
metabolites were also seen in the urine samples of the patients with PsA who responded to 
TNF antagonists (Figure 4.11).   
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 Patients on 
infliximab (n=18) 
Patients on 
etanercept (n=16) 
P 
value 
Age (years); mean (SD) 48.6 (10.60) 47.46 (14.78) 0.19‡ 
Female (number (%)) 13 (72) 13(81) 0.68‡‡ 
BMI; mean (SD) 28.43 (4.56) 28.36 (9.33) 0.98‡ 
Prednisolone (patient 
number) 
6 3 0.63‡‡ 
NSAIDs (patient number) 10 9 0.99‡‡ 
DAS28 at baseline (RA 
patients only); mean (SD) 
6.22 (0.95) 6.35 (1.05) 0.80‡ 
 
Table 4.4: Characteristics of all RA and PsA patients divided according to treatment. 
‡p value calculated using unpaired t test. 
‡‡p value calculated using Fishers exact test. 
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Figure 4.11 Metabolic fingerprinting enables identification of metabolites that alter 
post treatment with TNF antagonists in patients that have a good response. 
A. 1D 1H NMR spectra of  urine samples from RA patients at baseline (○) and 12 
weeks (●)who go on to have a good response to TNF antagonists at 12 months 
were subjected to supervised analysis (PLS-DA). The values on the axis labels 
indicate the proportion of the variance captured by each latent variable.   
B. Weightings plot of the PLS-DA model of spectral data from urine samples of the 
patients with RA who responded to TNF antagonists highlights major regions of 
the spectra that distinguish between the baseline and 12 week samples.  The values 
on the x axis indicate chemical shift (ppm) and the values on the y axis indicate the 
proportion of the variance captured by each latent variable.   
C. 1D 1H NMR spectra of  urine samples from PsA patients at baseline (○) and 12 
weeks (●)who go on to have a good response to TNF antagonists at 12 months 
were subjected to supervised analysis (PLS-DA). The values on the axis labels 
indicate the proportion of the variance captured by each latent variable.   
D. Weightings plot of the PLS-DA model of spectral data from urine samples of the 
patients with PsA who responded to TNF antagonists highlights major regions of 
the spectra that distinguish between the baseline and 12 week samples.  The values 
on the x axis indicate chemical shift (ppm) and the values on the y axis indicate the 
proportion of the variance captured by each latent variable.   
Chemical shift (PPM)  
Chemical shift (PPM)  
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Combining RA and PsA patients with a good response, we assessed which urinary 
metabolites changed after 12 weeks treatment with infliximab and with etanercept using 
supervised PLS-DA analysis (sensitivity 84.6% and specificity 55.6%) (Figure 4.12) and 
GALGO (sensitivity 86.2% and specificity 100%).  Using the weightings plot we found 
that increases in hippuric acid, citrate and lactic acid were seen with infliximab treatment 
and increases in choline, phenylacetic acid, urea, creatine and methylamine were seen with 
etanercept treatment.  Due to the small patient numbers, we could not investigate the 
effects of etanercept and infliximab in RA and PsA separately.  
 
Figure 4.12 Metabolic fingerprinting of urine samples from RA and PsA patients. 
A. 1D 1H NMR spectra of urine samples from RA and PsA patients 12 weeks post 
treatment with infliximab (○) and etanercept (●)who had a good response to 
treatment were subjected to supervised analysis (PLS-DA). The values on the axis 
labels indicate the proportion of the variance captured by each latent variable.   
B. Weightings plot of the PLS-DA model of spectral data from  urine samples of the 
RA and PsA patients post treatment with infliximab and etanercept who go on to 
have good response at 12 months highlight major regions of the spectra that 
distinguish between the sample groups.  The values on the x axis indicate chemical 
shift (ppm) and the values on the y axis indicate the proportion of the variance 
captured by each latent variable. 
Chemical shift (PPM) 
B 
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4.4 Discussion 
4.4.1 RA and PsA at baseline 
Our NMR data illustrate that there are differences in the urinary metabolite profiles 
between patients with RA and PsA.  Since acquiring these data other research has shown 
that patients with RA and PsA can be distinguished using mass spectroscopy of blood 
samples (Madsen et al. 2011), thus giving us further confidence in our data. The 
differences we observed were not due to differing levels of inflammation since there were 
no significant differences between the CRP levels of the PsA and the RA patients and our 
regression analysis did not show any significant association between CRP and metabolites.   
 
We have demonstrated that urine can be used to detect differences in metabolism in 
patients with RA and PsA.  No previous work on urinary metabolomics in inflammatory 
arthritis has been published though there have been some analyses of serum and synovial 
fluid (Lauridsen et al. 2010;Madsen et al. 2011;Naughton et al. 1993b;Weljie et al. 2007).  
Urine has however been used to look at metabolism in inflammatory bowel disease 
(Williams et al. 2009) in both mouse (Lin et al. 2009;Schicho et al. 2010) and human 
models (Schicho et al. 2012;Williams et al. 2009). The metabolites identified vary between 
the different models and are not common to all inflammatory conditions and this may be 
due to other biofluids being used in studies of other inflammatory conditions.  
 
There were large gender differences between the RA and PsA patients.  Even when the 
variability of gender was removed there were still differences between the metabolic 
profiles of patients with RA and PsA.  Our work identified several metabolites which were 
responsible for the separation between patients with RA and PsA.  Creatinine was one of 
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the discriminating metabolites with higher levels in the urine samples from patients with 
PsA but none of the patients in our cohort had renal impairment (as defined by a raised 
serum creatinine) at baseline.  Other discriminating metabolites were phenylglycine and 
phenylacetic acid with levels raised in the urine samples of the RA patients.  Phenylglycine 
is a normal constituent of human urine and raised phenylacetic acid levels have been found 
in patients with end stage renal failure (Jankowski et al. 2003)and after chocolate 
consumption (Rios et al. 2003).  They have also been postulated as a marker for depression 
(Davis et al. 1994).  Reduced levels of phenylacetic acid have been found in the urine, 
plasma and cerebrospinal fluid of depressed patients (Davis et al. 1994).  We have no 
formal data on the mood status of our patients on joining the study but we were not aware 
of any differences in mood between the patients with PsA and the patients with RA.  
Generally patients with RA are more likely to have associated depression as they usually 
have a more debilitating disease than those with PsA and this may explain the higher levels 
of phenylglycine in our RA patients.  The metabolites that differentiated the urine samples 
of patients with PsA and RA in our study were different to the metabolites that have been 
found to distinguish plasma samples of patients with PsA and RA (Madsen et al. 2011). 
Madsen et al identified glutamine, aspartic acid, glutamic acid, succinate and histidine to 
be the major discriminatory metabolites but other work has illustrated that the same 
metabolites are not found to differentiate different disease states in different biofluids 
(Sreekumar et al. 2009).  
 
4.4.2 Predictors of response to anti-TNFα therapy in RA 
There were clear differences in the metabolic profiles of baseline urine samples of patients 
with RA who responded well to anti-TNF therapy compared with those who did not.  This 
difference may be important as a novel predictor of responses to TNF antagonists.  We 
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have used 3 different data analysis methods to predict response and each found that similar 
metabolites contributed.  We have used GALGO as well as PLS-DA as it has been shown 
that genetic algorithms optimise the results by removing irrelevant variables and 
dramatically improve the classification ability of models (Ramadan et al. 2006).  All three 
methods identified histamine, glutamine, xanthurenic acid and ethanolamine, while both 
PLS-DA and PLSR identified creatinine, p-hydroxyphenylpyruvic acid and 
phosphocreatine and both PLS-DA and GALGO identified phenylacetic acid and xanthine. 
Histamine, glutaminephenylacetic acid, xanthine, xanthurenic acid and creatinine were up 
regulated in the urine samples of the patients that had a good response to therapy whilst 
ethanolamine, p-hydroxyphenylpyruvic acid and phosphocreatine were down regulated. 
 
One metabolite we identified as a strong discriminator in baseline urinary metabolites was 
histamine. Urinary histamine metabolites have also been suggested as a marker of disease 
activity in inflammatory bowel disease (Winterkamp et al. 2002) suggesting it may be a 
generic marker of inflammatory processes.  Histamine is most obviously associated with 
mast cell dependent processes such as allergy, and histamine has been identified as a 
constituent of synovial fluid in arthritis (Buckley et al. 1997).  Histological examination of 
synovial infiltrates in early rheumatoid arthritis has shown mast cells to be present (Tak et 
al. 1997), suggesting that these cells could be the source of the discriminating histamine.  
However, an alternative but significant route for histamine generation is via histidine 
degradation.  Histamine arises in many tissues by the decarboxylation of histidine (Stifel 
and Herman 1971).  It has long been known that TNF α promotes cachexia associated with 
chronic inflammatory disease and this cytokine is known to have direct effects in 
accelerating muscle breakdown leading to the release of free amino acids including 
histidine (Goodman 1991).  Consistent with this, levels of histidine have been shown to be 
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Kynurenine 
considerably higher in patients with RA and systemic lupus erythematosus (Sitton et al. 
1987) compared to controls.  Several of the other metabolites that we have observed were 
also associated with catabolic processes and tissue degradation for example, glutamine, 
xanthurenic acid and ethanolamine, can result from tryptophan (Figure 4.13) and other 
amino acid degradation pathways. Tryptophan has been shown to be down-regulated in 
plasma of patients with ankylosing spondylitis (AS) compared with to controls (Gao et al. 
2008).  The release of tryptophan from its binding serum protein has been shown to 
correlate with improvement in disease activity in AS (Gao et al. 2008) and this may be the 
same in RA.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Tryptophan metabolism 
Tryptophan 
3-hydoxykynurenine 
Xanthurenic acid Quinolinic acid 
Kynurenic 
acid 
Antranilic 
acid 
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A previous metabolomic study has suggested that alterations in serum levels of amino 
acids may be a useful marker of the presence and severity of osteoarthritis in the knee 
(Zhai et al. 2010), and the urine markers we have found may be indicators of either joint 
specific degradation processes, or may result from the systemic muscle and tissue changes 
associated with chronic disease, many of which are mediated through TNFα. 
 
Previous work has investigated predictors of response to TNF antagonists.  Analysis of 
patients in the British Society for Rheumatology Biologics Register found that treatment 
with methotrexate or NSAIDs predicted response to TNF antagonists (Hyrich et al. 2006).  
All the patients in our study were on methotrexate and there were an equal number of 
patients on NSAIDs who had a good response compared to those who did not.  Smoking 
has been associated with a poor response to infliximab (Hyrich et al. 2006) but only one of 
our patients smoked.  Another group has found that the presence of rheumatoid factor or 
anti-CCP antibodies is associated with a reduced response to TNF antagonists (Potter et al. 
2009) but all our RA patients were positive for rheumatoid factor and/or anti-CCP 
antibodies.  Baseline levels of TNF may predict the dose of infliximab needed for optimal 
response (Takeuchi et al. 2011) and other work has demonstrated that a combination of 
blood cytokines and autoantibodies can predict responses to etanercept (Hueber et al. 
2009).  In our cohort there was a significant difference between the CRP levels in the 
patients that responded to TNF antagonists compared to those that did not.  However, the 
PLSR analysis failed to find an association between CRP and baseline metabolites 
suggesting that the association between baseline metabolites and response is independent 
of CRP.   
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Infliximab and etanercept alter metabolites in the urine differently as there are clear 
differences in the metabolites at 12 weeks post treatment.  Increases in the metabolites 
hippuric acid, citrate and lactic acid were associated with infliximab treatment and 
increases in the metabolites choline, phenylacetic acid, urea, creatine and methylamine 
were associated with etanercept treatment.  Infliximab and etanercept are both TNF 
antagonist but they have different modes of action. Infliximab is a chimeric monoclonal 
antibody whereas etanercept is a fusion protein. Infliximab binds to soluble and 
transmembrane TNF α with high affinity and specificity (Wong et al. 2008). Infliximab 
has murine variable regions which can cause production of anti-mouse antibodies which 
can lead to diminished efficacy requiring concomitant use of methotrexate. They are 
known to differ in many ways. Infliximab has a higher rate of activating latent TB (Dixon 
et al. 2010) and higher risk of anti drug antibodies (Garces et al. 2013;Sandborn and 
Hanauer 1999). Etanercept is much less effective in inflammatory bowel disease and has 
been reported to cause inflammatory bowel disease (Flemming et al. 2013). Etanercept 
also has no evidence for treating uveitis whereas infliximab does not (Elewaut and 
Matucci-Cerinic 2009).  In view of these differences it is not surprising that they both alter 
metabolites in the urine differently. Further work is required in this area as certain patients 
obviously respond to one drug over another.  
 
We have also shown that the same metabolites alter in the urine samples of patients with 
RA and PsA that responded to TNF antagonists.  It may therefore be that chronic 
inflammatory diseases respond by a common mechanism to TNF antagonists.   
 
124 
 
This is the first demonstration that metabolomic techniques using 1D NMR spectra can 
predict outcome to TNF therapy in patients with severe RA providing a sensitivity and 
specificity for response that has potential clinical utility despite a small initial cohort of 
patients. Our findings are verified by repeat analysis using alternative statistical 
techniques. There is a pressing need to confirm and extend this finding in a larger cohort of 
patients, combining metabolomic with CRP and cytokine and autoantibody analyses to 
develop tests that can predict response without the need for empirical treatment, bringing 
closer the era of individually tailored therapy.   
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5.0 Assessment of metabolite profiles of serum from patients 
with early arthritis  
5.1 Introduction 
The aetiology of RA is not fully understood but involves both genetic and environmental 
factors.  In addition to synovitis, there are widespread systemic effects mediated by pro-
inflammatory cytokines that impact upon metabolism.  TNFα, IL1 and IL6 all promote 
cachexia, which is often associated with RA (Cederholm et al. 1997;Kotler 2000). The 
extent of the metabolic changes and the types of metabolites seen may therefore be good 
markers of cytokine mediated inflammatory processes in RA. Low serum levels of a 
number of specific metabolites, including histidine, have been reported in RA patients 
(Sitton et al. 1987) and this metabolite discriminated OA from RA (Sitton et al. 1986). 
Lactate levels in synovial fluids also vary, with higher levels seen in seropositive, 
compared to seronegative, RA (Gobelet and Gerster 1984). Changes in blood lipids in RA 
have been widely described (Steiner and Urowitz 2009;Toms et al. 2010). More recently, 
lipid changes (Myasoedova et al. 2010) and alterations in a range of serum cytokines and 
chemokines (Kokkonen et al. 2010) have been shown to pre-date the development of 
arthritis suggesting that changes in metabolites might be observable early in the 
development of RA.  
 
Altered metabolomic fingerprints have been seen in a number of inflammatory diseases, 
for example, analysis of faecal extracts differentiated between normal controls and patients 
with Crohn’s disease and ulcerative colitis. Significantly, these two patient groups could 
be distinguished using metabolic profiling (Marchesi et al. 2007) suggesting that the 
effects of inflammation on metabolism vary between conditions. This is supported by 
previous work in our group in which we used metabolite fingerprinting to differentiate 
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between two otherwise similar inflammatory eye diseases (Young et al. 2009) and between 
a number of neurological conditions (Sinclair et al. 2010) and also to predict treatment 
responses in patients with inflammatory arthritis (Kapoor et al. 2013). With this 
background, we hypothesised that metabolomic profiles may be useful in predicting the 
development of RA in patients with early arthritis - an area where better predictive tools 
are currently needed (Raza and Filer 2009).  We also wished to determine if this analysis 
could provide novel insights into disease mechanisms in arthritis as has been the case in 
other conditions (Sreekumar et al. 2009).  
 
To investigate the potential of metabolite fingerprinting in inflammatory arthritis, we have 
applied an NMR-based metabolomic approach to the analysis of serum from patients with 
newly presenting established RA and early arthritis. We initially sought to assess whether 
the metabolite fingerprint in patients with established RA differed from that of healthy 
controls and then whether this fingerprint differed in patients with early arthritis in relation 
to the extent of inflammation and final outcomes.  
 
We were interested to determine if metabolic differences could be observed in early 
synovitis and also to determine if the metabolic differences persisted on suppression or 
resolution of the inflammation. 
 
5.2 Patients 
Patients were recruited through the inflammatory arthritis clinic at Sandwell and West 
Birmingham Hospitals NHS Trust, Birmingham, UK. The study was conducted in 
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compliance with the Helsinki declaration and ethical approval was obtained from the local 
ethics committee.  All subjects gave written informed consent. Serum samples were 
collected from the patients and stored at -80°C until analysis. 
 
5.2.1 Established RA patients 
Serum samples were collected from 16 newly presenting DMARD naive patients fulfilling 
1987 ACR classification criteria for RA (Arnett et al. 1988) (due to the higher specificity 
of these criteria (section 1.1.1)) and with a symptom duration of > 3 months. Symptom 
onset was defined as the time of onset of inflammatory joint pain and/or early morning 
stiffness and/or joint related soft tissue swelling. 
 
5.2.2 Early arthritis patients 
Serum was collected from early arthritis patients at the time of initial presentation. All 
patients had one or more swollen joints and symptoms (inflammatory joint pain and/or 
early morning stiffness and/or joint related soft tissue swelling) of ≤ 3 months duration as 
previously described (Raza et al. 2005a). Different groups use different definitions of early 
arthritis in terms of symptom duration (Gossec et al. 2014). Several groups define early 
arthritis as symptom duration of less than 12 months (Harris et al. 2013;Kuijper et al. 
2013). Our patients were recruited within three months as evidence suggests that this time 
period enables a greater chance of drug free remission for patients with RA (van der 
Linden et al. 2010). Patients with evidence of previous inflammatory joint disease were 
excluded. Two groups of patients were studied, one recruited after the other. There were 
89 early arthritis patients in group 1 and 127 in group 2. Patients were followed for 18 
months and then assigned to their final diagnostic categories. Patients were classified as 
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having RA according to the 1987 ACR criteria (Arnett et al. 1988) due to the higher 
specificity of these criteria (section 1.1.1), allowing criteria to be satisfied cumulatively. 
Patients were diagnosed with reactive arthritis (ReA), psoriatic arthritis (PsA) and a 
number of miscellaneous conditions according to established criteria. Resolving arthritis 
was diagnosed if there was no evidence of joint related soft-tissue swelling on final 
examination and the patient had not received DMARD or steroid treatment within the 
previous 3 months (Raza et al. 2005a). Persistent joint related swelling or treatment with 
DMARDs or steroids for inflammatory joint symptoms (within the previous 3 months) 
defined persistence.  
Serum samples were prepared as per section 2.4.3.   
 
5.3 Results 
5.3.1 The metabolic profile differs in established RA patients compared to 
healthy controls. 
Details of patients with established RA and age/sex-matched healthy controls are shown in 
Table 5.1. The median DAS28ESR score in the RA patients was 5.88 (IQR 5.25-6.99). 
PCA was used to generate an unbiased overview of the major metabolic differences 
between established RA and control individuals. There was separation of the two groups 
which was dependent largely on PC2 (Figure 5.1A), the scores of which were significantly 
higher in the RA group (t-test; p<0.0001). To help discover the major discriminatory 
metabolites, these data were subjected to a supervised analysis using OPLS-DA (figure 
5.1B). Discriminatory metabolites are shown in table 5.2. 
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 Established RA 
(n=16) 
Healthy controls 
(n=14) 
P 
value 
Age (years); median (IQR) 57 (37-79) 54 (40-72) 0.47‡ 
Female; number (%) 12 (75) 9 (64) 0.69‡‡ 
Symptom duration (weeks); 
median (IQR) 
31 (18-52) - - 
NSAIDs; number (%) 7 (44) 0 (0) - 
CRP (mg/ml); median (IQR) 20.5 (7.5-55.5) - - 
RF positive; number (%) 12 (75) - - 
Anti CCP antibody positive; 
number (%) 
9 (56) - - 
Table 5.1: Baseline characteristics of established RA patients and, healthy controls. 
‡p value calculated using Mann Whitney test. 
‡‡p value calculated using Fisher’s exact test. 
 
Metabolite (ppm) RA vs. controls 
LDL-CH3 (0.80) Low (6.30) 
LDL-CH2 (1.21) Low (7.06) 
3-hydroxybutyrate (1.18, 1.19) High (4.21) 
Lactate (1.31, 4.11) High (54.51) 
Alanine (1.46,1.48) Low (20.00) 
Acetylglycine (2.03) High (48.67) 
Methylguanidine (2.81) Low (10.17) 
Taurine (3.26) High (8.12) 
Glucose (3.25,3.88) High (16.8) 
Lipid (5.32) Low (2.36) 
Table 5.2: Analysis of PLS-DA weightings illustrates the metabolites contributing to 
the differentiation between: established RA and healthy controls “High” implies the 
metabolite is at higher concentration in the RA disease phenotype. NMR chemical shifts 
(ppm), which identify the location of the major peaks in the spectra, are shown in brackets 
for each metabolite. . Variable importance of the projection (VIP) values are shown in 
brackets for all of the metabolites. 
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Supervised analysis enhanced the separation of the two groups and the optimised model 
comprised 4 latent variables (LV) which captured 97.8% of the variance in the metabolic 
data. The major contributions to the separation were made by LV1 and LV2 (Figure 5.1B). 
This model was cross-validated using the Venetian blinds approach and identified samples 
from the RA patients with a sensitivity of 93.3% and a specificity of 100%. 
 
5.3.2 Resolution of inflammation is reflected in metabolic profile changes. 
 
In 22 patients with early arthritis and active disease at baseline (median CRP 66 (IQR 47-
131)), serum samples were available at a follow up time point (a median of 49 weeks (IQR 
24-69) from the time of initial assessment and sample collection) at which CRP levels 
were significantly lower (median <5 (IQR <5 - <5)). This fall in CRP was associated with 
either spontaneous resolution of disease, or control of disease with therapy. Unbiased 
 
Figure 5.1. Metabolic fingerprinting distinguishes between sera from established 
rheumatoid arthritis and matched healthy. 
1D 1H NMR spectra of serum from DMARD naïve RA patients (●) and control 
individuals (○) were subjected to PCA (A) and to supervised analysis (PLS-DA) (B). 
The values on the axis labels indicate the proportion of the variance captured by each 
principal component.  
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Figure 5.2. Metabolic fingerprinting illustrates that metabolite profiles in patients 
with early arthritis are altered by control or resolution of inflammation. 
1D 1H NMR spectra of serum from a subset of patients with early arthritis before (●) and 
after (○) the level of CRP had diminished following therapy or spontaneous resolution 
were subjected to PCA (A) and to supervised analysis (OPLS-DA) (B). 
 
 
To provide an overall description of which regions discriminated in the PLS-DA analyses, 
weightings plots derived from the models were generated. Some common features were 
seen in these weightings plots from PLS-DA models separating RA from controls and 
from the analysis of the early synovitis patients from whom a second serum sample had 
been collected at a time when the CRP had significantly fallen (Table 5.3). 
  
PCA discriminated between samples at baseline and follow-up (Figure 5.2A) and 
OPLS-DA produced a model comprising of 2 LVs capturing 99.8% of the variance 
which could discriminate between these samples with 100% specificity and sensitivity 
(Figure 5.2B) demonstrating the influence of inflammation on the metabolic 
fingerprint. 
 
B A 
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Table 5.3: Analysis of PLS-DA weightings illustrates the metabolites contributing to 
the differentiation between: paired samples in early arthritis patients before and 
after resolution of inflammation. “High” implies the metabolite is at higher 
concentration in the active disease phenotype. NMR chemical shifts (ppm), which identify 
the location of the major peaks in the spectra, are shown in brackets for each metabolite. . 
Variable importance of the projection (VIP) values are shown in brackets for all of the 
metabolites. 
  
Metabolite (ppm) Active early arthritis vs. less active early 
arthritis 
LDL-CH3 (0.80) Low (3.03) 
LDL-CH2 (1.21) Low (31.81) 
3-hydroxybutyrate (1.18, 1.19) High (7.90) 
Alanine (1.46,1.48) Low (2.15) 
Acetylglycine (2.03) High (17.41) 
Taurine (3.26) High (9.11) 
Glucose (3.25,3.88) High (12.72) 
Lipid (5.32) Low (2.53) 
Urea (5.79) High (1.32) 
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5.3.3 Metabolic profiles of patients with early arthritis are linked to 
inflammation. 
Details of the 89 early arthritis patients from group 1 and the 127 early arthritis patients 
from group 2 are shown in Table 5.4.   
 Early 
arthritis 
patients 
group 1 
(n=89) 
Early 
arthritis 
patients 
group 2 
(n=127) 
P value 
 
Age (years); median 
(IQR) 
46 (36-61) 50 (35-65) 0.32‡ 
Female; number (%) 49 (55) 69 (54) 1.0‡‡ 
Symptom duration 
(weeks); median 
(IQR) 
5 (2-9) 6 (4-9) 0.02‡ 
NSAIDs; number 
(%) 
58 (65) 69 (54) 0.12‡‡ 
CRP (mg/ml); 
median (IQR) 
19 (5.5-54) 19.5 (5.25-
44.75) 
0.79‡ 
RF positive; number 
(%) 
12 (36) 30 (34) 0.83‡‡ 
 
Anti CCP antibody 
positive; number 
(%) 
13 (39) 29 (33) 0.39‡‡ 
Number with 
persistent arthritis 
(%) 
33 (37) 87 (68) <0.0001‡‡ 
Number with 
persistent arthritis 
who developed RA 
(%) 
18 (54) 55 (63) 0.41‡‡ 
Table 5.4: Baseline characteristics of early arthritis patients. 
‡p value calculated using Mann Whitney test. 
‡‡p value calculated using Fisher’s exact test. 
a CRP available for 84 patients in group 1.  
b CRP available for 126 patients in group 2 
c CCP data available for 126 patients in group 2 
 
PCA of NMR spectra of serum from 84 early arthritis patients (group 1) in whom the CRP 
levels were known, showed a broad spread on the scores plot (Figure 5.3A). When the 
level of CRP for each sample was superimposed on the PCA plot, it was clear that the 
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level of inflammation at the time of sampling influenced the distribution. To investigate 
this further, the relationship between baseline metabolite profiles and CRP was assessed 
using PLS-R. The analysis employed a forward selection approach to discover those NMR 
bins that were most predictive. A total of 154 bins created the optimal model with a cross-
validated r2 of 0.671 (Figure 5.3B). Permutation testing with these 154 NMR bins 
demonstrated that the regression model was statistically valid (p<0.001).  
 
To further validate this relationship between the level of inflammation and baseline 
metabolic profiles, the PLS-R analysis was carried out in a separate group of 127 early 
arthritis patients.  The maximum r2 for the regression of the real (i.e. ordered) data was 
0.416 (Figure 5.3C). Permutation testing with 1136 NMR bins included (as optimised by 
forward selection) again demonstrated that the regression model was statistically valid 
(p<0.001).   
The patients were divided into two groups as the samples were collected over a nine year 
period due to constraints of recruitment. While the samples were stored under optimal 
conditions at -80oC, some alterations in some metabolites may have occurred during 
storage since spectra for two cohorts were acquired 4 years apart.  The first group of 
patients were recruited between 2000 and 2004 and the samples run in 2005. The second 
group of patients were recruited between 2004 and 2009 and the samples run in 2010. 
Furthermore, updates in the spectrometer setup occurred over this period and so, for these 
reasons, the two cohorts showed some differences in the NMR spectra, which made 
combining them problematic.  However, in many ways keeping the two cohorts separate 
was an advantage, since we were able to validate most of the observations made on the 
first cohort with those from the second, in spite of the minor differences in the spectra. 
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Figure 5.3: The metabolic fingerprints of sera from patients with early arthritis prior 
to treatment with DMARDs are strongly influenced by the level of inflammation. 1D 
1H NMR spectra of serum from patients with very early arthritis (group 1) were subjected 
to PCA (A). Tertiles of CRP are indicated with high (●), intermediate (●) and low (○) 
levels. There were strong correlations between measured versus predicted CRP values for 
group 1 (B) and group 2 (C) (p<0.001 for both groups). The predicted values were 
calculated from the concentrations of a series of metabolites that were discovered using 
PLS-R. The inset plots in (B) and (C) show the optimisation of the multivariate regression, 
with the highest correlation between measured and predicted CRP occurring with 154 
NMR bins (maximum R2 of 0.671) for group 1 (B) and with 1136 NMR bins (maximum 
R2 of 0.4157) for group 2 (C). 
 
 
It is known that metabolic status and products of metabolism are influenced by several 
variables including age, gender, hypertension, diabetes, hyperuricaemia and smoking but 
when we adjusted our analysis for these confounding effects our results remained 
significant (Table 5.5).  We also excluded the effect of medication used at the time of 
sample collection (steroids, DMARDs and NSAIDs) and found that the relationship 
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between CRP and metabolic profile was still significant (Table 5.5 and 5.6).  The 
regression analysis was carried out to look at the relationship between metabolic profiles 
and CRP without the confounding effect of variables which are known to influence 
metabolic status by assessing only individuals who were not current smokers (n=67 group 
1, n=96 group 2) and individuals without hypertension (n=70 group 1, n=96 group 2), 
diabetes (n=89 group 1, n=118 group 2) or hyperuricaemia (defined as uric acid level > 
340µmol/l) (n=58 group 1, n=67 group 2). The effects of DMARDs and steroids on 
metabolic status were also excluded by carrying out the regression analyses only for those 
patients that were not on DMARDs (n=85 group 1, n=125 group 2; the few patients who 
were on DMARDs were on them for other co-morbidities e.g. inflammatory bowel 
disease) or steroids (n=86 group 1, n=123 group 2) at time of recruitment into the study.  
We excluded the effect of NSAIDs by only carrying out the regression analysis for those 
patients on NSAIDs at time of recruitment as the majority of patients were on NSAIDs 
(n=60 group 1, n=66 group 2). The significance of the relationship between the CRP and 
metabolic profiles is shown in table 5.6 and was statistically significant for all analyses 
apart from when women alone in group 1 were analysed. 
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Table 5.5 Number of patients with variables which can affect metabolism in group 1 
and group 2. 
‡p value calculated using Mann Whitney test. 
#p value calculated using Fisher’s exact test. 
  
 
Group 
1     
 
Group
2     
 
Resolvi
ng 
arthritis  
Persis
tent 
arthrit
is  
P 
value 
Persi
stent 
arthri
tis 
who 
devel
op 
RA  
P 
value 
Resol
ving 
arthrit
is  
Persiste
nt 
arthritis  
P value Persi
stent 
arthri
tis 
who 
devel
op 
RA  
P 
value 
Steroids; 
number 
(%) 0 (0) 2 (7)  0.14# 1 (6)  0.25# 0 (0) 4 (5)  0.31# 3 (5)  0.26# 
NSAIDs; 
number 
(%) 37 (66) 
23 
(70)  0.82# 
13 
(72)  0.78 
17 
(42) 49 (56) 0.18# 
37 
(69)  0.11# 
DMARDs; 
number 
(%) 0 (0) 1 (3)  0.38# 0 (0)  1 (2) 1 (1)  0.52# 1 (2)  1.0# 
Age 
(years); 
median 
(IQR) 
45 (36-
59) 
50 
(22-
64)  0.75‡ 
56 
(23-
70)  0.08‡ 
44 
(32-
56) 
57 (18-
67)  0.05‡ 
60 
(47-
68)  
0.002
6‡ 
Female; 
number 
(%) 33 (59) 
21 
(64)  0.82# 
15 
(83)  
0.089
# 
23 
(58) 47 (54)  0.85# 
26 
(48)  0.41# 
Hypertensi
on; 
number 
(%) 15 (27) 3 (9)  0.06# 
1 (6) 
0.1 
0.097
# 6 (15) 25 (29)  0.12# 
15 
(28)  0.21# 
Diabetes; 
number 
(%) 0 (0) 0 (0)  0 (0)  1 (2) 7 (8)  0.43# 5 (9)  0.23 
Hyperuric
aemia; 
number 
(%) 15 (29) 8 (28)  1.0# 
6 
(38)  
0.546
# 
10 
(31) 21 (32)  1.0# 
14 
(34)  1.0# 
Smokers; 
number 
(%) 12 (22) 8 (25)  0.79# 
6 
(33)  0.36# 9 (22) 22 (25)  0.83# 
15 
(28)  0.64# 
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 Group 1 (p value) Group 2 (p value) 
Non smokers <0.001 <0.001 
NSAIDs 0.01 <0.001 
No DMARDs <0.001 <0.001 
Females 0.07 0.01 
Males <0.001 0.01 
No hypertension <0.001 <0.001 
No DM <0.001 0.01 
No steroids <0.001 <0.001 
No hyperuricaemia <0.001 <0.001 
Table 5.6 Relationship between CRP and metabolic profiles for both groups without 
the effects of confounding drugs or other variables. 
 
 
We also used the PLS-R analysis that related the metabolite fingerprint to CRP, to generate 
a rank order of NMR bins which identified regions of the spectra which most strongly 
predicted the inflammatory burden in groups 1 and 2 (Table 5.7). Almost identical 
metabolites were identified for both patient groups suggesting a complex but real 
relationship between metabolism and inflammatory burden. 
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Ranked 
importance 
Metabolites identified in patient 
group 1 (ppm) 
Metabolites identified in 
patient group 2 (ppm) 
1 Total choline (3.20, 3.22, 3.23) LDL-lipids (1.24-1.27) 
2 LDL-lipids (1.24-1.27) Acetylglycine (2.03, 3.71, 3.76) 
3 Lactate (1.31, 1.33, 4.11) Glucose (3.24-3.26, 3.41, 3.48, 
3.68-3.69, 3.88) 
4 Acetylglycine (2.03, 3.71, 3.76) Fatty acids (0.8-0.84, 2.22-2.24) 
5 Urea (5.77, 5.78, 5.79, 5.80, 5.81, 
5.82) 
Methylguanidine (2.81) 
6 Glucose (3.24-3.26, 3.41, 3.48, 3.68-
3.69, 3.88) 
Lactate (1.31, 1.33) 
7 Methylguanidine (2.81) Threonine (3.58) 
8 Methylhistidine (3.70) Homocystine (3.86) 
9 Cholesterol (0.91) Glycine (3.55) 
10 Taurine (3.42) Taurine (3.42) 
11 Threonine (3.58) Methylxanthine (3.49) 
12 Fatty acids (0.8-0.84, 2.22-2.24) Total choline (3.20, 3.22, 3.23) 
13 Methylxanthine (3.49) Methylhistidine (3.70) 
14 Homocystine (3.86) Cholesterol (0.91) 
Table 5.7: Metabolites most strongly correlated with CRP for early arthritis groups 1 
and 2. Metabolites were identified from the PLS-R model and represent the regions of the 
spectra which had the greatest influence on the correlation with CRP. NMR chemical 
shifts (ppm), which identify the location of the major peaks in the spectra, are shown in 
brackets for each metabolite. 
 
5.3.4 Relationships between clinical outcomes and metabolic profiles in 
early arthritis patients  
A PLS-DA model was used to try and separate patients with resolving and persistent 
outcomes for both patient groups but did so with only moderate sensitivity and specificity 
of 59.4% and 58.9% for group 1 using 5 LVs (capturing 32% of the variance) (Figure 
5.4A) and sensitivity and specificity of 59.5% and 56.4% for group 2 using 6 LVs 
(capturing 28% of the variance) (Figure 5.4B). There was also no differentiation between 
resolving disease and persistent RA for group 1 (Figure 5.4C) (sensitivity of 50% and 
specificity of 69.6% using 2 LVs capturing 74% of the variance) though there was good 
separation for group 2 (Figure 5.4D) with a sensitivity of 73.1% and specificity of 67.6% 
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using 3 LVs capturing 98% of the variance. There was no differentiation between patients 
with RA and non RA outcomes for either cohort (Figure 5.5). Previous data has shown that 
therapeutic drug use can have effects on metabolic profiles (Kirschenlohr et al. 2006) but 
there was no significant difference between the number of patients on NSAIDs for either 
group (Table 5.4) and there was no significant difference in the use of NSAIDs between 
patients with persistent and resolving disease for group 1 (p=0.13) or group 2 (p=0.1) or 
between patients with persistent RA and resolving disease for group 1 (p=0.18) or group 2 
(p=0.17).   
 
 
Figure 5.4: The metabolic fingerprints of sera from patients with early arthritis from 
two different patient groups.  
Serum samples from early arthritis patients from group 1 (A) and group 2 (B) at first 
presentation were assessed using PLS-DA, to separate patients whose disease was 
resolving (●) or persistent (○). Sensitivity and specificity were 59.4% and 58.9% for group 
1 (A) and 59.5% and 56.4% for group 2 (B).   
Serum samples from early arthritis patients from group 1 (C) and group 2 (D) at first 
presentation were assessed using OPLS-DA, to separate patients whose disease was 
resolving (●) from those that developed persistent RA (○). Sensitivity and specificity were 
50% and 69.6% for group 1 (C) and 73.1% and 67.6% for group 2 (D).   
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Figure 5.5 The metabolic fingerprints of sera from patients with early arthritis from 
two different groups separated according to the eventual development of RA or not.  
Serum samples from early arthritis patients from group 1 (A) and group 2 (B) at first 
presentation were assessed using PLS-DA, to separate patients who developed RA (○) 
from those that did not develop RA (●). Sensitivity and specificity were 53.3%and 53.6% 
for group1 (A) and 62% and 63.6% for group 2 (B).   
 
 
Metabolites were identified that contributed the greatest to the separation for early arthritis 
patients split into resolving and persistent disease, and also for resolving and persistent RA 
for both patient groups (Table 5.8). Although some predictive metabolites were common 
to both patient groups there were some key differences in metabolites between the groups, 
suggesting that the metabolomic techniques as applied in this study cannot fully 
discriminate between resolving and persistent outcomes or resolving disease and persistent 
RA in early arthritis patients.   
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Metabolite (ppm) Persistent 
vs. 
Resolving 
arthritis 
(group 1) 
Persistent 
vs. 
Resolving 
arthritis 
(group 2) 
Persistent 
RA vs.  
Resolving 
arthritis 
(group 1) 
Persistent 
RA vs. 
Resolving 
arthritis 
(group 2) 
LDL-CH3 (0.80) Low (6.81) Low (2.87) - - 
LDL-CH2 (1.21) Low (7.40) Low (6.89) - Low (1.58) 
3-hydroxybutyrate 
(1.18, 1.19) 
- High (6.87) - - 
Lactate (1.31, 4.11) Low (12.85) High 
(27.90) 
Low (12.74) High (16.98) 
Alanine (1.46,1.48) - - - Low (3.84) 
Acetylglycine (2.03) High (6.55) High (6.80) High (4.57) Low (1.94) 
Methylguanidine 
(2.81) 
High (92.72) Low (38.15) High 
(34.76) 
Low (6.51) 
Taurine (3.26) - High 
(15.73) 
- High (8.66) 
Glucose (3.25,3.88) - High 
(11.55) 
- High (7.49) 
Urea (5.79) High (3.90) - High (1.25) - 
Table 5.8: Analysis of PLS-DA weightings illustrates the metabolites contributing to 
the differentiation between: patients with early arthritis who develop persistent 
disease or whose arthritis resolves for 2 groups; and patients with early arthritis who 
develop persistent RA or whose arthritis resolves for 2 groups. “High” implies the 
metabolite is at higher concentration in the persistent (column 2 and 3) or persistent RA 
(column 4 and 5) disease phenotypes. NMR chemical shifts (ppm), which identify the 
location of the major peaks in the spectra, are shown in brackets for each metabolite. . 
Variable importance of the projection (VIP) values are shown in brackets for all of the 
metabolites. 
 
5.4 Discussion 
Our data demonstrate that the serum metabolite fingerprint of patients with active RA 
differs from that of healthy controls and that the serum metabolite fingerprint in patients 
with early arthritis varies depending on the level of inflammation. These results from 
patients with established RA are broadly consistent with a recent study using a similar 
experimental approach which focussed on responses to therapy in a cohort of RA patients 
(Lauridsen et al. 2010). There is also some overlap in discriminating metabolites identified 
with a recent mass spectrometry-based analysis of established RA (Madsen et al. 2011). 
However, patients in both of those cohorts had already been exposed to DMARD therapy 
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and so it is possible that their metabolic fingerprints might be influenced by this. Our 
cohort of patients was sampled before any DMARD therapy and so was not exposed to this 
confounding factor.  
 
As with the study by Lauridsen et al (Lauridsen et al. 2010), we found that decreased 
NMR lipid signals were particularly discriminatory between patients with established RA 
and controls and Madsen et al (Madsen et al. 2011), using mass spectrometry, also 
observed changes in cholesterol comparing established RA and controls.  Such lipid 
changes were not seen in a mouse arthritis model (Weljie et al. 2007), probably because 
the investigators filtered samples to remove protein and the associated lipids. Changes in 
lipid profiles in the blood of RA patients have been widely described, and have been 
suggested to be a major contributing factor to the accelerated atherosclerosis associated 
with RA (Steiner and Urowitz 2009;Toms et al. 2010).  
 
We found that 3-hydroxybutyrate was raised in the established RA patients. This 
metabolite is known to be present in RA synovial fluid (Naughton et al. 1993a), in pouch 
fluid from the rat air pouch model (Claxson et al. 1999) and in the blood of mice with 
experimental arthritis (Weljie et al. 2007). The presence of 3-hydroxybutyrate, a ketone 
body, suggests an increased level of lipolysis in RA patients compared with controls. This 
may be another explanation for the decreased levels of lipid that we have observed, and 
supports earlier spectroscopic studies of synovial fluid (Naughton et al. 1993a) which 
determined that lipid metabolism may be a predominant source of energy in the hypoxic 
inflammatory joint.  
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Our PLS-R analysis revealed a clear correlation between the CRP level and the metabolites 
present. This was replicated in a separate group of patients. This approach identified that 
increased concentrations of many of the same metabolites discovered in the PCA and 
OPLS-DA models, for example LDL lipid, lactate, glucose, taurine, acetylglycine and 
methylguanidine, were predictive of the inflammatory phenotype. However, a number of 
amino acids (e.g. choline, threonine, methylhistidine) were also found to contribute 
strongly to the correlation (Table 5.7). 13 of the 14 metabolites which were most strongly 
associated with CRP were the same for both groups of patients.  
 
Many of the metabolites that correlated with inflammation, as measured by serum CRP 
levels, are associated with lipid metabolism and may again contribute to the increased 
levels of atherosclerosis associated with inflammatory disease.  Abnormalities in lipids 
have been associated with pre-RA (van de Stadt et al. 2012) , early RA (Ahmed et al. 
2010;Park et al. 1999) and established RA (Dessein et al. 2002;Kavanaugh 1994;Toms et 
al. 2011) and lipid levels correlate with CRP even in the absence of clinically apparent 
inflammatory disease (Hrnciarikova et al. 2009). Furthermore, lipid lowering therapies 
influence inflammation (Leung et al. 2003;McCarey et al. 2004) and anti-inflammatory 
therapies influence lipids (Peters et al. 2007) demonstrating a complex relationship 
between inflammation and lipid metabolites which our data help to dissect. 
 
Blood donors who went on to develop RA at least a decade later have been shown to have 
significantly more atherogenic blood lipid profiles than those who did not develop RA 
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(van Halm et al. 2007).While this difference did not correlate with CRP levels it does 
suggest that lipid profiles early in disease might contribute to prediction of outcome. 
However, we were unable to discriminate between patients with early arthritis who went 
on to develop persistent disease and those whose arthritis resolved. Although there was 
some separation between patients with persistent and resolving outcomes in both groups 
the discriminating metabolites differed. One contributing factor may be the use of non 
filtered blood samples in our study as data suggest that filtered blood gives better results 
due to better resolution of the NMR spectra (Weljie et al. 2008) but we would then lose the 
effect of lipids which we know play a part in RA (Toms et al. 2010). There was also a 
delay between our sample collection and sample processing due to samples being collected 
at City hospital and processing occurring at the University of Birmingham.  Samples were 
not collected on ice and were not spun down promptly and our own quality control work 
(section 3.1) has demonstrated that the metabolites lactate and pyruvate can alter over time 
without these precautions being taken. When the metabolites lactate and pyruvate were 
removed from our NMR spectra there was little change in the prediction of outcome. We 
decided to include these metabolites in our analysis as most of our samples were processed 
prior to six hour post collection and also due to the fact that lactate and pyruvate are such 
key metabolites in cell metabolism.  Our work has illustrated that metabolites do not alter 
too much if samples are collected in an adhoc manner (section 3.1) and the fact that the 
metabolite data correlate strongly with CRP suggests that the metabolite profile hasn’t 
been perturbed in a too random manner by ex vivo processing issues.  
 
Hence, while we may be able to improve predictive ability if samples are processed more 
rigorously it is more likely that the lack of discrimination may result from the 
heterogeneity between the two groups of early arthritis patients for example in terms of the 
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proportion whose disease persisted (Table 5.4). Group 1 had very few patients whose 
arthritis persisted and very few of these were ACPA positive. We know that ACPA 
positive and ACPA negative RA are very different in terms of aetiology (Klareskog et al. 
2008) and it may be that they behave very different metabolically. Due to the small 
number of patients we were unable to do sub analysis of these patients.  
 
Several approaches have been used to predict the outcome of patients with early arthritis as 
identifying these patients early enables earlier treatment and better outcome (Raza and 
Filer 2009). The most widely used predictive tool is the ‘Leiden rule’ which consists of 9 
clinical and serological variables: sex, age, localisation of symptoms, morning stiffness, 
tender joint count, CRP level, IgM RF and the presence of anti-CCP antibodies (van der 
Helm-van Mil et al. 2007). Genetic susceptibility markers have also been used in the 
prediction of outcome and the main susceptibility genes, the shared epitope and PTNP22 
are only associated with ACPA positive RA.  However, SNP markers within the 
TRAF1/C5 locus, which are also associated with ACPA positive RA, have demonstrated 
an association with the development of radiological erosions (Plant et al. 2011). The 
biochemical markers matrix metalloproteinase 3 in the serum and C-telopeptide of type II 
collagen in the urine have also demonstrated an association with radiographic progression 
in patients with early RA especially if used as part of a multivariate model (Young-Min et 
al. 2007). Synovial fluid analysis can also aid outcome prediction and research has 
demonstrated that certain cytokine patterns are associated with different outcomes in 
patients with undifferentiated arthritis (Raza et al. 2005b). Imaging has also been used to 
try and predict outcome in patients with undifferentiated arthritis.  Groups have used 
Magnetic resonance imaging of the wrists and finger joints and illustrated that bone 
oedema adds to the prediction obtained by serological and clinical factors alone (Tamai et 
147 
 
al. 2009). Ultrasound is widely used in rheumatology and the use of ultrasound counts in 
our cohort of patients increased the prediction of RA compared to clinical and serological 
markers alone (Filer et al. 2011). Other groups have not duplicated the additional benefit 
of ultrasound and this may be due to the inclusion of patients with arthralgia only in their 
cohorts and the fact that only limited joint examination was done in this study (Pratt et al. 
2013). All these measures have shortcomings in predicting outcome in patients with 
inflammatory arthritis and the prediction outcome may be greatly increased by combining 
these variables with metabolomic data in the future. Therefore to confirm and extend the 
observations we have made, these analyses need to be replicated in independent cohorts.  
 
In conclusion, the metabolomic fingerprint reflects inflammatory disease activity in 
patients with a new onset of arthritis. This suggests that the underlying inflammatory 
processes drive significant changes in metabolism that can be measured in the peripheral 
blood.  This may give us further insights into the mechanism of disease in inflammatory 
arthritis as has been the case following the identification of contributing metabolites in 
other diseases (Sreekumar et al. 2009). Furthermore, metabolomics may prove useful as a 
measure of the extent of disease, potentially separating low disease activity states from 
patients in true remission. 
  
148 
 
6.0 Assessment of metabolite profiles of cultured synovial 
fibroblasts from patients with early arthritis 
6.1 Introduction 
Fibroblasts are the major cell in the expanded RA synovium. Their transformation may be 
dependent on immune cells and so describing the interactions between these cell types is 
important. Inflammation, and its persistence in RA, results from complex interactions 
between haematopoietic and stromal cells (Buckley et al. 2001;Parsonage et al. 2005) but 
research into the pathogenesis of the disease often neglects the role of stromal cells. 
Activated RA synovial fibroblasts have an important role in determining the site at which 
inflammation occurs and the persistence of inflammation in the joint microenvironment 
(Takemura et al. 2001).  Fibroblast activation results in the accumulation, survival and 
retention of leukocytes at sites of inflammation (Iwamoto et al. 2008;Parsonage et al. 
2005) by chemokine and cytokine production, thus preventing the resolution of chronic 
inflammation (Filer et al. 2006).  Synovial fibroblasts play a key role in joint destruction in 
RA and numbers are expanded. They directly invade cartilage and they contribute to bone 
destruction through activation of osteoclasts (Bartok and Firestein 2010). 
 
In the joint, fibroblasts have limited access to nutrients and oxygen within the poorly 
vascularised hypoxic synovium and yet expansion of fibroblast numbers still occurs. This 
suggests fibroblasts may adapt their metabolism to this environment and this process may 
be involved in driving the persistence of inflammation. It is possible that this adaptation 
occurs in an incremental manner and so metabolic changes might relate to the stage of the 
disease. To investigate the potential of metabolite fingerprinting in increasing our 
understanding of the role of fibroblast in inflammatory arthritis, we have used NMR-based 
metabolomics in the analysis of synovial fibroblasts from patients with newly presenting 
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established RA and early arthritis. We sought to identify differences in metabolite 
fingerprints in fibroblasts from patients with established RA, early arthritis and healthy 
controls and to determine if inflammatory cytokine production by fibroblasts is related to 
their metabolic profile. 
 
6.1.1 Cytokines in RA 
A broad spectrum of cytokines are involved in the pathogenesis of RA but here I will focus 
on those produced by synovial fibroblasts since these, together with macrophage 
cytokines, are dominant in RA. Activated macrophages and fibroblasts interact via 
secretion of soluble mediators leading to further activation of cells, recruitment of new 
cells to the joint and increased production of inflammatory mediators (Bartok and Firestein 
2010). The cytokines present in the joint may vary dependent on the stage of RA with 
some evidence that there is a prevalence of IL 4 (Th2 cytokines) in early RA and more 
established RA being characterised by a Th1 response (Raza et al. 2005b). Several 
cytokines and chemokines are produced by synovial fibroblasts and different ones are 
associated with different stages of RA. CXCL9 has been found in cultured synovial 
fibroblasts from patients with early RA (Tsubaki et al. 2005) and some cytokines have also 
only been detected in fibroblasts which have been stimulated with, for example, IFN-γ or 
TNF α (Tsubaki et al. 2005). 
 
6.1.1.1 IL 6 
Fibroblasts are the primary source of IL 6 in RA and this cytokine increases differentiation 
of B cells and their production of antibodies; increases T cell differentiation, proliferation 
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and survival; activates osteoclasts and chondrocytes and induces acute phase response 
(Park and Pillinger 2007). 
 
IL 6 binding to its receptor (IL 6R) does not in itself convey a signal. For this to occur a 
transmembrane accessory molecule (gp 130) needs to associate with the IL 6/ IL6R 
complex.  Gp130 is expressed by most cells but membrane bound IL 6R expression is 
restricted to hepatocytes, neutrophils, monocytes/macrophages and some lymphocytes. IL 
6 can transmit signals using the conventional membrane bound IL6R or in conjunction 
with a soluble IL 6 receptor (sIL6R).  Both forms of signalling can activate gp 130 
(Scheinecker et al. 2008). In the rheumatoid joint both IL 6 and sIL6R are abundant and 
have been shown to mediate osteoclast formation, synovial fibroblast proliferation and 
cartilage degradation (Kotake et al. 1996).  
 
The importance of IL6 in RA is illustrated by the successful therapeutic use of tocilizumab 
(TCZ), a humanised antibody to the IL 6R targeting both IL6R and sIL6R. TCZ in 
combination with methotrexate has an efficacy similar to TNF antagonists in the treatment 
of RA (Scheinecker et al. 2008;Smolen et al. 2013).  
 
6.1.1.2 VEGF 
Vascular endothelial growth factor (VEGF) induces angiogenesis in the RA synovium. 
VEGF expression is upregulated in both macrophages and synovial fibroblasts (Taylor 
2002). Hypoxia is a potent inducer of VEGF (Berse et al. 1999;Jackson et al. 1997).  
151 
 
6.1.1.3 Matrix metalloproteinases (MMP) 
Fibroblasts are a major source of proteins of the MMP family which are involved in both 
the physiological and the pathophysiological breakdown of extracellular matrix as seen in 
RA. Most MMPs are secreted as inactive proproteins which are activated when cleaved by 
extracellular proteinases.  RA synovial fibroblast synthesise and secrete MMP 1, 3, 9, 10 
and 13 (Abeles and Pillinger 2006). MMP-1 is a collagenase and degrades collagen type I, 
II, III, V and XI. MMP-1 is produced in response to cytokine stimulation and is the only 
MMP which can digest type II collagen, the major collagen in cartilage, if the collagen has 
not been degraded previously (Abeles and Pillinger 2006). Its production from cultured 
synovial fibroblasts is increased under hypoxic conditions (Ahn et al. 2008). MMP-3 is 
involved in the breakdown of extracellular matrix. Its production from cultured synovial 
fibroblasts is increased under hypoxic conditions and is directly controlled by activation of 
HIF-1α (Ahn et al. 2008). 
 
MMP9 causes degradation of collagen IV in basement membrane and extracellular matrix 
and can stimulate angiogenesis (Ram et al. 2006).  MMP13 degrades collagen type I, II, III, 
IV, V, IX, X and XI. It is over expressed in rheumatoid arthritis (Amalinei et al. 2010). 
 
6.1.1.4 Chemokines 
Several fibroblast derived chemokines are expressed in the RA synovium (Bartok and 
Firestein 2010). CCL2 (or monocyte chemotactic protein-1 (MCP-1)) is produced by 
synovial fibroblasts and recruits monocytes and macrophages to sites of inflammation in 
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RA (Bartok and Firestein 2010). Its expression by synovial fibroblasts is reduced by 
hypoxia (Safronova et al. 2003).  
CCL3 (or Macrophage inflammatory protein-1α (MIP-1α)), is also produced by cultured 
fibroblasts. It is involved in the recruitment and activation of T cells, monocytes and 
natural killer cells (Szekanecz et al. 2010).  
CCL5 (or RANTES; regulated on activation, normal T cell expressed and secreted) is 
produced by cultured synovial fibroblasts (Ahmed et al. 2006). CCL5 is chemotactic for T 
cells, eosinophils, and basophils, and plays an active role in recruiting leukocytes into 
inflammatory sites (Koch 2005).  
Although IL-8 (CXCL8) is produced by macrophages it can also be produced by 
fibroblasts in culture if they are stimulated with IL-1 or TNF (Szekanecz et al. 2010) , both 
of which are commonly present in the RA joint. IL-8 is an important mediator in the innate 
immune response as a neutrophil chemoattractant. Thus it may be responsible for the 
ingress of these cells into the synovium from where they enter the synovial fluid (where 
they are often the most prevalent cell) and furthermore it may enhance cell migration by 
stimulating new blood vessel formation (Bartok and Firestein 2010;Koch et al. 1992). 
CXCL10 (or Interferon gamma-induced protein 10 (IP-10)) is secreted by macrophages 
and fibroblasts in response to IFN-γ. CXCL10 recruits lymphocytes and macrophages 
(Szekanecz et al. 2010) and inhibits angiogenesis (Bartok and Firestein 2010). 
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6.1.2 Hypoxia in RA and the Warburg affect 
Angiogenesis is present during the earliest stages of RA and leads to increased leucocyte 
migration (Taylor and Sivakumar 2005), a critical factor underlying the significant 
increase in the number of macrophages, T, B and plasma cells in the RA synovium. 
Despite increased vascular supply there is a failure to restore tissue oxygen homeostasis. 
This is probably due to the metabolically active synovium requiring increased oxygen and 
the increased intra-articular pressure of joint swelling placing stress on the vascular supply 
(Ng et al. 2010). Hence rheumatoid synovial microenvironments exist under hypoxic 
conditions. In the synovial joint there is a Th1 response but the level of IL-2 is low and this 
may be secondary to hypoxia. Hypoxia upregulates the TNF and IL-1 produced by 
mononuclear cells but downregulates the IL-2 produced by T lymphocytes. Hypoxia also 
controls the Th2 to Th1 switch (Bodamyali et al. 1998). Hypoxia may drive inflammation 
in the joint as hypoxia per se induces cell migration (T cell and macrophage infiltrates) 
(Ng et al. 2010). Hence, hypoxia mediates persistent synovitis in RA. The reduction in 
perfusion of the synovial joint, along with the hypoxia and inflammatory cell infiltration 
lead to synovial fibroblast hyperplasia. This increased metabolic demand causes an 
increase in glycolysis.  
 
Synovial tissue in RA is hypoxic (Biniecka et al. 2010;Biniecka et al. 2011a;Ng et al. 
2010) and has low glucose and elevated lactate levels as hypoxia causes a transition to 
glycolytic metabolism (Bodamyali et al. 1998). This glycolytic metabolism has been found 
in cancer cells and is thought to exist in the rheumatoid joint.  In normal differentiated 
cells energy is generated through mitochondrial oxidative phosphorylation. In cancer cells 
(i.e. proliferating tissues) a process of aerobic glycolysis occurs which is also known as the 
‘Warburg effect’ i.e. glycolysis even in the presence of oxygen (Bayley and Devilee 
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2012;Koppenol et al. 2011). Aerobic glycolysis is inefficient in terms of ATP production 
but it is thought that it allows production of lipids and amino acids to enable cell 
proliferation (Vander Heiden et al. 2009) (See Figure 6.1).  
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Figure 6.1 Diagram to represent the differences between aerobic glycolysis (Warburg 
effect) in proliferating tissue such as malignancy (A) and oxidative phosphorylation 
and anaerobic glycolysis in normal differentiated tissue (B) (Vander Heiden et al. 
2009). 
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6.1.3 Aims within this chapter 
Since the level of oxygen in the inflamed joint decreases with increasing synovitis, we 
hypothesised that synovial fibroblasts taken from joints at different stages of disease would 
have metabolomic profiles, when cultured in vitro, that may predict the development of 
RA in patients with early arthritis - an area where better predictive tools are currently 
needed (Raza and Filer 2009).  We also wished to determine if this analysis could provide 
novel insights into disease mechanisms in arthritis as has been the case in other conditions 
(Sreekumar et al. 2009). We specifically planned to investigate the relationship between 
the ‘metabotype’ of in vitro synovial fibroblasts and the phenotypes and clinical outcomes 
of patients.  
 
6.2 Methods 
6.2.1 Patients 
Patients were recruited through the inflammatory arthritis clinic at Sandwell and West 
Birmingham Hospitals NHS Trust, Birmingham, UK. Patients were eligible for the early 
arthritis cohort if they had one or more swollen joints and symptoms of ≤ 3 months 
duration. Patients with evidence of previous inflammatory joint disease were excluded. 
Those with a joint amenable to ultrasound guided biopsy (Scire et al. 2007) and who gave 
consent to this procedure were recruited to this study. Biopsies were taken as described in 
section 2.1.3. Following the biopsy, patients were followed for 18 months and then 
assigned to their final diagnostic categories. Patients were classified as having RA 
according to the 1987 ACR criteria (Arnett et al. 1988) due to the higher specificity of 
these criteria compared with the 2010 ACR/ EULAR criteria (section 1.1.1), allowing 
criteria to be satisfied cumulatively. As previously described (Raza et al. 2005a) resolving 
arthritis was diagnosed if there was no evidence of joint related soft-tissue swelling on 
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final examination and the patient had not received DMARD or steroid treatment within the 
previous 3 months. Persistent joint related swelling or treatment with DMARDs or steroids 
for inflammatory joint symptoms (within the previous 3 months) defined persistence.  
 
Established RA and ‘normal’ patients were studied as control groups. Established RA 
patients were newly presenting DMARD naive patients fulfilling 1987 ACR classification 
criteria for RA (Arnett et al. 1988) and with a symptom duration of > 3 months. Symptom 
onset was defined as the time of onset of inflammatory joint pain and/or early morning 
stiffness and/or joint related soft tissue swelling. The ‘normal’ group comprised patients 
who underwent knee arthroscopy due to unexplained knee pain, with no evidence of 
inflammatory joint pathology upon clinical examination or arthroscopy. Clinical 
parameters and blood samples for routine clinical tests such as CRP were collected for all 
patients with inflammatory arthritis. The study was conducted in compliance with the 
Helsinki declaration and ethical approval was obtained from the local ethics committee.  
All subjects gave written informed consent. 
 
Four groups of patients were chosen for this study -patients with established RA, patients 
presenting with early arthritis who developed persistent rheumatoid arthritis (persistent 
early RA), patients presenting with early arthritis whose disease resolved (resolving 
arthritis) and patients with no evidence of inflammation (normal controls).  Limited 
numbers of fibroblasts were available so the patients were matched as closely as possible 
for autoantibody status (from early and established RA patients), joint biopsied, age and 
gender.  It was felt important to keep the individuals in each group as homogenous as 
possible, particularly in respect to antibody status as there is considerable debate as to 
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whether antibody negative RA is a different disease to antibody positive RA (Klareskog et 
al. 2008).  Hence, during matching, autoantibody status was given precedence over the 
joint from which the biopsy was taken as it has been illustrated that inflammation in one 
inflamed joint is representative of that in other inflamed joints (Kraan et al. 2002).  In this 
study fibroblasts were derived from 24 different patients (6 from each group).  The 
persistent early RA and the established RA group were all anti-CCP antibody positive.   
 
6.2.2 Fibroblast culture 
Fibroblasts were cultured as described in section 2.2. 
6.2.2.1 Oxygen status 
Fibroblasts were cultured in 20% oxygen as described in section 2.2. Once cells were 
confluent at P4 fibroblasts were extracted from two T75 flasks as per sections 2.23 and 2.3 
and samples prepared as per section 2.4.6.  Media were collected as per section 2.2.3 and 
this was used for NMR analysis as per section 2.4.5 and for analysis via ELISA as per 
section 2.7 and for Luminex assays as per section 2.8. One flask was trypsinised (section 
2.2.2) and split into 3 further flasks. Two of these flasks were then cultured under hypoxic 
conditions (3% oxygen) for 48 hours prior to extraction and media were collected from 
these for NMR spectroscopy (section 2.4.5), ELISA (section 2.7) and Luminex analysis 
(section 2.8). 3% was chosen as a large amount of literature suggests that the rheumatoid 
joint is hypoxic and that the average oxygen concentration of the rheumatoid joint is 3% 
(Biniecka et al. 2011b;Kennedy et al. 2011;Ng et al. 2010).  My aim was to investigate 
whether fibroblasts from the four groups could be distinguished using NMR based 
metabolomic analysis when cultured under conditions of 20% oxygen or 3% oxygen.   
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6.2.2.2 Treatment with IL 6 
Normal fibroblasts were treated with recombinant Human IL 6 (PeproTech) and soluble IL 
6 receptor (PeproTech) to determine if a normal ‘metabotype’ could be converted to an 
inflammatory ‘metabotype’ using IL 6. Synovial fibroblasts do not have IL 6 receptor so 
soluble Il 6 receptor (sIl6R) was also added (Ando et al. 2010;Kawashiri et al. 2009). Six 
normal fibroblast lines were studied and these were grown to confluence at passage 5 to 
obtain 8 confluent flasks. Once the fibroblasts were visually confluent the conditioned 
medium was removed and discarded and the flask was washed with 5mls PBS. The media 
in four flasks were replaced with 12mls of fresh medium. For the other four flasks from 
each cell line, the media were replaced with 12mls medium with IL6 at 20ng/ml 
(Rosengren et al. 2012) and SIL6R at 100ng/ml (Rosengren et al. 2012). There were two 
time points to the experiment, 24hours and 72 hours.  Two of the control flasks and two of 
the IL6 treated flasks were extracted at 24 hours as per section 2.23 and 2.3 and the other 
two control flasks and two flasks treated with IL6 were extracted at 72 hours. 
 
6.2.2.3 Treatment with tocilizumab 
Synovial fibroblasts from patients with established RA were treated with tocilizumab 
(TCZ) (Chugai) or ivIG (Gammaplex) as a control. This was to determine if the 
metabotype found in fibroblasts from rheumatoid patients could be reversed by TCZ i.e. if 
we could block the effects of the fibroblasts’ own IL 6. The method was the same as 
section 6.2.2.2 but TCZ or ivIG was added in place of recombinant IL 6. Two established 
RA fibroblast lines were studied for this experiment and these were grown to confluence at 
passage 6 to obtain 8 confluent flasks. The media in four flasks were replaced with 12mls 
of media with ivIG incorporated at 500micrograms/ml (120µl) and SIL6R incorporated at 
100ng/ml (12µl). The other four flasks from each cell line was replaced with 12mls 
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medium with TCZ incorporated at 500micrograms/ml (670µl) (Kawashiri et al. 2009) and 
SIL6R incorporated at 100ng/ml (12µl). There were two time points to the experiment, 
24hours and 72 hours.  Two of the control flasks (iv IG treated) and two of the TCZ treated 
flasks were extracted at 24 hours as per section 2.23 and 2.3 and the other two control 
flasks and two flasks treated with TCZ were extracted at 72 hours. 
6.3 Results 
6.3.1 Prediction of outcome 
Details of the study participants are shown in Table 6.1.  Clinical characteristics were 
matched as closely as possible for all donors and all the parameters were very similar apart 
from the CRP, which, as expected, differed between different outcome groups. 
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 Established 
RA (n=6) 
Healthy 
controls 
(n=6) 
Early 
resolving 
arthritis 
patients 
(n=6) 
Early RA 
patients (n=6) 
Age (years); median (IQR) 55 (46-66) 43 (34-52) 40 (33-54) 50 (48-65) 
Female; number (%) 3 (50) 2 (33) 4 (67) 3 (50) 
Symptom duration (weeks); 
median (IQR) 
38 (26-152) - 4 (2-7) 5 (4-10) 
NSAIDs; number (%) 4 (67) 0 (0) 4 (67) 3 (50) 
CRP (mg/ml); median (IQR) 48 (3.5-66.5) - 7.5 (0-
20.5) 
22 (3.75-33.5) 
RF positive; number (%) 5 (83) - 0 (0) 5 (83) 
Anti CCP antibody positive; 
number (%) 
6 (100) - 0 (0) 6 (100) 
Clinical assessment score of 
the swollen biopsied joint; 
mean 
2.17 - 1.5 1.83 
Ultrasound grey scale score 
of swollen biopsied joint; 
mean 
2.67 - 1.67 2.5 
Joint biopsied 
Ankle; n (%) 
Knee; n (%) 
MCP; n (%) 
 
2 (33) 
4 (67) 
0 (0) 
 
0 (0) 
6 (100) 
0 (0) 
 
2 (33) 
4 (67) 
0 (0) 
 
2 (33) 
2 (33) 
2 (33) 
Table 6.1: Demographic and clinical characteristics of study participants. 
 
6.3.1.1 Culture medium from fibroblasts cultured at 20% oxygen 
Fibroblasts were cultured and the media were collected from these cells. These media were 
then investigated using NMR and the results analysed. Fibroblast medium was selected as 
an appropriate biofluid to study as it contains the metabolites accumulated by cells as is the 
case for other biofluids such as blood and urine. The metabolic profile of the media from 
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these fibroblasts cultured at 20% oxygen from patients with inflammatory arthritis was 
very different from that of healthy controls (Figure 6.2). 
 
Figure 6.2 Fibroblast medium from fibroblasts cultured at 20% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with inflammatory 
arthritis (established RA, early RA and early resolving arthritis) (●). PLSDA analysis 
separated the groups with a sensitivity of 78% specificity of 78%. 
 
There was good separation of the metabolic profiles of the healthy controls and early 
resolving arthritis (Figure 6.3), healthy controls and early RA (figure 6.4), and healthy 
controls and established RA (Figure 6.5) using the media from the synovial fibroblasts of 
these patients.  
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Figure 6.3 Fibroblast medium from fibroblasts cultured at 20% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with early 
resolving inflammatory arthritis (●). PLSDA analysis separated the groups with a 
sensitivity of 100% and specificity of 100% 
 
Figure 6.4 Fibroblast medium from fibroblasts cultured at 20% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with early RA (●). 
PLSDA analysis separated the groups with a sensitivity of 100% and specificity of 100%. 
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Figure 6.5 Fibroblast medium from fibroblasts cultured at 20% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with established 
RA (●). PLSDA analysis separated the groups with a sensitivity of 83% and specificity of 
89%. 
 
 
There was also a significant difference in the metabolic profiles of the media of synovial 
fibroblasts from patients with early RA and those whose early inflammatory arthritis 
resolved (Figure 6.6). The weightings plot (Figure 6.7) illustrates the regions of the spectra 
which are responsible for this separation and we used the plot with the VIP (Figure 6.8) to 
identify the most important discriminatory metabolites. These are shown in table 6.2. 
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Figure 6.6 Fibroblast medium from fibroblasts cultured at 20% oxygen from patients 
with resolving arthritis (○) and those with early RA (●). PLSDA analysis separated the 
groups with a sensitivity of 89% and specificity of 83%. 
  
Figure 6.7 Weightings plot of fibroblast media cultured at 20% oxygen from patients 
with resolving arthritis and those with early RA. 
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Figure 6.8 Variable importance of projection (VIP) of fibroblast media cultured at 
20% oxygen from patients with resolving arthritis and those with early RA.  
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Ranked 
importance 
(VIP) 
Metabolites differentiating early resolving 
arthritis and early RA (ppm) 
1 (43) Ethanol (1.19, 1.18, 1.2) low 
2 (36) Pyroglutamate (2.36, 2.35) low 
3 (36) Alanine (1.48, 1.46) low 
4(26) Histidine (7.92)  low 
5 (25) Asparagine (2.84) low 
6 (24) Methanol (3.37) low 
7 (22) Citrate (2.55) high 
8 (21) Aspartate (2.66, 2.69) high 
9 (18) Saccharopine (3.06) high 
10 (16) Glucose (3.49) low 
11 (13) Glycerol (3.672) low 
12 (13) Lactate (4.12, 1.32) high 
13 (12) Glutamine (2.07) low 
Table 6.2: Metabolites most strongly associated with the differentiation between the 
media from synovial fibroblast cultured at 20% oxygen of patients with early 
inflammatory arthritis that resolves compared to those that develop RA. Metabolites 
were identified from the PLS-DA model and represent the regions of the spectra which had 
the greatest influence on the separation. The metabolites for all peaks with a VIP > 10 
were identified. NMR chemical shifts (ppm), which identify the location of the major 
peaks in the spectra, are shown in brackets for each metabolite. ”High” implies the 
metabolite is at higher concentration in the early RA disease phenotype. 
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6.3.1.2 Culture medium from fibroblasts cultured at 3% oxygen 
Using PLSDA analysis I was able to detect a difference between the metabolic profiles of 
media from fibroblasts cultured at 3% oxygen between the healthy controls and those 
patients with inflammatory arthritis (Figure 6.9).  
 
Figure 6.9 Fibroblast medium from fibroblasts cultured at 3% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with inflammatory 
arthritis (established RA, early RA and early resolving arthritis) (●). PLSDA analysis 
separated the groups with a sensitivity of 89% and specificity of 94%. 
 
There was good separation of the metabolic profiles of the healthy controls and early 
resolving arthritis (Figure 6.10), healthy controls and early RA (Figure 6.11), and healthy 
controls and established RA (Figure 6.12) using the media from the synovial fibroblasts of 
these patients.  
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Figure 6.10 Fibroblast medium from fibroblasts cultured at 3% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with early 
resolving inflammatory arthritis (●). PLSDA analysis separated the groups with a 
sensitivity of 100% and specificity of 100%. 
 
Figure 6.11 Fibroblast medium from fibroblasts cultured at 3% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with early RA (●). 
PLSDA analysis separated the groups with a sensitivity of 100% and specificity of 100%. 
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Figure 6.12 Fibroblast medium from fibroblasts cultured at 3% oxygen from patients 
with no evidence of inflammatory arthritis (normal) (○) and those with established 
RA (●). PLSDA analysis separated the groups with a sensitivity of 94% and specificity of 
94%. 
 
 
There was also a significant difference in the metabolic profiles of the media of synovial 
fibroblasts from patients with early RA and those whose early inflammatory arthritis 
resolved (Figure 6.13). The weightings plot (Figure 6.14) illustrates the area of the spectra 
which are responsible for this separation and I used the plot with the VIP (Figure 6.15) to 
identify the most important discriminatory metabolites. These are shown in table 6.3. 
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Figure 6.13 Fibroblast medium from fibroblasts cultured at 3% oxygen from patients 
with resolving arthritis (○) and those with early RA (●). PLSDA analysis separated the 
groups with a sensitivity of 83% and specificity of 83%. 
 
 
Figure 6.14 Weightings plot of fibroblast media cultured at 3% oxygen from patients 
with resolving arthritis and those with early RA.
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Figure 6.15 Variable importance of projection (VIP) of fibroblast media cultured at 
3% oxygen from patients with resolving arthritis and those with early RA. 
 
Ranked 
importance 
(VIP) 
Metabolites differentiating early resolving 
arthritis and early RA (ppm) 
1 (140) Ethanol (1.18, 1.19, 1.2) high 
2 (51) Lactate (1.35, 1.33, 4.13) low 
3 (46) Pyroglutamate (2.38, 2.55) low 
4 (36) Glucose (3.38, 3.5, 3.68, 3.66, 3.57) high 
5 (30) Methanol (3.37) high 
6 (19) Asparagine (2.83) low 
7 (18) Alanine (1.49) low 
Table 6.3: Metabolites most strongly associated with the differentiation between the 
media from synovial fibroblast cultured at 3% of patients with early inflammatory 
arthritis that resolves compared to those that develop RA. Metabolites were identified 
from the PLS-DA model and represent the regions of the spectra which had the greatest 
influence on the separation. The metabolites for all peaks with a VIP > 10 were identified. 
NMR chemical shifts (ppm), which identify the location of the major peaks in the spectra, 
are shown in brackets for each metabolite. ”High” implies the metabolite is at higher 
concentration in the early RA disease phenotype. 
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6.3.1.3 Fibroblasts cultured at 20% oxygen 
As well as using the media produced by synovial fibroblasts I investigated the metabolic 
profiles of the cells themselves. Fibroblasts were cultured in vitro and metabolites 
extracted for NMR experiments. The resulting spectra were then further analysed. PLSDA 
analysis at 20% oxygen did not show any significant difference between synovial 
fibroblasts from healthy controls and those with inflammatory arthritis (Figure 6.16). 
 
Figure 6.16 Fibroblasts cultured at 20% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with inflammatory arthritis 
(established RA, early RA and early resolving arthritis) (●). PLSDA analysis separated 
the groups with a sensitivity of 50% and specificity of 61%. 
 
There was no significant difference in the metabolic profiles of fibroblasts from healthy 
controls compared with those from patients with early resolving arthritis (Figure 6.17) 
though there did seem to be some difference between the healthy controls and those that 
developed early RA (Figure 6.18).  
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Figure 6.17 Fibroblasts cultured at 20% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with early resolving inflammatory 
arthritis (●). PLSDA analysis separated the groups with a sensitivity of 100% and 
specificity of 33%. 
 
Figure 6.18 Fibroblasts cultured at 20% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with early RA (●). PLSDA analysis 
separated the groups with a sensitivity of 67% and specificity of 67%. 
-4 -2 0 2 4
-6
-5
-4
-3
-2
-1
0
1
2
3
Scores on LV 1 (31.11%)
Sc
or
es
 o
n 
LV
 2
 (2
5.
41
%
)
 
 
5 10 15 20
-5
-4
-3
-2
-1
0
1
2
3
4
Sample
Sc
or
es
 o
n 
LV
 1
 (3
7.
41
%
)
176 
 
 
There was no significant difference in the metabolic profiles of fibroblasts from healthy 
controls compared with those from patients with established RA (Figure 6.19). 
 
Figure 6.19 Fibroblasts cultured at 20% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with established RA (●). PLSDA 
analysis separated the groups with a sensitivity of 67% and specificity of 50%. 
 
 
There was a significant difference in the metabolic profiles of fibroblasts from patients 
with early RA and those whose early inflammatory arthritis resolved (Figure 6.20). The 
weightings plot (Figure 6.21) illustrates the regions of the spectra which are responsible 
for this separation and I used the plot with the VIP (Figure 6.22) to identify the most 
important discriminatory metabolites. These are shown in table 6.4. 
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Figure 6.20 Fibroblasts cultured at 20% oxygen from patients with resolving arthritis 
(○) and those with early RA (●). PLSDA analysis separated the groups with a sensitivity 
of 67% and specificity of 83%. 
 
 
Figure 6.21 Loadings plot of fibroblasts cultured at 20% oxygen from patients with 
resolving arthritis and those with early RA. 
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Figure 6.22 Variable importance of projection (VIP) of fibroblasts cultured at 20% 
oxygen from patients with resolving arthritis and those with early RA  
 
Ranked 
importance 
(VIP) 
Metabolites differentiating early resolving 
arthritis and early RA (ppm) 
1 (119) Formic acid (8.45) high 
2 (64) Glucose (3.23, 3.26, 3.24, 3.51, 3.41, 3.39, 
3.46) high 
3 (40) Glycerol (3.53, 3.65. 3.59, 3.67. 3.81, 3.71) 
low 
4 (32) Lactate (4.14, 4.13, 1.33) high 
5 (24) Myo-Inositol (3.29) high 
6 (16) 2-Phosphoglycerate (3.82) high 
Table 6.4: Metabolites most strongly associated with the differentiation between 
synovial fibroblast of patients with early inflammatory arthritis that resolves 
compared to those that develop RA. Metabolites were identified from the PLS-DA 
model and represent the regions of the spectra which had the greatest influence on the 
separation. The metabolites for all peaks with a VIP > 10 were identified. NMR chemical 
shifts (ppm), which identify the location of the major peaks in the spectra, are shown in 
brackets for each metabolite.”High” implies the metabolite is at higher concentration in the 
early RA disease phenotype. 
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6.3.1.4 Fibroblasts cultured at 3% oxygen 
Using PLSDA analysis I was unable to detect a difference between the metabolic profiles 
of fibroblasts cultured at 3% oxygen between the healthy controls and those patients with 
inflammatory arthritis (Figure 6.23).  
 
Figure 6.23 Fibroblasts cultured at 3% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with inflammatory arthritis 
(established RA, early RA and early resolving arthritis) (●). PLSDA analysis separated 
the groups with a sensitivity of 50% and specificity of 89%. 
 
There was good separation between the metabolic profiles of fibroblasts cultured at 3% 
oxygen between the healthy controls and those patients with early resolving arthritis 
(Figure 6.24) and the healthy controls and those patients with established RA (Figure 
6.26). However there was poor separation between the metabolic profiles of fibroblasts 
cultured at 3% oxygen between the healthy controls and those patients with early RA 
(Figure 6.25). 
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Figure 6.24 Fibroblasts cultured at 3% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with early resolving inflammatory 
arthritis (●). PLSDA analysis separated the groups with a sensitivity of 100% and 
specificity of 67%. 
 
Figure 6.25 Fibroblasts cultured at 3% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with early RA (●). PLSDA analysis 
separated the groups with a sensitivity of 50% and specificity of 67%. 
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Figure 6.26 Fibroblasts cultured at 3% oxygen from patients with no evidence of 
inflammatory arthritis (normal) (○) and those with established RA (●). PLSDA 
analysis separated the groups with a sensitivity of 67% and specificity of 100%. 
 
There was also poor separation between the metabolic profiles of fibroblasts cultured at 
3% oxygen between those patients with early resolving arthritis and those who had early 
RA (Figure 6.27). 
 
Figure 6.27 Fibroblasts cultured at 3% oxygen from patients with resolving arthritis 
(○) and those with early RA (●). PLSDA analysis separated the groups with a sensitivity 
of 67% and specificity of 50%. 
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6.3.2. Correlation of baseline metabolite profiles with CRP 
The relationship between baseline metabolite profiles and CRP (at the time of biopsy) of 
the patient from whom the synovial biopsy was collected was assessed using PLS-R. The 
analysis employed a forward selection approach to discover those NMR bins that were 
most predictive. A total of 204 bins created the optimal model with a cross-validated r2 of 
0.9366 (Figure 6.27). Permutation testing with these 204 NMR bins demonstrated that the 
regression model was statistically valid (p<0.0001). 
 
Figure 6.28 Metabolic profiles in cultured synovial fibroblasts from patients' serum 
CRP level at the time of biopsy 
 
The metabolites identified for this association are illustrated in table 6.5. 
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Ranked 
importance 
(VIP) 
Metabolites identified associated with CRP 
(ppm) 
1 (33) Cholesterol (0.9-1.1) 
2 (31) Fatty acids (0.8-0.84, 2.22-2.24)  
3 (29) Leucine (0.94-0.96) 
3 (21) Citrate (2.54, 2.66, 2.62) 
4 (17) Pyroglutamate (2.52) 
5 (16) Carnosine (2.69) 
6 (15) Alanine (1.48) 
7 (13) Lactate (1.31, 1.33) 
 
Table 6.5: Metabolites most strongly correlated with CRP. Metabolites were identified 
from the top 50 bins of the PLS-R model and represent the regions of the spectra which 
had the greatest influence on the correlation with CRP. NMR chemical shifts (ppm), which 
identify the location of the major peaks in the spectra, are shown in brackets for each 
metabolite. 
 
6.3.3 Correlation of baseline metabolite profiles with cytokines 
6.3.3.1 Correlation with IL-6 
The synovial fibroblasts from inflamed joints produced more IL6 in culture than the 
healthy controls (Figure 6.29). This was significant between the healthy controls and the 
early RA groups.  
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Figure 6.29 Fibroblasts from inflamed joints produce more IL6 in culture 
 
The relationship between baseline metabolite profiles of the media and IL-6 was assessed 
using PLS-R. The analysis employed a forward selection approach to discover those NMR 
bins that were most predictive. A total of 111 bins created the optimal model with a cross-
validated r2 of 0.7729 (Figure 6.30). Permutation testing with these 111 NMR bins 
demonstrated that the regression model was statistically valid (p<0.0001). There was also a 
significant correlation between the patient’s CRP and the amount of IL 6 produced in 
culture (p=0.03).  
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Figure 6.30 Metabolic profiles in cultured synovial fibroblasts from patients correlate 
with fibroblast IL6 production 
The metabolites identified with this association are illustrated in table 6.6. 
Ranked 
importance 
(VIP) 
Metabolites identified associated with IL 6 
(ppm) 
1 (161) Citrate (2.54, 2.66, 2.62) 
2 (123) Carnosine (2.69) 
3 (78) Pyroglutamate (2.52) 
3 (69) Alanine (1.48) 
4 (54) Lactate (1.31, 1.33) 
5 (50) Glycerol (3.57) 
6 (49) Leucine (0.94-0.96) 
7 (44) Acetylglycine (3.76, 3.77) 
8 (37) Glucose (3.38, 3.5, 3.68) 
 
Table 6.6: Metabolites most strongly correlated with IL-6. Metabolites were identified 
from the top 50 bins of the PLS-R model and represent the regions of the spectra which 
had the greatest influence on the correlation with IL-6. NMR chemical shifts (ppm), which 
identify the location of the major peaks in the spectra, are shown in brackets for each 
metabolite. 
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Due to this strong correlation between IL6 and the metabolic profiles I wished to 
determine whether it was the IL6 that was directly responsible for this alteration in 
metabotype. Hence, we treated synovial fibroblasts from healthy controls with IL6 and 
synovial fibroblasts from patients with RA with TCZ. The demographics of the patients 
used in this experiment are illustrated in table 6.7. 
 
 Established RA 
(n=2) 
Healthy 
controls 
(n=6) 
Age (years); median (IQR) 64 (63-64) 42 (40-52) 
Female; number (%) 2 (100) 4 (67) 
Symptom duration (weeks); 
median (IQR) 
66 (27-104) - 
NSAIDs; number (%) 1 (50) 0 (0) 
CRP (mg/ml); median (IQR) 5 (0-10) - 
RF positive; number (%) 2 (100) - 
Anti CCP antibody positive; 
number (%) 
2 (100) - 
Joint biopsied 
Knee; n (%) 
MCP; n (%) 
 
1 (50) 
1 (50) 
 
6 (100) 
0 (0) 
Table 6.7: Demographic and clinical characteristics of study participants for the IL 6 
related experiments. 
 
 
Analysis of the media from fibroblast from healthy controls demonstrated a change in the 
metabolic profile following stimulation with IL6 as illustrated by the PLSDA plot (Figure 
6.31). This model comprised of 3LVs which captured 62% of the variance. Metabolites 
associated with this separation were identified from VIP plots and are listed in table 6.8.  
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Figure 6.31 PLSDA plot of fibroblast media from fibroblasts cultured at 20% oxygen 
from healthy controls (○) and those treated with IL6 (●). PLSDA analysis separated the 
groups with a sensitivity of 67% and specificity of 67%. 
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Ranked 
importance 
(VIP) 
Metabolites differentiating healthy 
controls and those treated with IL6 (ppm) 
1 (66) Glycerol (3.66, 3.65, 3.67, 3.58, 3.57) high 
2 (46) Lactate (1.34, 1.32) high 
3(40) Pyruvate (2.37) high 
4 (30) Ethanol (1.18) low 
5 (29) Glucose (3.45, 3.71, 3.51, 3.91, 3.23, 3.38, 
3.70, 3.81) low 
6 (24) Histamine (7.85) high 
7 (24) Methanol (3.36) high 
8 (17) Asparagine (2.84, 2.83) low 
9 (12) Aspartate (2.66) low 
10 (12) Fructose (4.02) low 
11 (12) Saccharopine (3.06) low 
Table 6.8: Metabolites most strongly associated with the differentiation between 
healthy controls and those treated with IL6. Metabolites were identified from the PLS-
DA model and represent the regions of the spectra which had the greatest influence on the 
separation. The metabolites for all peaks with a VIP > 10 were identified. NMR chemical 
shifts (ppm), which identify the location of the major peaks in the spectra, are shown in 
brackets for each metabolite. ”High” implies the metabolite is at higher concentration in 
the samples treated with IL6. 
 
Stimulation of synovial fibroblasts from healthy controls with IL6 did not alter the 
metabolic profile of the fibroblasts themselves (as opposed the media in which they were 
grown) significantly as the PLSDA plot (model comprised of 3LVs which captured 52% of 
the variance) did not show any clear separation between the healthy controls stimulated 
with IL6 and those that were not (Figure 6.32).   
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Figure 6.32 PLSDA plot of fibroblasts cultured at 20% oxygen from healthy controls 
(○) and those treated with IL6 (●). PLSDA analysis separated the groups with a 
sensitivity of 42% and specificity of 46%. 
 
Metabolic profiles of media from fibroblasts from patients with established RA were 
altered greatly post treatment with TCZ and this can be illustrated by the PCA plot (Figure 
6.33) and the PLSDA plot (Figure 6.34).  The PLSDA model comprised of 2LVs which 
captured 89% of the variance. The metabolites responsible for this separation were 
identified from the VIP plots and are listed in table 6.9.  
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Figure 6.33 PCA plot of fibroblast media from fibroblasts cultured at 20% oxygen 
from patients with established RA (○) and those treated with TCZ (●) 
 
Figure 6.34 PLSDA plot of fibroblast media from fibroblasts cultured at 20% oxygen 
from patients with established RA (○) and those treated with TCZ (●). PLSDA 
analysis separated the groups with a sensitivity of 75% and specificity of 80%. 
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Ranked 
importance 
(VIP) 
Metabolites differentiating established RA 
treated with TCZ and those treated with 
IVIg (ppm) 
1 (114) Sucrose (4.22, 4.23) high 
2 (109) Glucose (3.69, 3.83, 3.85) high 
3 (83) Myo-Inositol (4.06, 4.07, 4.05) high 
4 (68) Glycero-3-phosphocholine (3.65, 3.66) low  
5 (45) Fructose (3.58) high 
6 (48) Ethanol (3.64) low  
6 (15) Arginine (1.92) low 
Table 6.9: Metabolites most strongly associated with the differentiation between 
established RA treated with TCZ and those treated with IVIg. Metabolites were 
identified from the PLS-DA model and represent the regions of the spectra which had the 
greatest influence on the separation. The metabolites for all peaks with a VIP > 10 were 
identified. NMR chemical shifts (ppm), which identify the location of the major peaks in 
the spectra, are shown in brackets for each metabolite. ”High” implies the metabolite is at 
higher concentration in the samples treated with TCZ. 
 
Treatment of fibroblasts themselves (as opposed the media in which they were grown) 
from patients with established RA with TCZ also altered the metabolic profile 
considerably as there is a clear separation on PCA (Figure 6.35) and PLSDA (Figure 6.36). 
The PLSDA model comprised of 1 LV which captured 92% of the variance. One of the 
control samples did not ‘lock’ in the NMR spectrometer so we were unable to analyse this 
sample. The metabolites responsible for this separation are listed in table 6.10.  
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Figure 6.35 PCA plot of fibroblasts cultured at 20% oxygen from patients with 
established RA treated with ivIG (○) and those treated with TCZ (●) 
 
 
 
Figure 6.36 PLSDA plot of fibroblasts cultured at 20% oxygen from patients with 
established RA treated with ivIG (○) and those treated with TCZ (●). PLSDA analysis 
separated the groups with a sensitivity of 100% and specificity of 100%. 
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Ranked 
importance 
(VIP) 
Metabolites differentiating established RA 
treated with TCZ and those treated with 
IVIg (ppm) 
1 (76) Glucose (3.69, 3.67, 3.83, 3.47, 3.27, 3.46, 
3.52, 3.87) high 
2 (57) Sucrose (4.06, 4.07, 4.22, 4.24) high 
3 (30) Glycero-3-phosphocholine (3.64) low 
4 (26) Lactate (1.34, 1.33) high  
5 (22) Myo-Inositol (3.28) low 
6(10) Arginine (1.93) low 
Table 6.10: Metabolites most strongly associated with the differentiation between 
established RA treated with TCZ and those treated with IVIg. Metabolites were 
identified from the PLS-DA model and represent the regions of the spectra which had the 
greatest influence on the separation. The metabolites for all peaks with a VIP > 10 were 
identified. NMR chemical shifts (ppm), which identify the location of the major peaks in 
the spectra, are shown in brackets for each metabolite. ”High” implies the metabolite is at 
higher concentration in the samples treated with TCZ. 
 
The IL6 production in culture at 3% oxygen from the different fibroblasts from different 
outcome groups is illustrated in (Figure 6.37). Again, less IL6 was produced by the healthy 
controls compared to the cells with inflammatory arthritis. 
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Figure 6.37 Fibroblasts from inflamed joints cultured at 3% oxygen produce more 
IL6 in culture. 
 
The relationship between baseline metabolite profiles at 3% and Il-6 was assessed using 
PLS-R but permutation testing with these NMR bins demonstrated that the regression 
model was not statistically valid (p =0.06).  
 
6.3.3.2 Multiplex analysis 
There was no significant difference between any of the outcome group for any of the other 
cytokines that we tested for at 20% oxygen (Figure 6.38) or 3% oxygen (Figure 6.39). 
Only five of the twelve cytokines that we tested for were detected in our samples but our 
samples were all unstimulated and several of these cytokines have only been detected in 
stimulated samples. 
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Figure 6.38 Multiplex analyses of cytokines from fibroblasts from inflamed joints  
cultured at 20% oxygen.  
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Figure 6.39 Multiplex analyses of cytokines from fibroblasts from inflamed joints 
cultured at 3% oxygen. 
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6.4 Discussion 
 
Metabolomics provides a novel “systems” approach to the investigation of disease 
mechanisms in RA and here we have used it to study metabolism in one of the key cell 
types found in the synovial membrane.  We have discovered that the metabolic profile 
found in culture media and cell extracts derived from synovial fibroblasts from an 
individual patient in the earliest stage of inflammatory arthritis can predict the subsequent 
course of the disease.  The cellular metabolic profiles of patients with early inflammatory 
arthritis whose arthritis resolves could be clearly distinguished from those who developed 
early RA when we used synovial fibroblasts and their media grown under 20% oxygen 
(though the media gave better predictive values) and the media of synovial fibroblasts 
cultured at 3% oxygen. These outcome groups could not be distinguished using profiling 
of fibroblasts cultured at 3% oxygen. This discrepancy may be a result of the cells of both 
outcome groups undergoing anaerobic respiration, hence resulting in similar metabolic 
profiles. 3% oxygen may not have been the most appropriate oxygen sate to use as several 
studies have used 1% oxygen and low FCS to mimic extreme hypoxic conditions (Ahn et 
al. 2008). Microarray studies identified differences in gene expression between synovial 
fibroblasts from healthy controls and those from RA patients but most of these changes 
were at 0.5% oxygen rather than 3% (Del Rey et al. 2010). However, direct measurement 
of oxygen shows that the average oxygen concentration in the RA joint is 3% (Biniecka et 
al. 2011a;Kennedy et al. 2011) and so we are confident that the conditions we have used 
are the most appropriate. We also cultured our fibroblasts in 10% FCS and the changes 
may have been more prominent if we had cultured the fibroblasts in 0.1% FCS, as is the 
case in the microarray studies (Ahn et al. 2008;Rinn et al. 2006).  
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Different metabolites were identified in the cells and the media of synovial fibroblasts but 
the media from cells cultured at 20% oxygen and those cultured at 3% gave similar 
metabolite results. Lactate was a larger contributor from cells cultured at 3% oxygen 
compared to 20% and this may represent a manifestation of anaerobic respiration and 
increased glycolysis, usually associated with cancer cells. In cancer cells hypoxia causes 
an epigenetic and biochemical response to counteract the decrease in energy supply from 
mitochondrial respiration (Frezza et al. 2011). The metabolites identified and their 
relationships are illustrated in figure 6.40. The majority of the metabolites identified are 
involved in glycolysis and are thought to prevent pyruvate from entering the Krebs cycle. 
This is similar to that seen in the Warburg effect where cells use glycolysis during growth. 
We are aware that metabolites such as pyroglutamate, which we found contributed to the 
correlation with CRP and IL6, accumulate if there is a reduced amount of ATP available, 
which is the case in anaerobic respiration. Our work is supported by other research which 
has demonstrated that hypoxia causes increased migration and invasion of fibroblasts and 
that this is mediated by HIF-1α (Li et al. 2013). Research into osteoclast activity in RA has 
also demonstrated that during hypoxia there is an increase in glucose consumption and 
lactate production and this switch to anaerobic respiration enables an increase in ATP 
production during hypoxia which is required due to the increased metabolic demand 
(Morten et al. 2013).  
 
Several other metabolites were also identified which are related to cell growth. 
Saccharopine is a lysine metabolite and multiple metabolites such as histidine, alanine, 
asparagine and glutamine are protein intermediates which may be required for cell growth. 
The enzyme that is involved in the production of saccharopine (LOR/SDH) has been 
detected in a number of mammalian tissues, mainly in the liver and kidney, contributing 
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not only to the general nitrogen balance in the organism but also to the controlled 
conversion of lysine into ketone bodies (Elpeleg et al. 1990). The metabolite glycerol was 
also identified which is a fatty acid intermediate and lipolysis is an alternative method 
which may contribute to the energy required for cell growth (Guppy et al. 2002). Raised 
levels of ketone bodies have been found in the synovial fluid of patients with RA again 
supporting the use of lipolysis (Naughton et al. 1993b).  
 
Formic acid was identified as a discriminating metabolite for the fibroblast cells but the 
cells were extracted using chloroform and methanol and methanol metabolises to formic 
acid so we feel this was identified simply due to the experimental set up.  
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       glucose 
    glucose 6 phosphate                   myoinositol 
    2 phosphoglycerate 
  asparagine phosphoenolpyruvate 
pyroglutamate lactate           pyruvate                        alanine 
aspartate       oxaloacetate              citrate 
malate                                                 α-ketoglutarate            saccharopine 
fumarate                                                              glutamine             glutamate 
                                                      succinate                                      histidine 
Figure 6.40 Metabolites responsible for the difference in outcome in patients with 
early inflammatory arthritis. Metabolites in bold are the metabolites that were 
identified. 
 
The medium from cultured synovial fibroblasts was more useful at distinguishing outcome 
groups than the cells.  There was clear differentiation between the metabolic profile of 
healthy controls and those patients with inflammatory arthritis using the media but this 
separation was not as prominent using the cells.  This may be due to the fact that 
metabolites accumulate over time in the media whereas the metabolic profile in the cell 
extracts is just a snap shot of what is occurring in the cell. No previous metabolomic work 
has been done using synovial fibroblasts and from our control work (section 3.3) we 
concluded the use of fibroblasts from two T75 flasks was the minimum necessary to derive 
good spectra but this may not be a sufficient number to identify changes in outcome.  
glutamate 
glutamine 
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Another reason why the outcome groups may not be clearly distinguished may be due to 
our definitions of early and established RA. Some of our established RA patients had 
relatively short disease duration (less than 12 months) and in some cohorts they may be 
defined as early RA (Harris et al. 2013;Kuijper et al. 2013). We used the shorter disease 
duration in established RA to prevent potential drug interference in the metabolic profiles. 
Another possible confounder in our study is the use of healthy controls. Our healthy 
controls are not really ‘normal’ but they are the closest to ‘normal’ that we could use. 
However, they were experiencing knee related symptoms necessitating arthroscopy and 
any type of procedure such as an arthroscopy may cause a local inflammatory response.  
 
There was a significant association between CRP levels in the patients’ serum and the 
metabolic profile of their synovial fibroblasts. This implies that fibroblasts from 
inflammatory arthritis patients retain their metabolic fingerprint during culture ex vivo. 
There was also a significant association between the metabolomic fingerprint of synovial 
fibroblasts and their IL6 production, raising the possibility that IL6 production drives or is 
driven by significant changes in metabolism.  Several similar metabolites were associated 
with the correlation with CRP and the correlation with IL 6 which is not surprising since 
there was also a significant correlation between the CRP and IL 6. The metabolites that 
were identified for the correlation with IL 6 were not the same metabolites that were 
identified for the established RA treated with TCZ or the healthy controls treated with IL 6 
even though IL 6 production locally does seem to directly drive changes in metabolism.  
This is not surprising as the changes in metabolism as illustrated by the metabolic profile 
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are probably a cumulative effect of the systemic activity of IL6 and other environmental 
factors.  
 
Our Luminex analysis did not reveal any significant results and this may be because 
production of several cytokines requires prior stimulation of the cells.  The literature 
illustrates that hypoxia induces expressions of certain cytokines; MMP 1, MMP 3, Il6, IL8, 
VEGF (Hitchon et al. 2002) and we did find greater amounts of these cytokines in the 
fibroblasts cultured at 3% oxygen.  Certain cytokines which have been found to distinguish 
OA and RA such as CXCL12 are not detected in early disease (Tsubaki et al. 2005). It 
would have been interesting to test for CXCL9 and CXCL10 as these have been associated 
with early RA (Tsubaki et al. 2005) but this was not possible. Culturing synovial 
fibroblasts for several months in vitro may alter their cytokine production and make 
prediction of outcome difficult. However, the phenotype of synovial fibroblasts is 
imprinted for many months when cultured in vivo (Kiener et al. 2010) though primary 
culture cells markedly differ from cells of passage four (Zimmermann et al. 2001). 
However, central pathological characteristics such as IL6 expression remain present over 
many passages using the SCID mouse model (Hirth et al. 2002;Mueller-Ladner et al. 
1996). Researchers have found that using microarrays passage 2 to passage 4 is the best 
window (Neumann et al. 2010) but this may not be the case for metabolomics or cytokine 
analysis.   
 
In summary, we have found that the metabolic profile of an individual early arthritis 
patient’s cultured synovial fibroblasts (media and to a lesser extent cells) predicts the 
subsequent course of the patient’s disease. We have found a significant association 
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between CRP levels in the patients’ serum and the metabolic profile of their synovial 
fibroblasts and a significant association between the metabolomic fingerprint of synovial 
fibroblasts and their IL6 production. Though local activity of IL 6 is only one of the 
contributing factors to systemic inflammation systemic activity of IL 6 as measured by 
metabolic profiles may be a useful measure of the inflammatory burden in a patient with 
inflammatory arthritis.  
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7.0 General Discussion 
 
Since the start of this project there have been significant advances in the field of 
metabolomics. Prior to my work there were no publications applying metabolomics to 
studies of RA and we have now successfully assessed metabolomic profiles of several 
different biofluids relevant to RA, to detect changes in metabolism. The central aims of my 
work have been discussed in the individual chapters but I will use this overall discussion to 
discuss the common themes in further detail. Using urine samples we have shown that two 
different inflammatory conditions (RA and PsA) can be distinguished using NMR 
spectroscopy and our work with serum has demonstrated that patients with RA can be 
distinguished from healthy controls. We have also found clear differences in the metabolic 
profiles of baseline urine samples of patients with RA who responded well to anti-TNF 
therapy compared with those who did not.  This difference may be important as a novel 
predictor of responses to TNF antagonists, an area which requires further exploration.  
 
One of the metabolites that contributed to this prediction of response to therapy was 
histamine, and histidine degradation products have also been found in patients with 
inflammatory bowel disease. Hence, this may be a generic marker of inflammatory 
processes rather than being specific to RA. The literature suggests that there are a number 
of such metabolites which are common to several inflammatory conditions and thus 
markers of inflammation. Indeed, our work on the serum of patients with early 
inflammatory arthritis clearly illustrates the strong relationship between inflammation and 
the metabolic profile and histidine degradation products again contributed to this 
relationship.  
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As with data on the serum profiles, we found a strong relationship between inflammation 
and the metabolites from synovial fibroblasts. Furthermore, there was some overlap 
between the metabolites in the fibroblast media that correlated with patient CRP and those 
in serum that correlated with CRP (Table 7.1). However, lipids made a significant 
contribution to the serum correlation but this was not the case for the fibroblast media. 
This difference may be because the serum samples were not filtered whereas the media 
samples were, a process likely to remove most of the lipids since they would be present as 
micelles or protein-bound.  
Metabolites identified in 
the sera of patient group 1 
Metabolites identified in 
the sera of patient group 2 
Metabolites identified in 
the fibroblast media 
Choline  LDL-lipids  Cholesterol 
LDL-lipids  Acetylglycine  Fatty acids 
Lactate  Glucose  Leucine 
Acetylglycine  Fatty acids  Citrate 
Urea  Methylguanidine  Pyroglutamate 
Glucose  Lactate  Carnosine 
Methylguanidine  Threonine  Alanine 
Methylhistidine  Homocystine  Lactate 
Cholesterol  Glycine   
Taurine  Taurine   
Threonine  Methylxanthine   
Fatty acids  Choline   
Methylxanthine  Methylhistidine   
Homocystine  Cholesterol   
 
Table 7.1: Metabolites in the serum and fibroblast media that most strongly 
correlated with patient CRP. 
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We found a significant association between the metabolomic fingerprint of synovial 
fibroblasts and their IL6 production. Local activity of IL 6 alters metabolism (Boettger et 
al. 2010) and systemic activity of IL 6 and metabolic profiles may be a useful measure of 
the inflammatory burden in a patient with inflammatory arthritis. 
 
We were able to use metabolic profiles of synovial fibroblasts from the earliest stage of 
inflammatory arthritis to predict the subsequent course of the disease. The metabolic 
profiles of fibroblasts from patients with early inflammatory arthritis whose arthritis 
resolved could be clearly distinguished from those from patients who developed RA.  This 
was true of metabolites from the cells and their media when grown at 20% oxygen and 
also true of the media from synovial fibroblasts cultured at 3% oxygen. The metabolites 
associated with this prediction were mainly linked to glycolysis but also related to 
increased glutamine consumption, lipolysis and protein metabolism. These observations 
suggest that the “Warburg effect” may be in play in the inflamed joint since it is known 
that this characterises cells which actively use glycolysis during cell growth rather than 
mitochondrial respiration. The Warburg effect is usually discussed in the context of cancer 
but these observations suggest the same metabolic deviation may occur in RA.  
 
In cancer there is an increased requirement for ATP with 10% more ATP being produced 
by cancer cells compared to normal cells (Koppenol et al. 2011). Traditionally glucose and 
glutamine are felt to be the major energy sources for cancer metabolism but recent data 
suggest that glucose and glutamine contribute to less than half of the ATP production 
(Guppy et al. 2002). One of the methods by which this extra ATP may be produced is 
through lipolysis (Guppy et al. 2002) and in hypoxia increased metabolites which are lipid 
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derivatives, particularly acyl-carnitine, have been found (Frezza et al. 2011). We identified 
the fatty acid intermediate ethanolamine to be an important metabolite contributing to the 
prediction of responses to TNF antagonists in patients with RA. We also observed the fatty 
acid intermediate glycerol in our work on synovial fibroblasts. Catabolic intermediates 
derived from proteins have also been observed in cancer cells under hypoxia (Frezza et al. 
2011) suggesting that hypoxic cancer cells require catabolic processes in addition to the 
increased glycolytic flux to provide the increased ATP required for their proliferation.  
One of the key metabolites identified in that study on cancer were tryptophan metabolites 
and we also identified tryptophan metabolites to be key players in the urine in predicting 
responses to TNF antagonists in patients with RA.  
 
It is likely that the hypoxic nature of the RA joint requires a metabolic switch in fibroblasts 
to anaerobic respiration in order that they have sufficient energy to drive the bone loss 
which is seen in RA (Morten et al. 2013). The metabolic changes which we have seen in 
the RA synovial fibroblasts, with increased glycolysis and increased glutamine 
consumption, have been seen by others (Chang and Wei 2011;Morten et al. 2013) 
confirming that significant metabolic shifts occur within the cells of the inflamed joint.  
 
Several groups including ours (Young et al. 2013) have detected an increase in lactate in 
the blood of RA patients which provides supporting evidence for this shift to anaerobic 
respiration (Lauridsen et al. 2010;Morten et al. 2013).  In cancer, elevated lactate 
concentrations facilitate sustained glycolysis by the tumour and lead to an acidic tumour 
environment which is closely correlated with clinical outcome (Bayley and Devilee 2012). 
Lactate is thought to stimulate angiogenesis via the VEGF/VEGF2 signalling pathway 
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which is under the regulation of HIF-1α. Recent research has shown that lactate can 
promote NF-κB activation in endothelial cells, leading to the production of IL-8/CXCL8 as 
an autocrine signal, mediating the effects of lactate on angiogenesis and tumour perfusion 
(Vegran et al. 2011). All these events can occur in the presence of glucose thus providing 
an alternative route through which cell metabolism and angiogenesis may be linked 
independently of oxygen status and this may occur in RA as well as cancer.  
 
Current data suggest that inflammatory pathways such as those regulated by NF-κB 
interact with other pathways which are regulated by hypoxia. NF-κB can control the 
expression of genes for TNF, Il 6, Il 8, VEGF, MMP1, MMP3 and MMP13. Hypoxia can 
activate NF-κB; hence regulate cytokines in HIF 1 independent or dependent pathways 
(Konisti et al. 2012). There is now significant evidence for cross talk between HIF-1α and 
NF-κB pathways and hypoxia can activate both.  
 
Tumour hypoxia has an important role in several aspects of cancer biology but evidence 
suggests that it is a late-occurring event which may not be the major contributor in the 
switch to aerobic glycolysis in cancer cells (Vander Heiden et al. 2009). This may be the 
case in RA too. We have found that synovial fibroblasts from patients with the early stage 
of inflammatory arthritis undergo glycolysis and produce lactate. Our clinical data of the 
biopsied joint suggest that these patients have minimal synovitis both clinically and by 
ultrasound compared to established RA and hence their joints will not be hypoxic as the 
level of hypoxia is related to the degree of synovitis (Kennedy et al. 2011). The production 
of lactate by these cells may then cause the joint to become acidic and contribute to the 
hypoxia and sustain glycolysis. As is the case in cancer, mutations or significant epigenetic 
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changes might be required to give cells in RA the ability to acquire nutrients and regulate 
metabolic pathways in the joint.  
 
In cancer, aerobic glycolysis can occur concurrently with mitochondrial respiration. The 
increase in glycolysis in cancer is caused by damage to the regulation of glycolysis which 
may result from the activity of oncogenes and tumour suppressor genes. Oncogenic 
mutations in mitochondrial metabolic enzymes cause increased levels of HIF-1α. MYC is 
related to the biogenesis of ribosomes and mitochondria (Dang et al. 2009) and can 
stimulate aerobic glycolysis as MYC targets include glucose and glutamine transporters, 
glutaminase and glycolytic enzymes. It is also implicated in inducing the gene lactate 
dehydrogenase-A which generates lactate (Doherty et al. 2014). AKT oncogenes can also 
induce aerobic glycolysis and increase the activity of HIF-1α. P53 is involved in the 
regulation of mitochondrial respiration and glycolysis and loss of p53 leads to aerobic 
glycolysis (Koppenol et al. 2011). Work in the field of ageing has revealed that alterations 
in the naturally occurring isoform p53 causes changes in amino acids and derivatives of 
glycolysis (Lin et al. 2013). This alteration may be relevant in RA as well as in ageing and 
cancer.  
 
RA synovial fibroblasts continue to display an abnormal phenotype when grown in vitro 
and are able to directly invade cartilage when cultured in vitro. We have demonstrated that 
fibroblasts cultured in vitro continue to use glycolysis and this leads to increased 
production of lactate and in vivo would promote hypoxia in the joint. The reason why 
these features continue in vitro is most likely to result from epigenetic changes in the cells 
(Ospelt et al. 2011). Many of these have been seen in synovial fibroblasts in RA including 
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a reduction in methylation in the gene which encodes the chemokine CXCL12 (Bottini and 
Firestein 2013). CXCL12 stimulates production of MMPs which are partly responsible for 
the destructive behaviour of RASFs. Further investigation into the epigenetic changes 
which may be responsible for the glycolysis in fibroblasts could reveal novel and 
successful treatment targets.  
 
We obtained conflicting results when we used the metabolite profiles of serum from 
patients with early inflammatory arthritis to predict differences in outcome but we were 
able to predict differences in outcome using the in vitro synovial fibroblasts of these 
patients.  The metabolites that we identified which were associated with the prediction of 
outcome using in vitro synovial fibroblasts were different from the metabolites that we 
identified using serum (Table 7.2). There was some overlap with the metabolites lactate, 
alanine and glucose but lipids were an important metabolite in the serum. One of the other 
reasons for this difference in metabolites may be due to all the early RA outcome patients 
in the in vitro fibroblast study being auto antibody positive whereas the early RA group in 
the serum study were a combination of antibody positive and negative patients. We were 
unable to identify lipids in the fibroblast cells as we only analysed the polar layer which 
did not contain any lipids and we were unable to identify lipids in the media again due to 
filtering of samples.  It is not surprising that the metabolites that we identified are different 
in the different biofluids as this has been the case in other research (Schicho et al. 
2012;Sreekumar et al. 2009) and we are aware that the metabolic profile in serum will also 
reflect all the systemic changes seen in inflammatory arthritis, in addition to those 
focussed in the joint. 
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Persistent RA 
vs. resolving 
arthritis 
(synovial 
fibroblast 
media 20%) 
 
Persistent RA 
vs. resolving 
arthritis 
(synovial 
fibroblast 
media 3%) 
Persistent RA 
vs. resolving 
arthritis 
(synovial 
fibroblast cells 
20%) 
Persistent RA 
vs. resolving 
arthritis Group 
1 (serum) 
Persistent RA 
vs. resolving 
arthritis Group 
2 (serum) 
Ethanol Ethanol Formic acid Methylguanidine  Lactate 
Pyroglutamate Lactate Glucose Lactate Taurine 
Alanine Pyroglutamate Glycerol Acetylglycine Glucose  
Histidine Glucose Lactate Urea Methylguanidine  
Asparagine Methanol Myo-inositol  Alanine 
Methanol Asparagine 2-
phosphoglycerate 
 Acetylglycine 
Citrate Alanine   LDL-CH2 
Aspartate     
Saccharopine     
Glucose     
Glycerol     
Lactate     
Glutamine     
 
Table 7.2: Metabolites most strongly associated with the differentiation between 
persistent RA and arthritis that resolves using synovial fibroblasts and serum. 
 
 
Metabolomics is still largely a research tool and has yet to move out into the clinical arena. 
Nevertheless it is an approach that has great potential for widespread clinical application. 
For example, a large metabolomic study in prostate cancer identified sarcosine as a 
metabolite that differentiated between benign prostate, clinically localised prostate cancer 
and metastatic disease (Sreekumar et al. 2009).  This group then used this to reveal that 
sarcosine was a potentially important metabolic intermediary of cancer cell invasion and 
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aggressivity, thus providing both a novel biomarker in addition to new insights into disease 
pathology.  The work described in this thesis goes a small way to emulating that study 
since the cellular metabolites that we have identified provide some novel insights into the 
mechanisms underlying the persistence of inflammatory arthritis and potential therapeutic 
targets to halt or prevent disease.   
 
7.1 Limitations 
Lactate is an important molecule in metabolism and we have demonstrated that it is a key 
player in the development of persistent arthritis using in vitro synovial fibroblasts. We 
obtained conflicting results regarding lactate in our serum studies and it is important that 
clinical serum samples are revisited with better control of collection sampling, as 
demonstrated by our control work, in order to ascertain whether serum lactate levels could 
be a biomarker for disease persistence in people presenting with early inflammatory 
arthritis.  
 
Our in vitro work has focussed on synovial fibroblasts which are an important cell in the 
pathogenesis of RA but fibroblasts do not act in isolation. Other important cell types in RA 
include macrophages, T cells and B cells and it may be that we would have obtained a 
better model of disease if we had used co-cultures of fibroblasts and macrophages for our 
metabolomic studies.  We investigated the action of IL6 on synovial fibroblasts but 
macrophages not fibroblasts have membrane bound IL6 receptor so a co-culture of 
macrophages and fibroblasts may have given us further insights into the mechanism of 
disease in RA. Co-cultures of RASFs and T cells have been used as a model in other 
studies (Bradfield et al. 2003;Hu et al. 2013) and there has also been published work using 
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co-cultures of macrophages and fibroblasts in studies looking at bone destruction in RA 
(Kim et al. 2011;Kwok et al. 2012). 
 
Hypoxia is also important in macrophages and evidence suggests that knockout of HIF-1 α 
causes cells to develop a M2 phenotype, which is more anti inflammatory. Studies have 
also demonstrated that knockout of HIF-1 α in a mouse model of CIA caused a reduction 
of the clinical synovitis symptoms of CIA (Konisti et al. 2012). This suggests that 
macrophages as well as fibroblasts play an important role in the regulation of metabolism 
in RA.  
 
7.2 Future work 
Conventional treatments target established RA late on in disease and in a non personalised 
manner. We have demonstrated for the first time that metabolomic techniques using 1D 
NMR spectra can predict outcome to antiTNF therapy in patients with severe RA 
providing a sensitivity and specificity for response that has potential clinical utility despite 
a small initial cohort of patients. There is a pressing need to confirm and extend this 
finding in a larger cohort of patients, combining metabolomic with cytokine and 
autoantibody analyses to develop tests that can predict response without the need for 
empirical treatment, bringing closer the era of individually tailored therapy.   
 
We have used serum and synovial fibroblasts to investigate prediction of outcome in 
patients with early inflammatory arthritis but our work in established RA has demonstrated 
what a useful biofluid urine is. Urine samples are extremely user friendly for NMR 
spectroscopy as they require little preparation, remain stable for several hours and you are 
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able to obtain very good spectra from these samples. Urine samples are not collected 
routinely in rheumatology practice which is why our work focussed on serum but over the 
last two years we have been collecting urine samples in the clinic. It would be extremely 
useful and interesting to try and use these urine samples to predict outcome in the future.  
 
We have demonstrated an increase in the metabolites related to glycolysis using our in 
vitro synovial fibroblasts but it would be useful to examine this relationship more closely 
by the use of metabolic flux.  Our results for the synovial media were much more 
convincing than our results for the cells. The metabolic profile obtained from the cell is 
just a snap shot whereas the metabolic profile in the media is the result of accumulation 
over several days at least. For this reason it would be useful to apply metabolic flux to 
these samples to examine the exact relationships between the metabolites and the temporal 
relationship for this. This would hopefully give us further insights into the pathogenesis of 
RA. In vivo Magnetic Resonance Spectroscopy has been used in cancer and may be a 
useful tool to classify early arthritis in the future using the metabolic differences that I 
have seen in vitro with the synovial fibroblasts (Vicente et al. 2013).  
 
Targeting the metabolites in glycolysis and reducing the Warburg effect may be ideal 
options for treating RA, as has been the case in cancer. Changes to signalling of the 
transcription factor HIF lead to alterations in expression of approximately 1% of all human 
genes including glucose transporter 1, glyceraldehydes-3-phosphate and VEGF (Konisti et 
al. 2012). We have found changes in several steps of glycolysis and it would be very 
interesting and important to identify how much of this was due to HIF. Inhibiting HIF in 
future experiments would enable us to determine whether these changes were reversed and 
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would allow us to target HIF in addition to other intermediates of glycolysis in the 
treatment of RA.  
 
In conclusion, our work has given us significant novel insights into the pathogenesis of 
RA. Current therapeutic options for RA have improved the outcome for patients with RA 
but they are still inadequate. They target established RA late on in disease but our research 
provides novel markers with the potential to justify the early treatment of early 
inflammatory arthritis and thus prevent the development of RA. This work also suggests 
that targeting the intermediates of glycolysis, HIF-1α pathway and therefore angiogenesis 
may be important new therapeutic pathways which will enable us to make further progress 
in preventing the development of RA.  
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8.0 Appendix 
8.1 Composition of RPMI 
Component g/l 
Inorganic salts  
Calcium Nitrate • 4H2O  0.1 
Magnesium Sulfate (anhydrous)  0.04884 
Potassium Chloride  0.4 
Sodium Bicarbonate  2 
Sodium Chloride  6 
Sodium Phosphate Dibasic (anhydrous)  0.8 
Amino Acids  
L-Alanyl-L-Glutamine  —  
L-Arginine  0.2 
L-Asparagine (anhydrous)  0.05 
L-Aspartic Acid  0.02 
L-Cystine • 2HCl  0.0652 
L-Glutamic Acid  0.02 
L-Glutamine  —  
Glycine  0.01 
L-Histidine  0.015 
Hydroxy-L-Proline  0.02 
L-Isoleucine  0.05 
L-Leucine  0.05 
L-Lysine • HCl  0.04 
L-Methionine  0.015 
L-Phenylalanine  0.015 
L-Proline  0.02 
L-Serine  0.03 
L-Threonine  0.02 
L-Tryptophan  0.005 
L-Tyrosine • 2Na • 2H2O  0.02883 
L-Valine  0.02 
Vitamins  
D-Biotin  0.0002 
Choline Chloride  0.003 
Folic Acid  0.001 
myo-Inositol  0.035 
Niacinamide  0.001 
p-Aminobenzoic Acid  0.001 
D-Pantothenic Acid (hemicalcium)  0.00025 
Pyridoxine • HCl  0.001 
Riboflavin  0.0002 
Thiamine • HCl  0.001 
Vitamin B12  0.000005 
Other  
D-Glucose  2 
Glutathione (reduced)  0.001 
Phenol Red • Na  0.0053 
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8.2 Early arthritis healthy controls 
Information leaflet for healthy individuals 
Predicting outcome in patients with early inflammatory arthritis  
Invitation to take part 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. Thank you for reading this. 
What is the purpose of the study? 
Patients develop inflammatory arthritis because the cells of their immune system start 
attacking their joints. At the moment we do not know why this happens. What we do know 
is that in some patients the arthritis settles by itself, whereas in others it can go on to 
persist and can develop into a condition like rheumatoid arthritis. We are studying why 
patients develop arthritis and why in some patients the arthritis does not get better.  We are 
doing this by looking at the patterns of patients’ arthritis for example which joints are 
affected. We will assess this by examining the joints and by looking at them with an 
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ultrasound machine.  To understand more about what is going on with the cells of the 
immune system in patients with arthritis we are studying these cells and what they produce 
in the blood and urine. In addition we wish to see which genes are working in these cells. 
Eventually we hope to be able to predict how a patient’s arthritis is going to progress from 
their pattern of arthritis and the characteristics of their inflammatory cells when the patient 
is first seen in clinic. 
Why have I been chosen? 
You have been chosen because you have been identified as being a healthy individual. It is 
important for us to study healthy individuals so we can compare results from such people 
to results from patients with arthritis. This will allow us to understand how things have 
changed in patients with arthritis and will help us understand why they have developed 
problems with their joints (whilst you have not). 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form which you will 
be given a copy of. If you have been identified by a friend / relative of yours as being a 
healthy individual who may be interested in taking part in this study and you do not want 
to take part, the care of your friend / relative will not be affected in any way. 
 
What will happen to me if I take part? 
This study has several components. You can choose on the consent form to take part 
in some parts of the study but not in others. 
We will need to ask you a few questions to make sure that you do not have arthritis at the 
moment and that you do not have any of the following conditions: a current or recent 
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infection, inflammatory bowel disease, psoriasis, liver disease, inflammatory lung disease 
or asthma (requiring regular steroids), kidney disease or multiple sclerosis. We would also 
like to study a blood samples, up to 30 mls (1 syringe). Some blood will be analyzed 
immediately and some stored for analysis at a later date.  
 
We would also like you to collect the urine that you produce over a 24 hour period. This 
will allow us to study the levels of natural steroid and other small molecules in your urine. 
These substances are produced as a normal process in everyone – we wish to see if the 
level in the urine of healthy people differs from those in people with arthritis. 
In addition, we would like to look at your joints with an ultrasound scan. This will take 
about 1 hour and is an entirely harmless procedure.  
You can opt out of either of these last two components of the study, while still taking part 
in the research study, by allowing us to collect blood samples.  
The majority of the samples that we collect will be analysed in Birmingham. Some of the 
samples may be sent to research groups with whom we work in the UK and Europe 
including a Biotechnology Company called Cellzome. 
Any samples from you will be given a unique code number and no identifiable details 
about you will be stored. The researchers analyzing your samples will not be able to 
identify who the sample has come from. 
What do I have to do? 
If you agree to take part in this study we will ask you a few questions to ensure you do not 
have any condition listed above and collect the blood sample. We will arrange a 
convenient time for the ultrasound scan of the joints to be performed. We will give you a 
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bottle to take home to collect the urine sample which you will need to return to us the 
following day.   
What are the side effects of taking part? 
You may develop a bruise around where the needle is introduced into the arm where the 
blood is taken; these will settle within a few days. There are no other side effects you are 
likely to experience. 
What are the possible disadvantages and risks of taking part? 
None besides the possible side effects noted above and the inconvenience associated with 
collecting a 24 hour urine sample. 
 
What are the possible benefits of taking part? 
Whilst there will be no direct benefit to you, the information we get will allow a better 
understanding of why patients develop arthritis and hopefully lead to improved treatments. 
 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you.  
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Will my taking part in this study be kept confidential? 
All information given by you and all results obtained will be treated in the strictest 
confidence. It would not be possible for the researchers to link the results of the research 
tests back to you as an individual.  
 
What will happen to the results of the research study? 
The results of the research study are likely to be published in a scientific journal. 
Information from the tests carried out on you will be included but you will not be 
individually identified. 
 
Who is organising and funding the research? 
This study is organised by the Departments of Rheumatology at the Sandwell and West 
Birmingham Hospitals NHS Trust and the University of Birmingham. This study is being 
funded, in part, by the Arthritis Research Campaign (ARC) and in part by the European 
Commission and the Medical Research Council (MRC). 
 
Who has reviewed the study? 
The study was reviewed by the Birmingham East, North and Solihull Research Ethics 
Committee. 
 
Contact for Further Information 
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A copy of this information sheet and a signed consent form will be given to you to 
keep. 
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Title of Project: Predicting outcome in patients with early inflammatory 
arthritis 
Name of Researcher: Dr Karim Raza   
 
Healthy volunteer screening form 
 
Screening questions  
 
If “No” to the following the volunteer is excluded as a healthy volunteer from this study: 
 
Do you consider yourself to be in good health? Yes  No 
 
If “Yes” to any of the following the volunteer is excluded as a healthy volunteer from this 
study: 
Do you currently have an infection?    Yes    No  
 
Have you had an infection in the last 1 month?  Yes    No 
 
Do you have a chronic inflammatory disease, including any of the following: 
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inflammatory arthritis 
inflammatory bowel disease 
psoriasis 
liver disease 
inflammatory lung disease or asthma (requiring regular steroids) 
kidney disease 
multiple sclerosis     Yes    No 
 
 
If the volunteer can be included and informed consent has been obtained: 
1. Collect blood sample 
2. Label sample and this form with Accession number and complete “Transient 
Research Sample” form 
3. Complete the following: 
 
 
Age (Years):   
 
Gender:   Male    Female 
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Consent form for healthy individuals 
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8.3 Early arthritis study patients 
Consent form for patients with early arthritis 
                                                                         
    
252 
 
  
253 
 
 
Participant Information Sheet 
 
Study title: Ultrasound guided synovial biopsy in patients with 
arthritis 
 
Invitation 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask us if there is anything that 
is not clear or if you would like more information.  If you do decide to take part, you are free to withdraw 
at any time without explanation and your subsequent treatment will not be affected.  
 
Why have I been chosen? 
You have been invited to participate because you have an arthritis, or symptoms suggestive of 
arthritis, and when your joints were scanned using ultrasound, one of your joints would be suitable 
to allow a sample (biopsy) of the joint lining (synovium) to be taken. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this information 
sheet to keep and be asked to sign a consent form. You are still free to withdraw at any time and 
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without giving a reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care that you receive. 
 
What is the purpose of the study? 
We know that in rheumatoid arthritis (RA) considerable thickening of the lining layer (synovium) in 
the joints occurs. This represents the accumulation of considerable numbers of new cells and 
tissue. However recently work suggests that the processes going on in the joint in very early RA 
are different to those occurring in the joints of patients whose arthritis will get better spontaneously. 
In order to find out what are the “switches” that convert early joint inflammation to chronic arthritis 
such as RA or get better in others, we need to study small samples (biopsies) of the joint lining. To 
do this we will use the same ultrasound machine which we used to show the inflammation in your 
joints to guide a miniature pair of tweezers (2mm thick, the thickness of a pencil lead) to take 
samples of the lining through a keyhole cut (of the same size, 2mm). These samples will be 
analysed in studies at the Rheumatology Department in the University of Birmingham, and may be 
sent to our collaborators within the European Union. Samples from finger joints use a special, even 
smaller (1.5mm) biopsy needle to obtain tiny samples. 
 
What will happen to me if I take part? 
The ‘keyhole’ procedure known as ultrasound guided synovial biopsy will be performed in a day 
surgery unit by a doctor trained in the procedure. The whole procedure should take no longer than 
90 minutes and uses local anaesthesia. One 2mm incision is made to the upper outer aspect of the 
joint which allows us to take small samples from inflamed areas guided by the ultrasound probe, 
which remains on the skin of the joint just as it was during your ultrasound scan. The tiny piece of 
skin from this incision is also used for research instead of being thrown away. After samples have 
been taken, the wound will be closed with a dry dressing. If your samples are taken from a knee 
joint or ankle, then sterile saline (salt water) will be run into the joint until full and then allowed to 
run out at the end of the procedure. This will be repeated several times to wash away inflammatory 
liquids from the joint. This is what we call a ‘wash-out’. You will be able to walk afterwards but we 
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recommend you are accompanied home after the procedure. If you cannot be accompanied we will 
pay for a taxi to bring you and drive you home. The visit should last no longer than 2 hours 
including rest. The cut will heal leaving a tiny 2-3mm scar (less than 1/8th of an inch). 
 
 
 
What are the benefits? 
We hope this research will allow us to identify the mechanisms which convert early joint 
inflammation to established persistent RA in some patients. If your doctor has suggested a knee or 
ankle joint could be biopsied, then the wash-out of the joint at the end of the biopsy procedure 
often makes the joint feel better for some months. 
 
What are the risks? 
Keyhole-procedures to joints (arthroscopy) are performed under local anaesthetic. Once the local 
anaesthetic wears off there may be mild, transient pain and discomfort in around a third of patients; 
temporary swelling of the joint can also occasionally occur. The procedure will leave a tiny 2-3mm 
scar (less than 1/8th of an inch). The risk of significant complications, such as infection or a 
thrombosis in the veins of the knee, occurring as a result of the procedure is less than 1 in 500. 
 
What if there is a problem? 
 
 
  
 
Will my taking part in this study be kept confidential? 
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All information given by you and all results obtained will be treated in the strictest confidence. It will 
be possible for the researchers to link the results of the research tests back to you as an individual. 
However you would never be identified individually in any publications. 
 
Who is organising and funding the research? 
This study is organised by the Departments of Rheumatology at University Hospitals Birmingham  
NHS Foundation Trust and Sandwell and West Birmingham Hospitals NHS Trust and, and the 
University of Birmingham. This study is funded by Arthritis Research UK. 
 
Where can I obtain further information? 
 
You will be given a copy of this information sheet and a signed consent form to 
keep. 
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CONSENT FORM 
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8.4 DATA study consent form 
CONSENT FORM 
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8.5 Publications  
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